Document:

Exhibit 10.1

 

SECURITIES PURCHASE AGREEMENT

 

This SECURITIES
PURCHASE AGREEMENT (the “Agreement”), dated as of May 7, 2019, by and between MyDx, Inc., a Nevada corporation,
with headquarters located at 6335 Ferris Square, Suite B, San Diego, CA 92121 (the “Company”) and ODYSSEY CAPITAL
FUNDING, LLC, a a Delaware limited liability company, with its address at 1249 Broadway, Suite 103, Hewlett, NY 11557 (the
Buyer”).

 

WHEREAS:

 

A. The
Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded
by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the “SEC”) under
the Securities Act of 1933, as amended (the “1933 Act”);

 

B. Buyer
desires to purchase and the Company desires to issue and sell, upon the terms and conditions set forth in this Agreement a 12%
convertible note of the Company, in the form attached hereto as Exhibit A in the aggregate principal amount of $100,000 (together
with any note(s) issued in replacement thereof or as a dividend thereon or otherwise with respect thereto in accordance with the
terms thereof, the “Note”), convertible into shares of common stock, of the Company (the “Common Stock”),
upon the terms and subject to the limitations and conditions set forth in such Note. The Note shall be paid for by the Buyer as
set forth herein.

 

C. The
Buyer wishes to purchase, upon the terms and conditions stated in this Agreement, such principal amount of Note as is set forth
immediately below its name on the signature pages hereto; and

 

NOW THEREFORE,
the Company and the Buyer severally (and not jointly) hereby agree as follows:

 

1. Purchase
and Sale of Note. 

 

a. Purchase
of Note. On the Closing Date (as defined below), the Company shall issue and sell to the Buyer and the Buyer agrees to purchase
from the Company such principal amount of Note as is set forth immediately below the Buyer’s name on the signature pages
hereto.

 

b. Form
of Payment. On the Closing Date (as defined below), (i) the Buyer shall pay the purchase price for the Note to be issued and
sold to it at the Closing (as defined below) (the “Purchase Price”) by wire transfer of immediately available funds
to the Company, in accordance with the Company’s written wiring instructions, against delivery of the Note in the principal
amount equal to the Purchase Price as is set forth immediately below the Buyer’s name on the signature pages hereto, and
(ii) the Company shall deliver such duly executed Note on behalf of the Company, to the Buyer, against delivery of such Purchase
Price.

 

    	_MyDx_
Company Initials
		 

     

    

 

c. Closing
Date. The date and time of the issuance and sale of the Note pursuant to this Agreement (the “Closing Date”) shall
be on or around May 7, 2019.

 

2. Buyer’s Representations and Warranties.
The Buyer represents and warrants to the Company that:

 

a. Investment Purpose.
As of the date hereof, the Buyer is purchasing the Note and the shares of Common Stock issuable upon conversion of or otherwise
pursuant to the Note, such shares of Common Stock being collectively referred to herein as the “Conversion Shares”
and, collectively with the Note, the “Securities”) for its own account and not with a present view towards the public
sale or distribution thereof, except pursuant to sales registered or exempted from registration under the 1933 Act; provided,
however, that by making the representations herein, the Buyer does not agree to hold any of the Securities for any minimum
or other specific term and reserves the right to dispose of the Securities at any time in accordance with or pursuant to a registration
statement or an exemption under the 1933 Act.

 

b. Accredited
Investor Status. The Buyer is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D (an
“Accredited Investor”). Any of Buyer’s transferees, assignees, or purchasers must be “accredited investors”
in order to qualify as prospective transferees, permitted assignees in the case of Buyer’s or Holder’s transfer, assignment
or sale of the Note.

 

c. Reliance
on Exemptions. The Buyer understands that the Securities are being offered and sold to it in reliance upon specific exemptions
from the registration requirements of United States federal and state securities laws and that the Company is relying upon the
truth and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and
understandings of the Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of the
Buyer to acquire the Securities.

 

d. Information.
The Buyer and its advisors, if any, have been, and for so long as the Note remain outstanding will continue to be, furnished with
all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of
the Securities which have been requested by the Buyer or its advisors. The Buyer and its advisors, if any, have been, and for so
long as the Note remain outstanding will continue to be, afforded the opportunity to ask questions of the Company. Notwithstanding
the foregoing, the Company has not disclosed to the Buyer any material nonpublic information and will not disclose such information
unless such information is disclosed to the public prior to or promptly following such disclosure to the Buyer. Neither such inquiries
nor any other due diligence investigation conducted by Buyer or any of its advisors or representatives shall modify, amend or affect
Buyer’s right to rely on the Company’s representations and warranties contained in Section 3 below. The Buyer understands
that its investment in the Securities involves a significant degree of risk. The Buyer is not aware of any facts that may constitute
a breach of any of the Company’s representations and warranties made herein.

 

    2

     

    

 

e. Governmental
Review. The Buyer understands that no United States federal or state agency or any other government or governmental agency
has passed upon or made any recommendation or endorsement of the Securities.

 

f. Transfer or
Re-sale. The Buyer understands that (i) the sale or resale of the Securities has not been and is not being registered under
the 1933 Act or any applicable state securities laws, and the Securities may not be transferred unless (a) the Securities are
sold pursuant to an effective registration statement under the 1933 Act, (b) in the case of subparagraphs (c), (d) and (e) below,
the Buyer shall have delivered to the Company, at the cost of the Buyer, an opinion of counsel that shall be in form, substance
and scope customary for opinions of counsel in comparable transactions to the effect that the Securities to be sold or transferred
may be sold, or transferred pursuant to an exemption from such registration, including the removal of any restrictive legend which
opinion shall be accepted by the Company, (c) the Securities are sold or transferred to an “affiliate” (as defined
in Rule 144 promulgated under the 1933 Act (or a successor rule) (“Rule 144”) of the Buyer who agrees to sell or otherwise
transfer the Securities only in accordance with this Section 2(f) and who is an Accredited Investor, (d) the Securities are sold
pursuant to Rule 144, or (e) the Securities are sold pursuant to Regulation S under the 1933 Act (or a successor rule) (“Regulation
S”); (ii) any sale of such Securities made in reliance on Rule 144 may be made only in accordance with the terms of said
Rule and further, if said Rule is not applicable, any re-sale of such Securities under circumstances in which the seller (or the
person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act) may require
compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC thereunder; and (iii) neither
the Company nor any other person is under any obligation to register such Securities under the 1933 Act or any state securities
laws or to comply with the terms and conditions of any exemption thereunder (in each case). Notwithstanding the foregoing or anything
else contained herein to the contrary, the Securities may be pledged as collateral in connection with a bona fide
margin account or other lending arrangement.

 

g. Legends.
The Buyer understands that the Note and, until such time as the Conversion Shares have been registered under the 1933 Act will
be sold pursuant to Rule 144 or Regulation S without any restriction as to the number of securities as of a particular date that
can then be immediately sold, the Conversion Shares may bear a restrictive legend in substantially the following form (and a stop-transfer
order may be placed against transfer of the certificates for such Securities):

 

“NEITHER THE ISSUANCE AND SALE
OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE,
SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE
FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING
THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT
SECURED BY THE SECURITIES.”

 

    3

     

    

 

The legend set forth
above shall be removed and the Company shall issue a certificate without such legend to the holder of any Security upon which it
is stamped, if, unless otherwise required by applicable state securities laws, (a) such Security is registered for sale under an
effective registration statement filed under the 1933 Act or otherwise may be sold pursuant to Rule 144 or Regulation S without
any restriction as to the number of securities as of a particular date that can then be immediately sold, and (b) such holder provides
the Company with an opinion of counsel, in form, substance and scope customary for opinions of counsel in comparable transactions,
to the effect that a public sale or transfer of such Security may be made without registration under the 1933 Act, and that legend
removal is appropriate, which opinion shall be accepted by the Company so that the sale or transfer is effected. The Buyer agrees
to sell all Securities, including those represented by a certificate(s) from which the legend has been removed, in compliance with
applicable prospectus delivery requirements, if any. In the event that the Company does not accept the opinion of counsel provided
by the Buyer with respect to the transfer of Securities pursuant to an exemption from registration, such as Rule 144 or Regulation
S, within 2 business days, it will be considered an Event of Default under the Note.

 

h. Authorization;
Enforcement. This Agreement has been duly and validly authorized. This Agreement has been duly executed and delivered on behalf
of the Buyer, and this Agreement constitutes a valid and binding agreement of the Buyer enforceable in accordance with its terms.

 

i. Residency.
The Buyer is a resident of the jurisdiction set forth immediately below the Buyer’s name on the signature pages hereto.

 

j. No
Short Sales. Buyer/Holder, its successors and assigns, agree that so long as the Note remains outstanding, neither the Buyer/Holder
nor any of its affiliates shall not enter into or effect “short sales” of the Common Stock or hedging transaction which
establishes a short position with respect to the Common Stock of the Company. The Company acknowledges and agrees that upon delivery
of a Conversion Notice by the Buyer/Holder, the Buyer/Holder immediately owns the shares of Common Stock described in the Conversion
Notice and any sale of those shares issuable under such Conversion Notice would not be considered short sales.

 

    4

     

    

 

3. Representations
and Warranties of the Company. The Company represents and warrants to the Buyer that:

 

a. Organization
and Qualification. The Company and each of its subsidiaries, if any, is a corporation duly organized, validly existing and
in good standing under the laws of the jurisdiction in which it is incorporated, with full power and authority (corporate and other)
to own, lease, use and operate its properties and to carry on its business as and where now owned, leased, used, operated and conducted.

 

b. Authorization;
Enforcement. (i) The Company has all requisite corporate power and authority to enter into and perform this Agreement, the
Note and to consummate the transactions contemplated hereby and thereby and to issue the Securities, in accordance with the terms
hereof and thereof, (ii) the execution and delivery of this Agreement, the Note by the Company and the consummation by it of the
transactions contemplated hereby and thereby (including without limitation, the issuance of the Note and the issuance and reservation
for issuance of the Conversion Shares issuable upon conversion or exercise thereof) have been duly authorized by the Company’s
Board of Directors and no further consent or authorization of the Company, its Board of Directors, or its shareholders is required,
(iii) this Agreement has been duly executed and delivered by the Company by its authorized representative, and such authorized
representative is the true and official representative with authority to sign this Agreement and the other documents executed in
connection herewith and bind the Company accordingly, and (iv) this Agreement constitutes, and upon execution and delivery by the
Company of the Note, each of such instruments will constitute, a legal, valid and binding obligation of the Company enforceable
against the Company in accordance with its terms.

 

c. Issuance
of Shares. The Conversion Shares are duly authorized and reserved for issuance and, upon conversion of the Note in accordance
with its respective terms, will be validly issued, fully paid and non-assessable, and free from all taxes, liens, claims and encumbrances
with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the
Company and will not impose personal liability upon the holder thereof.

 

d. Acknowledgment
of Dilution. The Company understands and acknowledges the potentially dilutive effect to the Common Stock upon the issuance
of the Conversion Shares upon conversion of the Note. The Company further acknowledges that its obligation to issue Conversion
Shares upon conversion of the Note in accordance with this Agreement, the Note is absolute and unconditional regardless of the
dilutive effect that such issuance may have on the ownership interests of other shareholders of the Company.

 

    5

     

    

 

e. No
Conflicts. The execution, delivery and performance of this Agreement, the Note by the Company and the consummation by the Company
of the transactions contemplated hereby and thereby (including, without limitation, the issuance and reservation for issuance of
the Conversion Shares) will not (i) conflict with or result in a violation of any provision of the Certificate of Incorporation
or By-laws, or (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default (or an event which
with notice or lapse of time or both could become a default) under, or give to others any rights of termination, amendment, acceleration
or cancellation of, any agreement, indenture, patent, patent license or instrument to which the Company or any of its Subsidiaries
is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state
securities laws and regulations and regulations of any self-regulatory organizations to which the Company or its securities are
subject) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries
is bound or affected (except for such conflicts, defaults, terminations, amendments, accelerations, cancellations and violations
as would not, individually or in the aggregate, have a Material Adverse Effect). All consents, authorizations, orders, filings
and registrations which the Company is required to obtain pursuant to the preceding sentence have been obtained or effected on
or prior to the date hereof. The Company is not in violation of the listing requirements of the OTC Markets Exchange (the “OTC
MARKETS”) and does not reasonably anticipate that the Common Stock will be delisted by the OTC MARKETS in the foreseeable
future, nor are the Company’s securities “chilled” by FINRA. The Company and its Subsidiaries are unaware of
any facts or circumstances which might give rise to any of the foregoing.

 

f. Absence
of Litigation. Except as disclosed in the Company’s Periodic Report filings with the SEC, there is no action, suit, claim,
proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body
pending or, to the knowledge of the Company or any of its subsidiaries, threatened against or affecting the Company or any of its
subsidiaries, or their officers or directors in their capacity as such, that could have a material adverse effect. Schedule 3(f)
contains a complete list and summary description of any pending or, to the knowledge of the Company, threatened proceeding against
or affecting the Company or any of its subsidiaries, without regard to whether it would have a material adverse effect. The Company
and its subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing.

 

g. Acknowledgment
Regarding Buyer’ Purchase of Securities. The Company acknowledges and agrees that the Buyer is acting solely in the capacity
of arm’s length purchasers with respect to this Agreement and the transactions contemplated hereby. The Company further acknowledges
that the Buyer is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this
Agreement and the transactions contemplated hereby and any statement made by the Buyer or any of its respective representatives
or agents in connection with this Agreement and the transactions contemplated hereby is not advice or a recommendation and is merely
incidental to the Buyer’ purchase of the Securities. The Company further represents to the Buyer that the Company’s
decision to enter into this Agreement has been based solely on the independent evaluation of the Company and its representatives.

 

h. No
Integrated Offering. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly
or indirectly made any offers or sales in any security or solicited any offers to buy any security under circumstances that would
require registration under the 1933 Act of the issuance of the Securities to the Buyer.

 

i. Title
to Property. The Company and its subsidiaries have good and marketable title in fee simple to all real property and good and
marketable title to all personal property owned by them which is material to the business of the Company and its subsidiaries,
in each case free and clear of all liens, encumbrances and defects except such as are described in Schedule 3(i) or such as would
not have a material adverse effect. Any real property and facilities held under lease by the Company and its subsidiaries are held
by them under valid, subsisting and enforceable leases with such exceptions as would not have a material adverse effect.

 

    6

     

    

 

j. Bad
Actor. No officer or director of the Company would be disqualified under Rule 506(d) of the Securities Act as amended on the
basis of being a “bad actor” as that term is established in the September 19, 2013 Small Entity Compliance Guide published
by the Securities and Exchange Commission.

 

k. Breach
of Representations and Warranties by the Company. If the Company breaches any of the representations or warranties set forth
in this Section 3, and in addition to any other remedies available to the Buyer pursuant to this Agreement, it will be considered
an Event of default under the Note.

 

4. COVENANTS.

 

a. Expenses.
At the Closing, the Company shall reimburse Buyer for expenses incurred by them in connection with the negotiation, preparation,
execution, delivery and performance of this Agreement and the other agreements to be executed in connection herewith (“Documents”),
including, without limitation, reasonable attorneys’ and consultants’ fees and expenses, transfer agent fees, fees
for stock quotation services, fees relating to any amendments or modifications of the Documents or any consents or waivers of provisions
in the Documents, fees for the preparation of opinions of counsel, escrow fees, and costs of restructuring the transactions contemplated
by the Documents. When possible, the Company must pay these fees directly, otherwise the Company must make immediate payment for
reimbursement to the Buyer for all fees and expenses immediately upon written notice by the Buyer or the submission of an invoice
by the Buyer.

 

b. Listing.
The Company shall promptly secure the listing of the Conversion Shares upon each national securities exchange or automated quotation
system, if any, upon which shares of Common Stock are then listed (subject to official notice of issuance) and, so long as the
Buyer owns any of the Note Securities, shall maintain, so long as any other shares of Common Stock shall be so listed, such listing
of all Conversion Shares from time to time issuable upon conversion of the Note. The Company will obtain and, so long as the Buyer
owns any of the Securities, maintain the listing and trading of its Common Stock on the OTC MARKETS or any equivalent replacement
market, the Nasdaq stock market (“Nasdaq”), or the New York Stock Exchange (“NYSE) and will comply in all respects
with the Company’s reporting, filing and other obligations under the bylaws or rules of the Financial Industry Regulatory
Authority (“FINRA”) and such exchanges, as applicable. The Company shall promptly provide to the Buyer copies of any
notices it receives from the OTC MARKETS and any other markets on which the Common Stock is then listed regarding the continued
eligibility of the Common Stock for listing on such markets.

 

    7

     

    

 

c. Corporate
Existence. So long as the Buyer beneficially owns the Note, the Company shall maintain its corporate existence and shall not
sell all or substantially all of the Company’s assets, except in the event of a merger or consolidation or sale of all or
substantially all of the Company’s assets, where the surviving or successor entity in such transaction (i) assumes the Company’s
obligations hereunder and under the agreements and instruments entered into in connection herewith and (ii) is a publicly traded
corporation whose Common Stock is listed for trading on the OTC MARKETS, Nasdaq or NYSE.

 

d. No
Integration. The Company shall not make any offers or sales of any security (other than the Securities) under circumstances
that would require registration of the Securities being offered or sold hereunder under the 1933 Act or cause the offering of the
Securities to be integrated with any other offering of securities by the Company for the purpose of any stockholder approval provision
applicable to the Company or its securities.

 

e. Breach
of Covenants. If the Company breaches any of the covenants set forth in this Section 4, and in addition to any other remedies
available to the Buyer pursuant to this Agreement, it will be considered an event of default under the Note.

 

5. Governing
Law; Miscellaneous.

 

a. Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York without regard
to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated
by this Agreement shall be brought only in the state courts of New York or in the federal courts located in the state and county
of New York. The parties to this Agreement hereby irrevocably waive any objection to jurisdiction and venue of any action instituted
hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. The Company
and Buyer waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorney’s
fees and costs. In the event that any provision of this Agreement or any other agreement delivered in connection herewith is invalid
or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that
it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may
prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement.
Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding
in connection with this Agreement or any other Transaction Document by mailing a copy thereof via registered or certified mail
or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

 

b. Counterparts;
Signatures by Facsimile. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original
but all of which shall constitute one and the same agreement and shall become effective when counterparts have been signed by each
party and delivered to the other party. This Agreement, once executed by a party, may be delivered to the other party hereto by
facsimile transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement.

 

    8

     

    

 

c. Headings.
The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the interpretation of,
this Agreement.

 

d. Severability.
In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then
such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform
with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect
the validity or enforceability of any other provision hereof.

 

e. Entire
Agreement; Amendments. This Agreement and the instruments referenced herein contain the entire understanding of the parties
with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company
nor the Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this Agreement
may be waived or amended other than by an instrument in writing signed by the majority in interest of the Buyer.

 

f. Notices.
All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing
and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return
receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, (iv) via electronic
mail or (v) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such
party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given
hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the
transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business
hours where such notice is to be received) or delivery via electronic mail, or the first business day following such delivery (if
delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business
day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt
of such mailing, whichever shall first occur. The addresses for such communications shall be:

 

If to the Company, to:

MyDx, Inc.

6335 Ferris Square, Suite B

San Diego, CA 92121

Attn: Matthew Bucciero, CEO

 

If to the Buyer:

ODYSSEY CAPITAL FUNDING, LLC

1249 Broadway, Suite 103

Hewlett, NY 11557

Attn: Ahron Fraiman, Manager

 

    9

     

    

 

Each party shall provide notice to the other party
of any change in address.

 

g. Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns.
Neither the Company nor the Buyer shall assign this Agreement or any rights or obligations hereunder without the prior written
consent of the other. Notwithstanding the foregoing, the Buyer may assign its rights hereunder to any “qualified person”,
any “permitted assigns”, or “prospective transferee” that acquires or purchases Note Securities in a private
transaction from the Buyer or to any of its “affiliates,” as that term is defined under the 1934 Act, without the consent
of the Company with Buyer’s Opinion of Counsel. A qualified person is an “accredited investor” transferee, assignee,
or purchaser of the Note who succeeds to the Holder’s right, title and interest to all or a portion of the Note accompanied
with an Opinion of Counsel as provided for in Section 2(f).

 

h. Third
Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

i. Survival.
The representations and warranties of the Company and the agreements and covenants set forth in this Agreement shall survive the
closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of the Buyer. The Company agrees to
indemnify and hold harmless the Buyer and all their officers, directors, employees and agents for loss or damage arising as a result
of or related to any breach or alleged breach by the Company of any of its representations, warranties and covenants set forth
in this Agreement or any of its covenants and obligations under this Agreement, including advancement of expenses as they are incurred.

 

j. Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

k. No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.

 

l. Remedies.
The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Buyer by vitiating
the intent and purpose of the transaction contemplated hereby. Accordingly, the Company acknowledges that the remedy at law for
a breach of its obligations under this Agreement will be inadequate and agrees, in the event of a breach or threatened breach by
the Company of the provisions of this Agreement, that the Buyer shall be entitled, in addition to all other available remedies
at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing
or curing any breach of this Agreement and to enforce specifically the terms and provisions hereof, without the necessity of showing
economic loss and without any bond or other security being required.

 

    10

     

    

 

IN WITNESS WHEREOF, the undersigned Buyer
and the Company have caused this Agreement to be duly executed as of the date first above written.

 

	MYDX, INC. 	 
	 	 	 
	By:	/s/ Matthew Bucciero	 
	Name:	Matthew Bucciero, CEO	 
	 	 	 
	ODYSSEY CAPITAL FUNDING, LLC.	 
	 	 	 
	By:		 
	Name:	Ahron Fraiman 	 
	Title:	Manager	 

 

	AGGREGATE SUBSCRIPTION AMOUNT:	 	$	100,000	 
	 	 	 	 	 
	Aggregate Principal Amount of Note:	 	 	 	 
	 	 	 	 	 
	Aggregate Purchase Price:	 	 	 	 

 

$100,000 less $5,000.00 in legal fees.

 

    11

     

    

 

EXHIBIT A

NOTE- $100,000

 

 

12EX-4.1

 Exhibit 4.1 

EXECUTION VERSION 
  

 
  

BAUSCH HEALTH COMPANIES INC. 

$750,000,000 7.000% SENIOR NOTES DUE 2028 

$750,000,000 7.250% SENIOR NOTES DUE 2029 
  

 
 INDENTURE

 DATED AS OF May 23, 2019 
  

 
 THE BANK OF NEW
YORK MELLON, 
 AS TRUSTEE, REGISTRAR AND PAYING AGENT 
  

 
  

 

 TABLE OF CONTENTS 
  

							
	Page	  

	
	ARTICLE 1	  

	
	DEFINITIONS AND INCORPORATION BY REFERENCE	  

			
	Section 1.1	  	Definitions	  	 	1	 
	Section 1.2	  	Other Definitions	  	 	26	 
	Section 1.3	  	[Reserved]	  	 	27	 
	Section 1.4	  	Rules of Construction	  	 	27	 
	
	ARTICLE 2	  

	
	THE SECURITIES	  

			
	Section 2.1	  	Form and Dating	  	 	27	 
	Section 2.2	  	Execution and Authentication	  	 	29	 
	Section 2.3	  	Registrar and Paying Agent	  	 	29	 
	Section 2.4	  	Paying Agent to Hold Money in Trust	  	 	30	 
	Section 2.5	  	Noteholder Lists	  	 	30	 
	Section 2.6	  	Transfer and Exchange	  	 	30	 
	Section 2.7	  	Replacement Notes	  	 	31	 
	Section 2.8	  	Outstanding Notes	  	 	31	 
	Section 2.9	  	Treasury Notes	  	 	31	 
	Section 2.10	  	Temporary Notes	  	 	32	 
	Section 2.11	  	Cancellation	  	 	32	 
	Section 2.12	  	Legend; Additional Transfer and Exchange Requirements	  	 	32	 
	Section 2.13	  	CUSIP, Common Code and ISIN Numbers	  	 	34	 
	
	ARTICLE 3	  

	
	REDEMPTION AND PURCHASES	  

			
	Section 3.1	  	Right to Redeem	  	 	34	 
	Section 3.2	  	Selection of Notes to Be Redeemed	  	 	34	 
	Section 3.3	  	Notice of Redemption	  	 	35	 
	Section 3.4	  	Effect of Notice of Redemption	  	 	36	 
	Section 3.5	  	Deposit of Redemption Price	  	 	36	 
	Section 3.6	  	Notes Redeemed in Part	  	 	36	 
	Section 3.7	  	Optional Redemption	  	 	36	 
	Section 3.8	  	Purchase of Notes at Option of the Holder Upon Change of Control	  	 	38	 
	Section 3.9	  	Effect of Change of Control Purchase Notice	  	 	40	 
	Section 3.10	  	Deposit of Change of Control Purchase Price	  	 	40	 
	Section 3.11	  	Notes Purchased in Part	  	 	40	 
	Section 3.12	  	Compliance with Securities Laws upon Purchase of Notes	  	 	41	 
	Section 3.13	  	Repayment to the Company	  	 	41	 
	Section 3.14	  	Offer to Purchase by Application of Excess Proceeds	  	 	41	 
	
	ARTICLE 4	  

	
	COVENANTS	  

			
	Section 4.1	  	Payment of Notes	  	 	42	 

  
 -i- 

					
	Page
			
	Section 4.2	  	Maintenance of Office or Agency	  	43
	Section 4.3	  	Reports	  	43
	Section 4.4	  	Compliance Certificates	  	44
	Section 4.5	  	Further Instruments and Acts	  	44
	Section 4.6	  	Maintenance of Corporate Existence	  	44
	Section 4.7	  	Changes in Covenants When Notes Rated Investment Grade	  	45
	Section 4.8	  	Restricted Payments	  	45
	Section 4.9	  	Incurrence of Indebtedness and Issuance of Preferred Stock	  	48
	Section 4.10	  	[Reserved]	  	51
	Section 4.11	  	Liens	  	51
	Section 4.12	  	Dividend and Other Payment Restrictions Affecting Restricted Subsidiaries	  	52
	Section 4.13	  	Transactions with Affiliates	  	53
	Section 4.14	  	Asset Sales	  	54
	Section 4.15	  	Additional Note Guarantees	  	57
	Section 4.16	  	Designation of Restricted and Unrestricted Subsidiaries	  	58
	Section 4.17	  	Business Activities	  	58
	Section 4.18	  	[Reserved]	  	58
	Section 4.19	  	Stay, Extension and Usury Laws	  	58
	Section 4.20	  	Notice of Default	  	58
	Section 4.21	  	Payment of Additional Amounts	  	58
	
	ARTICLE 5
	
	MERGER, CONSOLIDATION OR SALE OF ASSETS
			
	Section 5.1	  	Merger, Consolidation or Sale of Assets	  	61
	Section 5.2	  	Successor Substituted	  	62
	
	ARTICLE 6
	
	DEFAULT AND REMEDIES
			
	Section 6.1	  	Events of Default	  	62
	Section 6.2	  	Acceleration	  	64
	Section 6.3	  	Other Remedies	  	64
	Section 6.4	  	Waiver of Defaults and Events of Default	  	64
	Section 6.5	  	Control by Majority	  	65
	Section 6.6	  	Limitations on Suits	  	65
	Section 6.7	  	Rights of Holders to Receive Payment	  	65
	Section 6.8	  	Collection Suit by Trustee	  	65
	Section 6.9	  	Trustee May File Proofs of Claim	  	65
	Section 6.10	  	Priorities	  	66
	Section 6.11	  	Undertaking for Costs	  	66
	
	ARTICLE 7
	
	TRUSTEE
			
	Section 7.1	  	Duties of Trustee	  	66
	Section 7.2	  	Rights of Trustee	  	67
	Section 7.3	  	Individual Rights of Trustee	  	68
	Section 7.4	  	Trustee’s Disclaimer	  	68
	Section 7.5	  	Notice of Default or Events of Default	  	68
	Section 7.6	  	[Reserved]	  	68
	Section 7.7	  	Compensation and Indemnity	  	68
	Section 7.8	  	Replacement of Trustee	  	69

  
 -ii- 

					
	Page
			
	Section 7.9	  	Successor Trustee by Merger, Etc.	  	70
	Section 7.10	  	Eligibility; Disqualification	  	70
	Section 7.11	  	Preferential Collection of Claims Against the Company	  	70
	
	ARTICLE 8
	
	DEFEASANCE; SATISFACTION AND
	DISCHARGE OF INDENTURE
			
	Section 8.1	  	Satisfaction and Discharge of Indenture	  	70
	Section 8.2	  	Legal Defeasance	  	71
	Section 8.3	  	Covenant Defeasance	  	72
	Section 8.4	  	Application of Trust Money	  	73
	Section 8.5	  	Repayment to the Company	  	73
	Section 8.6	  	Reinstatement	  	73
	
	ARTICLE 9
	
	AMENDMENTS, SUPPLEMENTS AND WAIVERS
			
	Section 9.1	  	Without Consent of Holders	  	74
	Section 9.2	  	With Consent of Holders	  	74
	Section 9.3	  	Notice of Amendment, Supplement or Waiver	  	75
	Section 9.4	  	Revocation and Effect of Consents	  	75
	Section 9.5	  	Notation on or Exchange of Notes	  	76
	Section 9.6	  	Trustee to Sign Amendments, Etc.	  	76
	Section 9.7	  	Effect of Supplemental Indentures	  	76
	
	ARTICLE 10
	
	NOTE GUARANTEES
			
	Section 10.1	  	Note Guarantees	  	76
	Section 10.2	  	Execution and Delivery of Note Guarantees	  	77
	Section 10.3	  	Limitation on Note Guarantor Liability	  	78
	Section 10.4	  	Merger and Consolidation of Note Guarantors	  	78
	Section 10.5	  	Release	  	78
	
	ARTICLE 11
	
	MISCELLANEOUS
			
	Section 11.1	  	Certain Trust Indenture Act Sections	  	79
	Section 11.2	  	Notices	  	79
	Section 11.3	  	Communications by Holders With Other Holders	  	80
	Section 11.4	  	Certificate and Opinion of Counsel as to Conditions Precedent	  	80
	Section 11.5	  	Record Date for Vote or Consent of Holders	  	81
	Section 11.6	  	Rules by Trustee, Paying Agent and Registrar	  	81
	Section 11.7	  	Legal Holidays	  	81
	Section 11.8	  	Governing Law; Submission to Jurisdiction; Waiver of Jury Trial	  	81
	Section 11.9	  	No Adverse Interpretation of Other Agreements	  	81
	Section 11.10	  	No Recourse Against Others	  	81
	Section 11.11	  	Successors	  	81
	Section 11.12	  	Multiple Counterparts	  	81
	Section 11.13	  	Separability	  	82

  
 -iii- 

					
	Page
			
	Section 11.14	  	Table of Contents, Headings, etc.	  	82
	Section 11.15	  	Calculations in Respect of the Notes	  	82
	Section 11.16	  	Agent for Service and Waiver of Immunities	  	83
	Section 11.17	  	Judgment Currency	  	83
	Section 11.18	  	Foreign Currency Equivalent	  	83
	Section 11.19	  	Usury Savings Clause	  	83
	Section 11.20	  	Interest Act (Canada)	  	84
	Section 11.21	  	Tax Matters	  	84

 EXHIBITS 
  

					
	EXHIBIT A-1	  	-  	  	FORM OF 2028 NOTE
	EXHIBIT A-2	  	-  	  	FORM OF 2029 NOTE
	EXHIBIT B	  	-  	  	FORM OF GUARANTEE
	EXHIBIT C	  	-  	  	FORM OF CERTIFICATE FROM ACQUIRING INSTITUTIONAL ACCREDITED INVESTOR
	EXHIBIT D	  	-  	  	FORM OF CANADIAN NOTE GUARANTEE

  

  
 -iv- 

 THIS INDENTURE dated as of May 23, 2019 is among Bausch Health Companies Inc., a
corporation continued under the laws of the Province of British Columbia (the “Company”), the Note Guarantors party hereto and The Bank of New York Mellon (“BNY Mellon”), a New York banking corporation, not in its
individual capacity but solely as Trustee, Registrar, and Paying Agent (the “Trustee”). 
 In consideration of the premises
and the purchase of the Notes by the Holders thereof, all parties agree as follows for the benefit of the other and for the equal and ratable benefit of the registered Holders of the Company’s Notes. 

ARTICLE 1 
 DEFINITIONS AND
INCORPORATION BY REFERENCE 
 Section 1.1 Definitions. 

“144A Global Notes” means the 2028 144A Global Notes and the 2029 144A Global Notes. 

“2028 144A Global Note” means a Global Note substantially in the form of Exhibit
A-1 hereto bearing the Global Note Legend and the Private Placement Legend and deposited with or on behalf of, and registered in the name of, the Depositary or its nominee that will initially be issued in
a denomination equal to the principal amount of the 2028 Notes sold in reliance on Rule 144A. 
 “2029 144A Global Note”
means a Global Note substantially in the form of Exhibit A-2 hereto bearing the Global Note Legend and the Private Placement Legend and deposited with or on behalf of, and registered in the name of, the
Depositary or its nominee that will initially be issued in a denomination equal to the principal amount of the 2029 Notes sold in reliance on Rule 144A. 

“2028 Notes” means any of the 7.000% Senior Notes due 2028 (individually, a “2028 Note”), as amended
or supplemented from time to time, that are issued under this Indenture. 
 “2029 Notes” means any of the 7.250%
Senior Notes due 2029 (individually, a “2029 Note”), as amended or supplemented from time to time, that are issued under this Indenture. 

“2028 Regulation S Global Note” means a Global Note substantially in the form of Exhibit
A-1 hereto bearing the Global Note Legend and the Private Placement Legend and deposited with or on behalf of, and registered in the name of, the Depositary or its nominee that will initially be issued in
a denomination equal to the principal amount of the 2028 Notes sold in reliance on Regulation S. 
 “2029 Regulation S Global
Note” means a Global Note substantially in the form of Exhibit A-2 hereto bearing the Global Note Legend and the Private Placement Legend and deposited with or on behalf of, and registered in
the name of, the Depositary or its nominee that will initially be issued in a denomination equal to the principal amount of the 2029 Notes sold in reliance on Regulation S. 

“Acquired Debt” means, with respect to any specified Person: 

(1) Indebtedness of any other Person existing at the time such other Person is merged with or into or became a Subsidiary of
such specified Person and which is not satisfied in full at such time, whether or not such Indebtedness is incurred in connection with, or in contemplation of, such other Person merging with or into, or becoming a Subsidiary of, such specified
Person; and 
 (2) Indebtedness secured by a Lien encumbering any asset acquired by such specified Person. 

 

 “Additional 2028 Notes” means the additional principal amount of 2028 Notes
(other than the Initial 2028 Notes) that the Company may issue from time to time under this Indenture in accordance with Section 2.1(c) of this Indenture as part of the same series of 2028 Notes issued on the date hereof other than Notes issued
in exchange for, or replacement of outstanding Notes. 
 “Additional 2029 Notes” means the additional principal amount of
2029 Notes (other than the Initial 2028 Notes) that the Company may issue from time to time under this Indenture in accordance with Section 2.1(c) of this Indenture as part of the same series of 2029 Notes issued on the date hereof other than
Notes issued in exchange for, or replacement of outstanding Notes. 
 “Additional Notes” means any Additional 2028 Notes or
Additional 2029 Notes. 
 “Affiliate” of any specified Person means any other Person directly or indirectly controlling or
controlled by or under direct or indirect common control with such specified Person. For purposes of this definition, “control,” as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or
cause the direction of the management or policies of such Person, whether through the ownership of voting securities, by agreement or otherwise. For purposes of this definition, the terms “controlling”, “controlled by” and
“under common control with” have correlative meanings. 
 “Agent” means any Registrar or Paying Agent. 

“Applicable Premium” means, (x) with respect to the 2028 Notes, as determined by the Company, the greater of: 

(1) 1.0% of the then outstanding principal amount of such 2028 Notes, and 

(2) (a) the present value of all remaining required interest and principal payments due on such 2028 Notes and all premium
payments relating to such 2028 Notes assuming a redemption date of January 15, 2023, computed using a discount rate equal to the Treasury Rate plus 50 basis points, minus 

 (b) the then outstanding principal amount of such 2028 Notes, minus 

 (c) accrued interest paid on the date of redemption; and 

(y) with respect to the 2029 Notes, as determined by the Company, the greater of: 

(1) 1.0% of the then outstanding principal amount of such 2029 Notes, and 

(2) (a) the present value of all remaining required interest and principal payments due on such 2029 Notes and all premium
payments relating to such 2029 Notes assuming a redemption date of May 30, 2024, computed using a discount rate equal to the Treasury Rate plus 50 basis points, minus 

 (b) the then outstanding principal amount of such 2029 Notes, minus 

 (c) accrued interest paid on the date of redemption. 

“Applicable Procedures” means, with respect to any transfer or exchange of beneficial ownership interests in the Global
Notes, the rules and procedures of the Depositary, Euroclear and Clearstream, in each case to the extent applicable, to such transfer or exchange. 

“Asset Sale” means: 

(1) the sale, lease, conveyance or other disposition of any assets, property or rights outside of the ordinary course of
business; provided, that the sale, conveyance or other disposition of all or substantially all of the assets of the Company and its Restricted Subsidiaries taken as a whole will be governed by Section 3.8 and/or Section 5.1 hereof
and not by the provisions of Section 4.14 hereof; and 

  
 -2- 

 (2) the issuance of Equity Interests by any of the Company’s Restricted
Subsidiaries or the sale of Equity Interests in any of its Restricted Subsidiaries, in each case other than directors’ qualifying shares. 

Notwithstanding the preceding, none of the following items will be deemed to be an Asset Sale: 

(1) any single transaction or series of related transactions that involves assets having a Fair Market Value of less than
$100.0 million; 
 (2) a transfer of assets between or among the Company and its Restricted Subsidiaries; 

(3) an issuance of Equity Interests by a Restricted Subsidiary of the Company to the Company or to another Restricted
Subsidiary of the Company; 
 (4) any sale of receivables in connection with a Qualified Securitization Transaction; 

(5) the sale or other disposition of cash or Cash Equivalents; 

(6) a Restricted Payment or Permitted Investment that is permitted by Section 4.8 hereof; 

(7) the license or sublicense of intellectual property or other general intangibles and licenses, leases or subleases of other
property which do not materially interfere with the business of the Company and its Restricted Subsidiaries, taken as a whole, determined in good faith by the Company; 

(8) the sale, exchange or other disposition of obsolete, worn out, uneconomical or surplus assets, including any such
intellectual property; 
 (9) the sale, lease, conveyance or other disposition to the extent required by, or made pursuant
to, customary buy/sell arrangements between joint venture parties set forth in joint venture arrangements and similar binding agreements; 

(10) foreclosures on, or condemnation of, assets and the surrender or waiver of contract rights or the settlement, release or
surrender of contract, tort or other claims; 
 (11) sales, transfers or other dispositions of assets for consideration at
least equal to the Fair Market Value of the assets sold or disposed of, but only if the consideration received consists of property or assets (other than cash, except to the extent used as a bona fide means of equalizing the value of the property or
assets involved in the swap transaction; provided, however, that cash does not exceed 10% of the sum of the amount of the cash and the Fair Market Value of the assets received or given) of a nature or type that are used in a business
having property or assets of a nature or type or engaged in a Permitted Business (or Capital Stock of a Person whose assets consist of assets of the type described in this clause (11)); and 

(12) dispositions in connection with any Permitted Bond Hedge Transaction, any Permitted Warrant Transaction or any Packaged
Right. 
 “Attributable Debt” in respect of a sale and leaseback transaction means, at the time of determination, the
present value of the obligation of the lessee for net rental payments during the remaining term of the lease included in such sale and leaseback transaction including any period for which such lease has been extended or may, at the option of the
lessor, be extended. Such present value shall be calculated using a discount rate equal to the rate of interest implicit in such transaction, determined in accordance with GAAP. 

  
 -3- 

 “Bankruptcy Law” means any of Title 11 of the United States Code, the BIA,
the CCAA, the WURA and the CBCA, and any other applicable insolvency, corporate arrangement or restructuring or other similar law of any jurisdiction including any law of any jurisdiction permitting a debtor to obtain a stay or a compromise of the
claims of its creditors against it. 
 “Beneficial Owner” has the meaning assigned to such term in Rule l3d-3 and Rule 13d-5 under the Exchange Act, except that in calculating the beneficial ownership of any particular “person” (as that term is used in
Section 13(d)(3) of the Exchange Act), such “person” will be deemed to have beneficial ownership of all securities that such “person” has the right to acquire by conversion or exercise of other securities, whether such right
is currently exercisable or is exercisable only after the passage of time. The terms “Beneficially Owns” and “Beneficially Owned” have a corresponding meaning. 

“BHA” means Bausch Health Americas, Inc., a Delaware corporation, and its successors. 

“BIA” means the Bankruptcy and Insolvency Act (Canada). 

“Board of Directors” means: 

(1) with respect to a company or corporation, the board of directors of the company or corporation or any committee thereof
duly authorized to act on behalf of such board; 
 (2) with respect to a partnership, the Board of Directors of the general
partner of the partnership or any committee thereof duly authorized to act on behalf of such board; and 
 (3) with respect
to any other Person, the board or committee of such Person serving a similar function. 
 “Business Day” means each day
that is not a Legal Holiday. 
 “Canadian Note Guarantee” means each Guarantee of the obligations with respect to the Notes
issued by each Canadian Note Guarantor pursuant to the terms of this Indenture and substantially in the form of Exhibit D. 

“Canadian Note Guarantor” means each Note Guarantor that is organized under the laws of Canada or any province or territory
thereof. 
 “Capital Lease Obligations” means, at the time any determination is to be made, the amount of the liability in
respect of a capital lease that would at that time be required to be capitalized on a balance sheet in accordance with GAAP. 

“Capital Markets Indebtedness” means any Indebtedness consisting of bonds, debentures, notes or other similar debt securities
issued in (a) a public offering registered under the Securities Act, (b) a private placement to institutional investors that is resold in accordance with Rule 144A or Regulation S under the Securities Act, whether or not it includes
registration rights entitling the holders of such debt securities to registration thereof with the SEC or (c) a private placement to institutional investors. For the avoidance of doubt, the term “Capital Markets Indebtedness” does not
include any Indebtedness under the Credit Agreement, Indebtedness incurred in connection with a sale and leaseback transaction, Indebtedness incurred in the ordinary course of business of the Company, Capital Lease Obligations or recourse transfer
of any financial asset or any other type of Indebtedness incurred in a manner not customarily viewed as a “securities offering.” 

“Capital Stock” means: 

(1) in the case of a corporation, corporate stock; 

(2) in the case of an association or business entity, any and all shares, interests, participations, rights or other
equivalents (however designated) of corporate stock; 

  
 -4- 

 (3) in the case of a partnership or limited liability company, partnership
or membership interests (whether general or limited); and 
 (4) any other interest or participation (including, without
limitation, quotas) that confers on a Person the right to receive a share of the profits and losses of, or distributions of assets of, the issuing Person. 

“Cash Equivalents” means: 

(1) securities issued or directly and fully guaranteed or insured by the U.S. government or any agency or instrumentality
thereof (provided, that the full faith and credit of the U.S. is pledged in support thereof) having repricings or maturities of not more than one year from the date of acquisition; 

(2) certificates of deposit and time deposits with maturities of one year or less from the date of acquisition, bankers’
acceptances with maturities not exceeding one year and overnight bank deposits, in each case, with any U.S. commercial bank having capital and surplus in excess of $500.0 million; 

(3) repurchase obligations with a term of not more than 14 days for underlying securities of the types described in clauses
(1) and (2) above entered into with any financial institution meeting the qualifications specified in clause (2) above; 

(4) commercial paper having a rating of at least “P-2” or better from
Moody’s or at least “A-2” or better from S&P, or carrying an equivalent rating by an internationally recognized rating agency and, in each case, maturing within one year after the date of
acquisition; 
 (5) auction-rate, corporate and municipal securities, in each case (x) having either short-term debt
ratings of at least “P-2” or better from Moody’s or at least “A-2” or better from S&P or long-term senior debt ratings of “A2” or
better from Moody’s or at least “A” or better from S&P, or carrying an equivalent rating by an internationally recognized rating agency, (y) having repricings or maturities of not more than one year from the date of
acquisition and (z) which are classifiable as cash and cash equivalents under GAAP; 
 (6) money market funds at least
95% of the assets of which constitute Cash Equivalents of the kinds described in clauses (1) through (5) of this definition; or 

(7) in the case of the Company or any Foreign Subsidiary: 

(a) direct obligations of the sovereign nation, or any agency thereof, in which the Company or such Foreign Subsidiary is
organized or is conducting business or in obligations fully and unconditionally guaranteed by such sovereign nation, or any agency thereof; provided, that such obligations have repricings or maturities of not more than one year from the date
of acquisition and are used by the Company or such Foreign Subsidiary in accordance with normal investment practices for cash management in investments of the type analogous to clauses (1) through (5) above; or 

(b) investments of the type and maturity described in clauses (1) through (5) above of foreign obligors, which investments
or obligors have ratings described in such clauses or equivalent ratings from internationally recognized rating agencies; provided, that such investments are used by the Company or such Foreign Subsidiary in accordance with normal investment
practices for cash management in investments of the type analogous to clauses (1) through (5) above. 
 “CBCA” means
the Canada Business Corporations Act. 
 “CCAA” means the Companies’ Creditors Arrangement Act (Canada).

  
 -5- 

 “Change of Control” means the occurrence of any of the following: 

(1) any “person” (as that term is used in Section 13(d)(3) of the Exchange Act) becomes the Beneficial Owner,
other than by way of merger or consolidation of the Company, of shares of the Company’s Voting Stock representing 50% or more of the total voting power of all of the Company’s outstanding Voting Stock; 

(2) the Company consolidates with, or merges with or into, another Person, or the Company, directly or indirectly, sells,
assigns, conveys, transfers, leases or otherwise disposes of all or substantially all of the properties or assets of the Company and its Restricted Subsidiaries, taken as a whole (other than by way of merger or consolidation), in one or a series of
related transactions, or any Person consolidates with, or merges with or into, the Company, in any such event other than pursuant to a transaction in which the Persons that Beneficially Owned the shares of the Company’s Voting Stock immediately
prior to such transaction Beneficially Own at least a majority of the total voting power of all outstanding Voting Stock (other than Disqualified Stock) of the surviving or transferee Person; or 

(3) the holders of the Company’s Capital Stock approve any plan or proposal for the liquidation or dissolution of the
Company (whether or not otherwise in compliance with this Indenture). 
 Notwithstanding the foregoing, a transaction will not be deemed to
involve a Change of Control if (1) the Company becomes a direct or indirect wholly-owned Subsidiary of a holding company and (2) (a) the direct or indirect holders of the Voting Stock of the ultimate parent holding company immediately following
that transaction are substantially the same as the holders of the Company’s Voting Stock immediately prior to that transaction or (b) no “person” (as that term is used in Section 13(d)(3) of the Exchange Act) becomes the
Beneficial Owner of 50% or more of the total voting power of the Voting Stock of such ultimate parent holding company. 

“Clearstream” means Clearstream Banking, société anonyme, Luxembourg. 

“Company” means the party named as such in the first paragraph of this Indenture until a successor replaces it pursuant to
the applicable provisions of this Indenture, and thereafter “Company” shall mean such successor Company. 
 “Consolidated
Cash Flow” means, with respect to any specified Person for any period, the Consolidated Net Income of such Person for such period plus (without duplication): 

(1) taxes paid and any provision for taxes, including income, profits, capital, foreign, federal, state, local, Canadian
federal and provincial, sales, franchise and similar taxes, property taxes, foreign withholding taxes and foreign unreimbursed value added taxes (including penalties and interest related to any such tax or arising from any tax examination, and
including pursuant to any tax sharing arrangement or as a result of any tax distribution) of such Person and its Restricted Subsidiaries paid or accrued during the relevant period; plus 

(2) Fixed Charges of such Person and its Restricted Subsidiaries for such period, to the extent that any such expense was
deducted in computing such Consolidated Net Income; plus 
 (3) any restructuring charges or expenses (which, for the
avoidance of doubt, shall include retention, severance, systems establishment costs, excess pension charges, contract termination costs and costs to consolidate facilities and relocate employees), to the extent that any such charge or expense was
deducted in computing such Consolidated Net Income; plus 
 (4) fees and expenses in connection with any proposed or
actual issuance of any Indebtedness or Equity Interests, or any proposed or actual acquisitions, Investments, Asset Sales or divestitures permitted to be incurred under this Indenture; plus 

  
 -6- 

 (5) depreciation, amortization (including amortization of intangibles but
excluding amortization of prepaid cash expenses that were paid in a prior period), and other non-cash charges or expenses (including impairment charges and other write-offs of intangible assets and goodwill,
but excluding amortization of a prepaid cash expense that was paid in a prior period to the extent added back in such prior period) of such Person and its Restricted Subsidiaries for such period to the extent that such depreciation, amortization and
other non-cash charges or expenses were deducted in computing such Consolidated Net Income; provided, that if any such non-cash charge or expense (or any
portion thereof) represents an accrual or reserve for any potential cash items in any future period, (i) the Company may elect not to add back such non-cash charge in the then-current period and instead
add back such amount to a following period, and (ii) to the extent the Company elects to add back such non-cash charge, the cash payment in respect thereof in such future period shall be subtracted from
Consolidated Cash Flow to the same extent in such future period; plus 
 (6) pro forma “run rate” cost
savings, operating expense reductions, operational improvements and cost synergies (collectively, “Expected Cost Savings”) (net of actual amounts realized) that are reasonably identifiable, factually supportable and projected by the
Company in good faith to result from actions that have been taken or with respect to which substantial steps have been taken or are expected to be taken (in the good faith determination of such Person) related to any permitted asset sale,
acquisition (including the commencement of activities constituting a business line), combination, Investment, disposition (including the termination or discontinuance of activities constituting a business line), operating improvement, restructuring,
cost savings initiative, any similar initiative (including the effect of arrangements or efficiencies from the shifting of production of one or more products from one manufacturing facility to another) and/or specified transaction, in each case
prior to, on or after the Issue Date (any such operating improvement, restructuring, cost savings initiative or similar initiative or specified transaction, a “Cost Saving Initiative”) (in each case, calculated on a pro forma basis as
though such Expected Cost Savings and/or Cost Saving Initiative had been realized in full on the first day of such period); provided, that the results of such Expected Cost Savings and/or Cost Saving Initiatives are projected by the Company
in good faith to result from actions that have been taken or with respect to which steps have been taken or are expected to be taken (in the good faith determination of the Company) within 24 months after the date of any such operating improvement,
restructuring, cost savings initiative or similar initiative or specified transaction; provided further, that the aggregate amount added to or included in Consolidated Cash Flow pursuant to this clause (6) shall not, for any four
quarter period, exceed an amount equal to 25% of Consolidated Cash Flow for such period, calculated after giving effect to any such add-backs or inclusion; plus 

(7) Milestone Payments and Upfront Payments; plus 

(8) any expense or charge for extraordinary, unusual or non-recurring expenses or
charges (including costs of, and payments of, litigation expenses, actual or prospective legal settlements, fines, judgments or orders to the extent deducted in calculating Consolidated Net Income); minus 

(9) non-cash items increasing such Consolidated Net Income for such period, other than
the accrual of revenue in the ordinary course of business, in each case, on a consolidated basis and determined in accordance with GAAP. 

“Consolidated Net Income” means, with respect to any specified Person for any period, the aggregate of the Net Income of such
Person and its Restricted Subsidiaries for such period, on a consolidated basis, determined in accordance with GAAP; provided that: 

(1) the Net Income (but not loss) of any Person that is not a Restricted Subsidiary or that is accounted for by the equity
method of accounting will be included only to the extent of the amount of dividends or distributions paid in cash to the specified Person or a Restricted Subsidiary of the Person; 

(2) solely for purposes of Section 4.8 hereof, the Net Income of any Restricted Subsidiary (other than any Note Guarantor)
will be excluded to the extent that the declaration or payment of dividends or similar distributions by that Restricted Subsidiary of that Net Income is not at the date of determination 

  
 -7- 

 
permitted without any prior governmental approval (that has not been obtained or cannot be obtained other than pursuant to customary filings) or, directly or indirectly, by operation of the terms
of its charter or any agreement, instrument, judgment, decree, order, statute, rule or governmental regulation applicable to that Restricted Subsidiary or its stockholders; 

(3) the cumulative effect of a change in accounting principles will be excluded; 

(4) any unrealized net gain or loss resulting in such period from Hedging Obligations or other derivative instruments will be
excluded; 
 (5) any expense or charge attributable to the disposition of discontinued operations will be excluded; 

(6) non-cash goodwill or asset impairment charge and any
non-cash compensation expense recorded from grants of stock, stock appreciation or similar rights, stock options, restricted stock or other rights to officers, directors, employees or consultants of such
Person or any of its Restricted Subsidiaries will be excluded; 
 (7) any amortization expense incurred during such period
with respect to products acquired by the Company or any of its Subsidiaries that are used or useful in a Permitted Business will be excluded; 

(8) any gain or loss, together with any related provision for taxes on such gain or loss, realized in connection with:
(a) any Asset Sale; or (b) the disposition of any securities by such Person or any of its Restricted Subsidiaries or the extinguishment of any Indebtedness of such Person or any of its Restricted Subsidiaries will be excluded; 

(9) any (i) extraordinary, nonrecurring or unusual gain or loss, together with any related provision for taxes on such
extraordinary, nonrecurring or unusual gain or loss will be excluded and/or (ii) any charge associated with and/or payment of any actual or prospective legal settlement, fine, judgment or order, including ordinary legal expenses related thereto
(in the case of this clause (ii) (other than with respect to ordinary legal expenses), not to exceed in any fiscal year, $500.0 million, with unused amounts carried forward to the immediately succeeding fiscal year, provided that such amount
carried forward shall not exceed $500.0 million and such carried over amounts shall be deemed first applied in such succeeding fiscal year) will be excluded; 

(10) any (i) non-cash compensation charge or expense arising from any grant of
stock, stock options or other equity based awards and any non-cash deemed finance charges in respect of any pension liabilities or other provisions or on the
re-valuation of any benefit plan obligation and (ii) income (loss) attributable to deferred compensation plans or trusts, will be excluded; 

(11) any purchase accounting effects including adjustments to inventory, property and equipment, software and other intangible
assets and deferred revenue in component amounts required or permitted by GAAP and related authoritative pronouncements (including the effects of such adjustments pushed down to the Restricted Subsidiaries), as a result of any consummated
acquisition, or the amortization or write-off of any amounts thereof (including any write-off of in process research and development) will be excluded; 

(12) to the extent covered by insurance and actually reimbursed, or, so long as the Company has made a determination that there
exists reasonable evidence that such amount will in fact be reimbursed by the insurer and only to the extent that such amount is (a) not denied by the applicable carrier in writing within 90 days and (b) in fact reimbursed within 365 days
of the date of such evidence (with a deduction for any amount so added back to the extent not so reimbursed within 365 days), expenses with respect to liability or casualty events or business interruption; provided, that (x) if net
income is increased as a result of any amounts received from an insurer in respect of such a liability, casualty event or business interruption and the right to be so reimbursed was used in a prior period to increase Consolidated Net

  
 -8- 

 
Income pursuant to this clause (12), such amounts received shall be excluded from Consolidated Net Income and (y) to the extent the actual reimbursement received is less than the expected
reimbursement amount excluded in a prior period pursuant to this clause (12), Consolidated Net Income shall be reduced by the difference in the period in which such lower actual reimbursement amounts are received or in which a final judgment of a
court of competent jurisdiction is made that the Company is entitled to no reimbursement; 
 (13) any charges incurred
(a) in connection with any transaction (in each case, regardless of whether consummated), whether or not permitted under this Indenture, including any issuance and/or incurrence of Indebtedness and/or any issuance and/or offering of Equity
Interest, any Investment, any acquisition, any disposition, any recapitalization, any merger, consolidation or amalgamation, becoming a standalone company, any option buyout or any repayment, redemption, refinancing, amendment or modification of
Indebtedness (including any amortization or write-off of debt issuance or deferred financing costs, premiums and prepayment penalties) or any similar transaction and/or (b) in connection with any public
offering (whether or not consummated) will be excluded; and 
 (14) charges attributable to the undertaking and/or
implementation of new initiatives, business optimization activities, cost savings initiatives (including Cost Saving Initiatives), cost rationalization programs, operating expense reductions and/or cost synergies and/or similar initiatives and/or
programs (including in connection with any integration, restructuring or transition, any reconstruction, decommissioning, recommissioning or reconfiguration of fixed assets for alternative uses, any office or facility opening and/or pre-opening), including the following: any inventory optimization program and/or any curtailment, any business optimization charge, any restructuring charge (including any charge relating to any tax restructuring),
any charge relating to the closure or consolidation of any office or facility (including but not limited to rent termination costs, moving costs and legal costs), any systems implementation charge, any severance charge, any one time compensation
charge, any charge relating to rights fee arrangements (including any early terminations thereof), any charge relating to any strategic initiative or contract, any signing charge, any charge relating to any entry into new markets or contracts
(including, without limitation, any renewals, extensions or other modifications thereof) or new product introductions or exiting a market, contract or product, any retention or completion charge or bonus, any recruiting charge, any lease run-off charge, any expansion and/or relocation charge, any charge associated with any modification or curtailment to any pension and post-retirement employee benefit plan (including any settlement of pension
liabilities), any software or other intellectual property development charge, any charge associated with new systems design, any implementation charge, any transition charge, any charge associated with improvements to IT or accounting functions,
losses related to temporary decreases in work volume and expenses related to maintaining underutilized personnel, any project startup charge, any charge in connection with new operations, any charge in connection with unused warehouse space, any
charge relating to a new contract, any consulting charge and/or any corporate development charge will be excluded. 
 “Consolidated
Total Assets” means, as of any date of determination, the total assets shown on the consolidated quarterly or annual balance sheet of the Company and its Restricted Subsidiaries as of the most recent date for which such a quarterly or
annual balance sheet is available, determined on a consolidated basis in accordance with GAAP (and in the case of any determination relating to any incurrence of Indebtedness or Investment, on a pro forma basis). In addition, “Consolidated
Total Assets” will be calculated in a manner consistent with the definition of “Fixed Charge Coverage Ratio” to give effect to transactions that occurred after the date of the most recent quarterly or annual balance sheet date. 

“Convertible Indebtedness” means Indebtedness of the Company or any Restricted Subsidiary (which may be guaranteed by the
Company or any Restricted Subsidiary) permitted to be incurred hereunder that is either (a) convertible into or exchangeable for Equity Interests of the Company (and cash in lieu of fractional shares) or cash (in an amount determined by
reference to the price of such Equity Interests or a market measure of such Equity Interests), or a combination thereof, or (b) sold as units with call options, warrants or rights to purchase (or substantially equivalent derivative
transactions) that are exercisable for Equity Interests (other than Disqualified Stock) of the Company or cash (in an amount determined by reference to the price of such Equity Interests). 

  
 -9- 

 “Corporate Trust Office” means the designated office of the Trustee at
which at any particular time its corporate trust business shall be administered which office at the date of the execution of this Indenture is located at 240 Greenwich Street, Floor 7E, New York, New York 10286, Attention: Corporate Trust
Administration or at any other time at such other address as the Trustee may designate from time to time by notice to the Company. 

“Credit Agreement” means the Fourth Amended and Restated Credit and Guaranty Agreement, dated as of June 1, 2018, as
amended by that certain First Incremental Amendment, dated as of November 27, 2018, as in effect on the Issue Date (as it may be further amended, restated, replaced, supplemented or otherwise modified from time to time), among the Company,
certain subsidiaries of the Company, as guarantors, the lenders party thereto from time to time, JPMorgan Chase Bank, N.A. and Goldman Sachs Lending Partners LLC, as issuing banks and Barclays Bank PLC, as administrative agent and collateral agent,
together with the related documents thereto (including any guarantees and security documents), and in each case as amended, extended, renewed, restated, supplemented or otherwise modified (in whole or in part, and without limitation as to amount,
terms, conditions, covenants and other provisions) from time to time, and any agreement or instrument (and related documents) governing Indebtedness incurred to refinance or replace, in whole or in part, the borrowings and commitments then
outstanding or permitted to be outstanding under such facilities or a successor facility, whether by the same or any other bank, institutional lender, purchaser, investor, trustee or agent or group thereof. 

“Credit Facilities” means the facilities under the Credit Agreement and includes one or more other debt facilities, credit
agreements, commercial paper facilities, indentures or other agreements, in each case with banks, institutional lenders, purchasers, investors, trustees or agents providing for revolving credit loans, term loans, receivables financing (including
through the sale of receivables to such lenders or to special purpose entities formed to borrow from such lenders against such receivables), letters of credit or other extensions of credit or other Indebtedness, in each case including any notes,
mortgages, guarantees, collateral documents, instruments and agreements executed in connection therewith, and in each case as amended, extended, renewed, restated, supplemented or otherwise modified (in whole or in part, and without limitation as to
amount, terms, conditions, covenants and other provisions) from time to time, and any agreement or instrument (and related documents) governing Indebtedness incurred to refinance or replace, in whole or in part, the borrowings and commitments then
outstanding or permitted to be outstanding under such facilities or a successor facility, whether by the same or any other bank, institutional lender, purchaser, investor, trustee or agent or group thereof. 

“Custodian” means any receiver, trustee, assignee, liquidator, sequestrator, receiver-manager, custodian, administrative
receiver, administrator or similar official under any Bankruptcy Law. 
 “Default” means any event that is, or with the
passage of time or the giving of notice or both would be, an Event of Default. 
 “Definitive Notes” means Notes that are
in substantially the form attached hereto as Exhibit A-1 or Exhibit A-2, as applicable, and that do not include the information to which
footnotes 1, 5, 6 and 8 thereof apply. 
 “Depositary” means with respect to the Notes issuable or issued in whole or in
part in global form, DTC, including any and all successors thereto appointed as depositary hereunder and having become such pursuant to the applicable provisions of this Indenture. 

“Designated Noncash Consideration” means noncash consideration received by the Company or one of its Restricted Subsidiaries
in connection with an Asset Sale that is designated by the Company as Designated Noncash Consideration, less the amount of cash or Cash Equivalents received in connection with a subsequent sale of such Designated Noncash Consideration, which cash
and Cash Equivalents shall be considered Net Proceeds received as of such date and shall be applied pursuant to Section 4.14 hereof. 

“Disqualified Stock” means any Capital Stock that, by its terms (or by the terms of any security into which it is
convertible, or for which it is exchangeable, in each case at the option of the holder thereof), or upon the happening of any event, matures or is mandatorily redeemable, pursuant to a sinking fund obligation or otherwise, or redeemable at the
option of the holder thereof, in whole or in part, on or prior to the date that is 91 days after the date on which the applicable series of Notes mature. Notwithstanding the preceding sentence, any Capital Stock that would constitute Disqualified
Stock solely because the holders of the Capital Stock have the right to require the 

  
 -10- 

 
Company or a Restricted Subsidiary to repurchase such Capital Stock upon the occurrence of a change of control or an asset sale will not constitute Disqualified Stock if the terms of such Capital
Stock provide that the Company or such Restricted Subsidiary may not repurchase or redeem any such Capital Stock pursuant to such provisions unless such repurchase or redemption complies with Section 4.8 hereof. 

“Dollar Equivalent” of any amount means, at the time of determination thereof, 

(1) if such amount is expressed in U.S. dollars, such amount, or 

(2) if such amount is expressed in any other currency, the equivalent of such amount in U.S. dollars determined by using the
rate of exchange as published in The Wall Street Journal in the “Exchange Rates” column under the heading “Currency Trading” on the date no later than two Business Days prior to such determination or, if such rate is
unavailable, as quoted by a nationally recognized investment bank in New York, New York, selected by the Company, at 11:00 a.m. (New York City time) on the date of determination (or, if such date is not a Business Day, the last Business Day prior
thereto) to prime banks in New York, in either case for the spot purchase in the New York currency exchange market of such amount of U.S. dollars with such currency. 

“Domestic Subsidiary” means any Restricted Subsidiary that was formed under the laws of the United States or any state
thereof or the District of Columbia. 
 “Drug Acquisition” means any acquisition (including any license or any acquisition
of any license) solely or primarily of all or any portion of the rights in respect of one or more drugs or pharmaceutical products, whether in development or in market (including related intellectual property rights), but not of Equity Interests in
any Person or any operating business unit. 
 “DTC” means The Depository Trust Company. 

“Equity Interests” means Capital Stock and all warrants, options or other rights to acquire Capital Stock (but excluding any
debt security that is convertible into, or exchangeable for, Capital Stock and any Packaged Rights). 
 “Equity Offering”
means a public or private offering of Equity Interests (other than Disqualified Stock). 
 “Euroclear” means Euroclear Bank
S.A./N.V. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder, as in effect from time to time. 
 “Excluded Contribution” means the aggregate amount of cash or
Cash Equivalents or the fair market value of other assets or property (as determined by the Company in good faith, but excluding any amounts that are applied to increase the basket set forth in Section 4.8(a)(3) hereof) received by the Company
or any of its Restricted Subsidiaries after the Issue Date from: 
 (1) contributions in respect of Equity Interests (other than
Disqualified Stock or any amounts or other assets received from the Company or any of its Restricted Subsidiaries), and 
 (2) the sale of
Equity Interests of the Company or any of its Restricted Subsidiaries (other than (x) to the Company or any Restricted Subsidiary of the Company or (y) pursuant to any management equity plan or stock option plan or any other management or
employee benefit plan), 
 in each case, designated as an Excluded Contribution pursuant to an Officers’ Certificate on or promptly after the date the
relevant capital contribution is made or the relevant proceeds are received, as the case may be, and which are excluded from the calculation of the basket set forth in Section 4.8(a)(3) hereof. 

  
 -11- 

 “Existing Indebtedness” means Indebtedness of the Company and its
Restricted Subsidiaries (other than Indebtedness incurred under Section 4.9(b)(i) or (xx) hereof) in existence on the date of this Indenture, until such amounts are repaid. 

“Existing Notes” means the Existing Senior Notes and Existing Secured Notes. 

“Existing Secured Notes” means Company’s outstanding 6.50% Senior Secured Notes due 2022, 7.00% Senior Secured Notes due
2024, 5.500% Senior Secured Notes due 2025 and 5.750% Senior Secured Notes due 2027. 
 “Existing Senior Notes” means
(x) BHA’s outstanding 9.250% Senior Notes due 2026 and 8.500% Senior Notes due 2027 and (y) the Company’s outstanding 5.50% Senior Notes due 2023, 5.875% Senior Notes due 2023, 4.500% Senior Notes due 2023, 6.125% Senior Notes
due 2025 and 9.000% Senior Notes due 2025. 
 “Fair Market Value” means the price that could be negotiated in an arm’s-length transaction, for cash, between a willing seller and a willing and able buyer, neither of whom is under undue pressure or compulsion to complete the transaction, determined in good faith by
(i) a responsible financial or accounting officer of the Company with respect to valuations not in excess of $750.0 million and (ii) the Board of Directors of the Company with respect to valuations equal to or in excess of
$750.0 million, as applicable. 
 “Fall Away Event” means, with respect to a series of the Notes, such time as the
Notes of such series shall have an Investment Grade Rating and the Company shall have delivered to the Trustee an Officers’ Certificate certifying that the foregoing condition has been satisfied. 

“Final Maturity Date” means January 15, 2028 (with respect to the 2028 Notes) and May 30, 2029 (with respect to the
2029 Notes). 
 “Fixed Charge Coverage Ratio” means, with respect to any specified Person for any period, the ratio of the
Consolidated Cash Flow of such Person for such period to the Fixed Charges of such Person for such period. In the event that the specified Person or any of its Restricted Subsidiaries incurs, assumes, Guarantees, repays, repurchases or redeems any
Indebtedness (other than ordinary working capital borrowings) or issues, repurchases or redeems preferred stock subsequent to the commencement of the period for which the Fixed Charge Coverage Ratio is being calculated and on or prior to the date on
which the event for which the calculation of the Fixed Charge Coverage Ratio is made (the “Calculation Date”), then the Fixed Charge Coverage Ratio will be calculated giving pro forma effect to such incurrence, assumption,
Guarantee, repayment, repurchase or redemption of Indebtedness, or such issuance, repurchase or redemption of preferred stock, and the use of the proceeds therefrom as if the same had occurred at the beginning of the applicable four-quarter
reference period. 
 To the extent the Company elects pursuant to an Officers’ Certificate delivered to the Trustee to treat all or any
portion of the commitment under any Indebtedness as being incurred prior to the actual incurrence thereof pursuant to Section 4.9(e) hereof, the Company shall deem all or such portion of such commitment of such Indebtedness, as applicable, as
having been incurred and to be outstanding for purposes of calculating the Fixed Charge Coverage Ratio for any period in which the Company makes any such election and for any subsequent period until such commitments or such Indebtedness, as
applicable, are no longer outstanding. 
 In addition, for purposes of calculating the Fixed Charge Coverage Ratio: 

(1) acquisitions that have been made by the specified Person or any of its Restricted Subsidiaries, including through
consolidations or mergers and including any related financing transactions, during the four-quarter reference period or subsequent to such reference period and on or prior to the Calculation Date will be given pro forma effect as if they had
occurred on the first day of the four-quarter reference period and Consolidated Cash Flow for such reference period will be calculated (x) on a pro forma basis in accordance with Regulation S-X
promulgated by the SEC and, in addition, (y) to give effect to any Pro Forma Cost Savings; 

  
 -12- 

 (2) the Consolidated Cash Flow attributable to discontinued operations, as
determined in accordance with GAAP, and operations or businesses disposed of prior to the Calculation Date, will be excluded; and 

(3) the Fixed Charges attributable to discontinued operations, as determined in accordance with GAAP, and operations or
businesses disposed of prior to the Calculation Date, will be excluded, but only to the extent that the obligations giving rise to such Fixed Charges will not be obligations of the specified Person or any of its Restricted Subsidiaries following the
Calculation Date. 
 “Fixed Charges” means, with respect to any specified Person for any period, the sum, without
duplication, of: 
 (1) the consolidated interest expense of such Person and its Restricted Subsidiaries for such period,
whether paid or accrued, including, without limitation, amortization of debt issuance costs and original issue discount, non-cash interest payments, the interest component of any deferred payment obligations,
the interest component of all payments associated with Capital Lease Obligations, imputed interest with respect to Attributable Debt, commissions, discounts and other fees and charges incurred in respect of letter of credit or bankers’
acceptance financings, and net of the effect of all payments made or received pursuant to Interest Rate Hedging Obligations; plus 

(2) the consolidated interest of such Person and its Restricted Subsidiaries that was capitalized during such period;
plus 
 (3) any interest expense on Indebtedness of another Person that is Guaranteed by such Person or one of its
Restricted Subsidiaries or secured by a Lien on assets of such Person or one of its Restricted Subsidiaries; plus 

(4) all dividends, whether paid or accrued and whether or not in cash, on any Disqualified Stock or any series of preferred
stock of such Person or any of its Restricted Subsidiaries, other than dividends on Equity Interests payable solely in Equity Interests of the Company (other than Disqualified Stock) or to the Company or a Restricted Subsidiary of the Company, in
each case, on a consolidated basis and determined in accordance with GAAP; minus 
 (5) the consolidated interest
income of such Person and its Restricted Subsidiaries for such period; minus 
 (6) amortization of deferred financing
fees, debt issuance costs, commissions, fees and expenses and expensing of any financing fees. 
 “Foreign Subsidiary”
means a Restricted Subsidiary that is not organized or existing under the laws of the United States of America or any state or territory thereof or the District of Columbia or is a Restricted Subsidiary of such Foreign Subsidiary. 

“GAAP” means generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting
Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other entity as have been approved by a significant segment
of the accounting profession, as in effect on January 30, 2015. 
 “Global Note Legend” means the legend set forth in
Exhibit A-1 and Exhibit A-2 hereto, as applicable, which is required to be placed on all Global Notes issued under this Indenture. 

“Global Notes” means a Global Note substantially in the form attached hereto as Exhibit
A-1 and Exhibit A-2 hereto, as applicable, bearing the Global Note Legend and the Private Placement Legend deposited with or on behalf of, and registered in
the name of, the Depositary or its nominee. 

  
 -13- 

 “Government Securities” means, as applicable, (i) direct non-callable obligations of, or guaranteed by, the United States of America for the timely payment of which guarantee or obligations the full faith and credit of the U.S. is pledged and (ii) direct non-callable obligations of, or guaranteed by, a member state of the European Union for the timely payment of which guarantee or obligations the full faith and credit of the government of such member state is
pledged. 
 “Guarantee” means a guarantee other than by endorsement of negotiable instruments for collection in the
ordinary course of business, direct or indirect, in any manner including, without limitation, by way of a pledge of assets or through letters of credit or reimbursement agreements in respect thereof, of all or any part of any Indebtedness. 

“Hedging Obligations” means, with respect to any specified Person: 

(1) Interest Rate Hedging Obligations; and 

(2) the obligations of such Person under agreements or arrangements designed to protect such Person against fluctuations in
currency exchange rates; 
 provided, that no obligation in respect of any Packaged Right, Permitted Bond Hedge Transaction or
Permitted Warrant Transaction shall, in each case, constitute a Hedging Obligation. 
 “Holder” or
“Noteholder” means the Person in whose name a Note is registered on the Registrar’s books. 

“Indebtedness” means, with respect to any specified Person, any indebtedness of such Person, whether or not contingent
(without duplication): 
 (1) in respect of borrowed money; 

(2) evidenced by bonds, notes, debentures or similar instruments or letters of credit (or reimbursement agreements in respect
thereof); 
 (3) in respect of banker’s acceptances; 

(4) representing Capital Lease Obligations or Attributable Debt in respect of sale and leaseback transactions; 

(5) representing the balance deferred and unpaid of the purchase price of any property, which balance is (a) due more than
twelve months from the date of incurrence of the obligation in respect thereof or (b) evidenced by a note or similar written instrument, and except any such balance that constitutes an accrued expense or trade payable; or 

(6) representing net payment obligations under any Hedging Obligations, 

if and to the extent any of the preceding items (other than letters of credit, Attributable Debt and Hedging Obligations) would appear as a liability upon a
balance sheet of the specified Person prepared in accordance with GAAP. In addition, the term “Indebtedness” includes (x) all Indebtedness of others secured by a Lien on any asset of the specified Person (whether or not such
Indebtedness is assumed by the specified Person), the amount of such obligation being deemed to be the lesser of the Fair Market Value of such asset and the amount of the obligation so secured and (y) to the extent not otherwise included, the
Guarantee by the specified Person of any Indebtedness of any other Person. 
 Notwithstanding the foregoing, in connection with the purchase
by a Person or any of its Restricted Subsidiaries of any business, the term “Indebtedness” will exclude indemnification or post-closing payment adjustments or earn-out or similar obligations to which
the seller may become entitled to the extent such payment is determined by a final closing balance sheet, working capital calculation or other similar method or such payment 

  
 -14- 

 
depends on the performance of such business after the closing; provided, however, that, at the time of closing, the amount of any such payment is not determinable or is of a
contingent nature and, to the extent such payment thereafter becomes fixed and finally determined, the amount is paid within 60 days thereafter. 

The amount of any Indebtedness outstanding as of any date will be: 

(1) the accreted value of the Indebtedness, in the case of any Indebtedness issued with original issue discount; and 

(2) the principal amount of the Indebtedness, together with any interest on the Indebtedness that is more than 30 days past
due, in the case of any other Indebtedness. 
 “Indenture” means this Indenture as amended or supplemented from time to
time pursuant to the terms of this Indenture. 
 “Initial 2028 Notes” means the $750,000,000 aggregate principal amount of
2028 Notes issued on the date hereof. 
 “Initial 2029 Notes” means the $750,000,000 aggregate principal amount of 2029
Notes issued on the date hereof. 
 “Initial Notes” means the Initial 2028 Notes and the Initial 2029 Notes. 

“Interest Rate Hedging Obligations” means, with respect to any specified Person, the obligations of such Person under: 

(1) interest rate swap agreements, interest rate cap agreements and interest rate collar agreements; and 

(2) other agreements or arrangements designed to protect such Person against fluctuations in interest rates. 

“Investment Grade Rating” means a rating of Baa3 or better by Moody’s or BBB- or
better by S&P (or its equivalent under any successor rating categories of Moody’s or S&P) (or, in each case, if such Rating Agency ceases to rate the applicable series of Notes for reasons outside of the control of the Company, the
equivalent investment grade credit rating from any Rating Agency selected by the Company as a replacement Rating Agency). 

“Investments” means, with respect to any Person, all direct or indirect investments by such Person in other Persons
(including Affiliates) in the forms of loans (including Guarantees or other obligations), advances or capital contributions (excluding commission, travel and similar advances to officers and employees made in the ordinary course of business),
purchases or other acquisitions for consideration of Indebtedness, Equity Interests or other securities, together with all items that are or would be classified as investments on a balance sheet prepared in accordance with GAAP. If (i) the
Company or any Restricted Subsidiary of the Company sells or otherwise disposes of any Equity Interests of any direct or indirect Restricted Subsidiary of the Company such that, after giving effect to any such sale or disposition, such Person is no
longer a Restricted Subsidiary of the Company or (ii) a Restricted Subsidiary of the Company is redesignated as an Unrestricted Subsidiary, the Company will be deemed to have made an Investment on the date of any such sale, disposition or
redesignation equal to the Fair Market Value of the Company’s Investments in such Subsidiary that were not sold or disposed of in an amount determined as provided in Section 4.8(c) hereof. For the avoidance of doubt, acquisitions of or
licenses for products or assets used or useful in a Permitted Business do not constitute Investments. 
 “Issue Date” means
May 23, 2019, the date of the initial issuance of the Notes under this Indenture. 

  
 -15- 

 “Lien” means, with respect to any asset, any mortgage, lien, pledge, charge
(fixed and/or floating), security interest or encumbrance of any kind in respect of such asset, whether or not filed, recorded or otherwise perfected under applicable law, including any conditional sale or other title retention agreement, any lease
in the nature thereof, any option or other agreement to sell or give a security interest in and any filing of or agreement to give any financing statement under the UCC or Personal Property Security Act (Ontario) (or equivalent statutes) of any
jurisdiction. 
 “Milestone Payments” means payments made under contractual arrangements in connection with any permitted
acquisition or similar Investment to sellers (or licensors) of the assets or Equity Interests acquired (or licensed) therein based on the achievement of specified revenue, profit or other performance targets (financial or otherwise). 

“Moody’s” means Moody’s Investors Service, Inc., or any successor to the rating agency business thereof. 

“Net Income” means, with respect to any specified Person, the net income (loss) of such Person, determined in accordance with
GAAP and before any reduction in respect of preferred stock dividends. 
 “Net Proceeds” means the aggregate cash proceeds
received by the Company or any of its Restricted Subsidiaries in respect of any Asset Sale (including, without limitation, any cash received upon the sale or other disposition of any non-cash consideration
received in any Asset Sale), net of the direct costs relating to such Asset Sale, including, without limitation, legal, accounting and investment banking fees, and sales commissions, and any relocation expenses incurred as a result of the Asset
Sale, taxes paid or payable as a result of the Asset Sale, in each case, after taking into account any available tax credits or deductions and any tax sharing arrangements, and amounts required to be applied to the repayment of Indebtedness, other
than Indebtedness under the Credit Agreement, secured by a Lien on the asset or assets that were the subject of such Asset Sale and any reserve for adjustment in respect of the sale price of such asset or assets established in accordance with GAAP.

 “Non-Guarantor Subsidiary” means a Restricted Subsidiary that is not a Note
Guarantor. 
 “Non-Recourse Debt” means Indebtedness: 

(1) as to which none of the Company or any of its Restricted Subsidiaries (a) provides credit support of any kind
(including any undertaking, agreement or instrument that would constitute Indebtedness), (b) is directly or indirectly liable as a guarantor or otherwise, or (c) constitutes the lender; 

(2) no default with respect to which (including any rights that the holders of the Indebtedness may have to take enforcement
action against an Unrestricted Subsidiary) would permit upon notice, lapse of time or both any holder of any other Indebtedness (other than the Notes) of the Company or any of its Restricted Subsidiaries to declare a default on such other
Indebtedness or cause the payment of the Indebtedness to be accelerated or payable prior to its Stated Maturity; and 
 (3)
as to which the lenders have been notified in writing that they will not have any recourse to the stock or assets of the Company or any of its Restricted Subsidiaries. 

“Non-U.S. Person” means a Person who is not a U.S. Person. 

“Note Guarantee” means each Guarantee of the obligations with respect to the Notes issued by a Subsidiary of the Company
pursuant to the terms of this Indenture. 
 “Note Guarantor” means each Subsidiary of the Company that becomes a guarantor
of the Notes pursuant to the terms of this Indenture. 
 “Notes” means any of the 2028 Notes or 2029 Notes, as
applicable, (individually, a “Note”). 

  
 -16- 

 “Obligations” means any principal, interest, penalties, fees,
indemnifications, reimbursements, damages and other liabilities payable under the documentation governing any Indebtedness (including interest, fees, and expenses accruing on or after the filing of any petition in bankruptcy or for reorganization
relating to the Company, whether or not a claim for such post-petition interest, fees, or expenses is allowed or allowable in such proceedings). 

“Offering Memorandum” means the Offering Memorandum dated May 9, 2019, with respect to the Notes. 

“Officer” means the Chairman of the Board, the Chief Executive Officer, the President, any Vice President, the Chief
Financial Officer, the Controller, Treasurer, the Secretary or any Assistant Controller, Assistant Treasurer or Assistant Secretary of the Company. 

“Officers’ Certificate” means a certificate signed by two Officers; provided, however, that for purposes
of Section 4.4 hereof, “Officers’ Certificate” means a certificate signed by the principal executive officer, principal financial officer or principal accounting officer of the Company and by one other Officer. 

“Opinion of Counsel” means a written opinion from legal counsel reasonably acceptable to the Trustee. The counsel may be an
employee of or counsel to the Company. 
 “Packaged Rights” means warrants, options or other rights to acquire shares of
any class of the Equity Interests of the Company or a Restricted Subsidiary (whether settled in Equity Interests, cash or any combination thereof), regardless of the issuer of such warrants, options or other rights, that are initially issued as a
unit with Indebtedness of the Company or any Restricted Subsidiary (which may be guaranteed by the Guarantors, the Company or any Restricted Subsidiary) permitted to be incurred hereunder, even if such Indebtedness is separable from such warrants,
options or other rights by a holder thereof. 
 “Participant” means, a member of, or participant or account holder in, DTC,
Euroclear and/or Clearstream. 
 “Permitted Asset Swap” means the substantially concurrent purchase and sale or exchange of
assets used or useful in a Permitted Business or a combination of such assets and cash or Cash Equivalents between the Company or any of its Restricted Subsidiaries and another Person; provided that any cash or Cash Equivalents received must
be applied in accordance with Section 4.14 hereof. 
 “Permitted Bond Hedge Transaction” means any bond hedge or call
or capped call option (or similar transaction) on the Company’s Equity Interests in connection with the issuance of any Convertible Indebtedness; provided that the purchase price for such Permitted Bond Hedge Transaction, less the proceeds
received from the sale of any related Permitted Warrant Transaction, does not exceed the net proceeds received from the sale of such Convertible Indebtedness. 

“Permitted Business” means any business conducted by the Company and its Restricted Subsidiaries on the Issue Date and any
business that is in the judgment of the Company reasonably related, ancillary or complementary to the business of the Company and its Restricted Subsidiaries on the Issue Date or a natural extension thereof. 

“Permitted Investments” means: 

(1) any Investment in the Company or in a Restricted Subsidiary of the Company; 

(2) any Investment in cash and Cash Equivalents; 

(3) any Investment by the Company or any Subsidiary of the Company in a Person, if as a result of such Investment: 

(a) such Person becomes a Restricted Subsidiary of the Company; or 

  
 -17- 

 (b) such Person is merged or consolidated with or into, or transfers or
conveys substantially all of its assets to, or is liquidated into, the Company or a Restricted Subsidiary of the Company; 
 and, in each
case, any Investment held by such Person; provided, that such Investment was not acquired by such Person in contemplation of such acquisition, merger, consolidation, transfer, conveyance or liquidation; 

(4) any Investment made as a result of the receipt of non-cash consideration from an
Asset Sale that was made pursuant to and in compliance with Section 4.14 hereof; 
 (5) any Investments made solely in
exchange for the issuance of Equity Interests (other than Disqualified Stock) of the Company; 
 (6) (i) any Investments
received in compromise of obligations owed to the Company or any of its Restricted Subsidiaries created in the ordinary course of business, including pursuant to any plan of reorganization or similar arrangement upon the bankruptcy or insolvency of
any trade creditor or customer or in satisfaction of judgments and (ii) Investments by the Company or any of its Restricted Subsidiaries in a Securitization Special Purpose Entity or any Investment by a Securitization Special Purpose Entity in
any other Person, in each case, in connection with a Qualified Securitization Transaction; 
 (7) receivables owing to the
Company or any Restricted Subsidiary of the Company if created or acquired in the ordinary course of business and payable or dischargeable in accordance with customary trade terms (which trade terms may include such concessionary trade terms as the
Company or any such Restricted Subsidiary deems reasonable under the circumstances), and other Investments to the extent such Investments consist of prepaid expenses, negotiable instruments held for collection and lease, utility and workers’
compensation, performance and other similar deposits made in the ordinary course of business by the Company or any Restricted Subsidiary; 

(8) Investments represented by Hedging Obligations; 

(9) Investments in existence on the date of this Indenture and any extension, modification or renewal of any such Investments,
but only to the extent such extension, modification or renewal does not involve additional advances, contributions or other Investments of cash or other assets or other increases thereof (other than as a result of the accrual or accretion of
interest or original issue discount or the issuance of pay-in-kind securities, in each case, pursuant to the terms of such Investment as in effect on the date of this
Indenture); 
 (10) payroll, travel and similar advances to cover matters that are expected at the time of such advances
ultimately to be treated as expenses for accounting purposes and that are made in the ordinary course of business; 
 (11)
loans and advances to officers, directors and employees in the ordinary course of business in the aggregate amount outstanding at any one time not to exceed $25.0 million; 

(12) Investments in a Permitted Joint Venture or Unrestricted Subsidiary, when taken together with all other Investments made
pursuant to this clause (12) that are at the time outstanding, not to exceed the greater of (x) $675.0 million and (y) 2.5% of Consolidated Total Assets; 

(13) other Investments in any Person having an aggregate Fair Market Value (measured on the date each such Investment was made
and without giving effect to subsequent changes in value), when taken together with all other Investments made pursuant to this clause (13) that are at the time outstanding, not to exceed the greater of (x) $2.0 billion and (y) 7.5% of
Consolidated Total Assets; and 
 (14) Permitted Bond Hedge Transactions. 

  
 -18- 

 “Permitted Joint Venture” means any joint venture (which may be in the form
of a limited liability company, partnership, corporation or other entity) in which the Company or any of its Restricted Subsidiaries is a joint venturer; provided, however, that the joint venture is engaged solely in a Permitted
Business. 
 “Permitted Liens” means: 

(1) Liens securing Indebtedness and other Obligations under Credit Facilities permitted by the terms of this Indenture to be
incurred under Section 4.9(b)(i) or (xx) hereof; 
 (2) Liens in favor of the Company or any Note Guarantor; 

(3) Liens on property of a Person existing at the time such Person is merged with or into or consolidated with or is acquired
by the Company or any Subsidiary of the Company; provided, that such Liens were not incurred in contemplation of such merger, consolidation or acquisition and do not extend to any assets other than those of the Person merged into,
consolidated with or acquired by the Company or the Subsidiary; 
 (4) Liens on property existing at the time of acquisition
of the property by the Company or any Subsidiary of the Company, provided, that such Liens were not incurred in contemplation of such acquisition; 

(5) Liens to secure the performance of statutory obligations, surety or appeal bonds, performance bonds or other obligations of
a like nature incurred in the ordinary course of business; 
 (6) Liens to secure Indebtedness (including Capital Lease
Obligations) permitted by Section 4.9(b)(iv) or Section 4.9(b)(v) hereof, covering only the assets acquired with such Indebtedness (and improvements or accessions thereto); 

(7) Liens existing on the date of this Indenture and Liens securing the Existing Secured Notes; 

(8) Liens for taxes, assessments or governmental charges or claims that are not yet delinquent or that are being contested in
good faith by appropriate proceedings promptly instituted and diligently concluded, provided, that any reserve or other appropriate provision as is required in conformity with GAAP has been made therefor; 

(9) (i) Liens securing Hedging Obligations and (ii) Liens existing under or by reason of Indebtedness or other contractual
requirements of a Securitization Special Purpose Entity or any Standard Securitization Undertaking, in each case in respect of this subclause (ii) in connection with a Qualified Securitization Transaction; 

(10) Liens arising by reason of deposits necessary to obtain standby letters of credit in the ordinary course of business; 

(11) Liens to secure any Permitted Refinancing Indebtedness permitted to be incurred under this Indenture; provided,
however, that: 
 (a) the new Lien shall be limited to all or part of the same property and assets that secured or,
under the written agreements pursuant to which the original Lien arose, could secure the original Lien (plus improvements and accessions to, such property or proceeds or distributions thereof); and 

(b) the Indebtedness secured by the new Lien is not increased to any amount greater than the sum of (x) the outstanding
principal amount or, if greater, committed amount, of the Permitted Refinancing Indebtedness and (y) an amount necessary to pay any fees and expenses, including premiums, related to such refinancing, refunding, extension, renewal or
replacement; 

  
 -19- 

 (12) Liens of the Company or any Restricted Subsidiary of the Company with
respect to obligations that do not exceed the greater of (x) $350.0 million and (y) 1.25% of Consolidated Total Assets at any one time outstanding; 

(13) survey title exceptions, title defects, encumbrances, easements, reservations of, or rights of others for, rights of way,
sewers, electric lines, telegraph or telephone lines and other similar purposes or zoning or other restrictions as to the use of real property not materially interfering with the business of the Company and its Restricted Subsidiaries taken as a
whole; 
 (14) Liens arising by operation of law in favor of landlords, mechanics, carriers, warehousemen, materialmen,
laborers, employees, suppliers or the like, incurred in the ordinary course of business for sums which are not yet delinquent or are being contested in good faith by negotiations or by appropriate proceedings which suspend the collection thereof;

 (15) Liens arising out of judgments, decrees, orders or awards in respect of which the Company or a Restricted Subsidiary
of the Company shall in good faith be prosecuting an appeal or proceedings for review which appeal or proceedings shall not have been finally terminated, or if the period within which such appeal or proceedings may be initiated shall not have
expired; 
 (16) Liens securing the Notes issued on the Issue Date and the Note Guarantees with respect thereto; 

(17) Liens securing one or more local working capital facilities of Foreign Subsidiaries, so long as such Liens do not extend
to the assets of any Person other than such foreign Restricted Subsidiaries; 
 (18) (a) Liens on assets of Foreign
Subsidiaries securing Indebtedness incurred by Foreign Subsidiaries pursuant to Section 4.9(b)(xiii) hereof and (b) Liens on assets of Non-Guarantor Subsidiaries securing Indebtedness incurred by Non-Guarantor Subsidiaries; 
 (19) Liens imposed pursuant to licenses, sublicenses, leases
and subleases which do not materially interfere with the ordinary conduct of the business of the Company and its Restricted Subsidiaries taken as a whole; 

(20) Liens incurred to secure cash management services in the ordinary course of business; 

(21) customary restrictions on, or options, contracts or other agreements for, transfers of assets contained in agreements
related to any sale of assets pending such sale; provided that such restrictions apply only to the assets to be sold and such sale is otherwise permitted by this Indenture; 

(22) Liens securing obligations to the Trustee arising under this Indenture and similar Liens in favor of trustees, agents and
representatives arising under instruments governing Indebtedness permitted to be incurred under this Indenture; 
 (23) Liens
on trusts, cash or Cash Equivalents or other funds in connection with the defeasance (whether by covenant or legal defeasance), discharge or redemption of Indebtedness, pending consummation of a strategic transaction, or similar obligations;
provided that such defeasance, discharge or redemption is otherwise permitted by this Indenture; 
 (24) Liens to
secure any Indebtedness permitted to be incurred pursuant to Section 4.9 hereof, provided that, in the case of this clause (24), at the time of its incurrence and after giving pro forma effect thereto, the Secured Leverage Ratio would be
no greater than 3.50 to 1.0; and 

  
 -20- 

 (25) Liens securing obligations in an aggregate outstanding principal amount
not to exceed the greater of $600.0 million and 2.0% of Consolidated Total Assets. 
 In the event that a Permitted Lien meets the
criteria of more than one of the types of Permitted Liens (at the time of incurrence or at a later date), the Company in its sole discretion may divide, classify or from time to time reclassify all or any portion of such Permitted Lien in any manner
that complies with this definition and such Permitted Lien shall be treated as having been made pursuant only to the clause or clauses of the definition of “Permitted Lien” to which such Permitted Lien has been classified or reclassified.

 “Permitted Refinancing Indebtedness” means any Indebtedness of the Company or any of its Restricted Subsidiaries issued
in exchange for, or the net proceeds of which are used to extend, refinance, renew, replace, defease or refund other Indebtedness of the Company or any of its Restricted Subsidiaries (other than intercompany Indebtedness); provided, that:

 (1) the principal amount (or accreted value, if applicable) of such Permitted Refinancing Indebtedness does not exceed the
principal amount (or accreted value, if applicable) of the Indebtedness extended, refinanced, renewed, replaced, defeased or refunded (plus all accrued interest on the Indebtedness and the amount of all expenses and premiums incurred in connection
therewith); 
 (2) such Permitted Refinancing Indebtedness has a final maturity date later than the final maturity date of,
and has a Weighted Average Life to Maturity equal to or greater than the Weighted Average Life to Maturity of, the Indebtedness being extended, refinanced, renewed, replaced, defeased or refunded; 

(3) if the Indebtedness being extended, refinanced, renewed, replaced, defeased or refunded is contractually subordinated in
right of payment to the Notes, such Permitted Refinancing Indebtedness has a final maturity date later than the final maturity date of, and is subordinated in right of payment to, the Notes on terms at least as favorable to the Holders of Notes as
those contained in the documentation governing the Indebtedness being extended, refinanced, renewed, replaced, defeased or refunded; and 

(4) if the Indebtedness being refinanced is Indebtedness of the Company or a Note Guarantor, such Permitted Refinancing
Indebtedness is also Indebtedness of the Company or a Note Guarantor. 
 “Permitted Warrant Transaction” means any call
option, warrant or right to purchase (or similar transaction), on the Company’s or a Restricted Subsidiary’s Equity Interests, regardless of the issuer or seller thereof, issued substantially concurrently with any purchase of a related
Permitted Bond Hedge Transaction. 
 “Person” means any individual, corporation, partnership, joint venture, association,
joint-stock company, trust, unincorporated organization, limited liability company or government or other entity. 

“Principal” or “principal” of a debt security, including the Notes, means the principal of the security
plus, when appropriate, the premium, if any, on the security. 
 “Pro Forma Cost Savings” means, without duplication, with
respect to any period, the reductions in costs and other operating improvements or operating synergies with respect to an acquisition that are reasonably identifiable, factually supportable, reasonably attributable to the action specified and
reasonably anticipated to result from such actions; provided, that the relevant actions have been taken or initiated and the benefits resulting therefrom are anticipated to be realized within 18 months of the date of such acquisition
(including, for the avoidance of doubt, actions that will be taken or initiated so long as the benefits resulting therefrom are anticipated to be realized within 18 months of the date of such acquisition), as if all such reductions in costs and
other operating improvements or operating synergies had been effected as of the beginning of such period, decreased by any recurring incremental expenses incurred or to be incurred during such four-quarter period in order to achieve such reduction
in costs. Pro Forma Cost Savings described in the preceding sentence shall be calculated in good faith by a responsible financial or accounting officer of the Company and shall be accompanied by a certificate delivered to

  
 -21- 

 
the Trustee from the Company’s chief financial officer that generally outlines the specific actions taken or expected to be taken and the net cost reductions and other operating improvements
or operating synergies achieved or expected to be achieved from each such action and certifies that such cost reductions and other operating improvements or synergies meet the criteria set forth in the preceding sentence. 

“Qualified Securitization Transaction” means any transaction or series of transactions that may be entered into by the
Company or any of its Restricted Subsidiaries pursuant to which the Company or such Restricted Subsidiary may sell, convey, grant a security interest in or otherwise transfer to a Securitization Special Purpose Entity, and such Securitization
Special Purpose Entity may sell, convey, grant a security interest in or otherwise transfer to any other Person, any Securitization Program Assets (whether now existing or arising in the future). 

“Rating Agency” means (1) each of Moody’s and S&P and (2) if Moody’s or S&P ceases to rate the
Notes for reasons outside of the control of the Company, a nationally recognized statistical rating organization under the Exchange Act selected by the Company as a replacement agency for Moody’s or S&P, as the case may be. 

“Redemption Date” or “redemption date” means the date specified for redemption of the Notes in accordance
with the terms thereof and this Indenture. 
 “Regulation S” means Regulation S under the Securities Act or any successor
to such regulation. 
 “Regulation S Global Note” means a 2028 Regulation S Global Note or 2029 Regulation S Global Note,
as applicable. 
 “Regulation S-X” means Regulation
S-X under the Securities Act or any successor to such regulation. 
 “Restricted Global
Note” means a permanent Global Note that is substantially in the form of Exhibit A-1 or Exhibit A-2, as applicable, attached hereto that bears the
Global Note Legend and that has the “Schedule of Exchanges of Interests in the Global Note” attached thereto, and that is deposited with or on behalf of and registered in the name of the Depositary or a nominee of the Depositary,
representing Notes that bear the Legend. 
 “Restricted Investment” means an Investment other than a Permitted Investment.

 “Restricted Note” means a Note required to bear the restricted legend set forth in the form of Notes set forth in
Exhibit A-1 or Exhibit A-2, as applicable, of this Indenture. 

“Restricted Subsidiary” of a Person means any Subsidiary of the referent Person that is not an Unrestricted Subsidiary. For
the avoidance of doubt, BHA shall at all times be considered a Restricted Subsidiary of the Company. 
 “Rule 144” means
Rule 144 promulgated under the Securities Act or any successor to such rule. 
 “Rule 144A” means Rule 144A promulgated
under the Securities Act or any successor to such rule. 
 “Rule 903” means Rule 903 promulgated under the Securities Act.

 “Rule 904” means Rule 904 promulgated under the Securities Act. 

“S&P” means S&P Global Ratings, or any successor to the rating agency business thereof. 

“SEC” means the U.S. Securities and Exchange Commission. 

“Secured Leverage Ratio” means the ratio of (i) the Total Consolidated Indebtedness of the Company and its Restricted
Subsidiaries that is secured by a Lien on assets of the Company and its Restricted Subsidiaries that are also pledged to secure the Credit Agreement and the Existing Secured Notes, after giving effect to all incurrences and repayments of
Indebtedness on the relevant transaction date (net of unrestricted cash and Cash Equivalents of 

  
 -22- 

 
the Company and its Restricted Subsidiaries as of such date); provided, that in the event the Company proposes to incur Indebtedness pursuant to clauses (i) and (xx) of
Section 4.9(b) hereof on the same day, Indebtedness incurred under clause (1) on that date shall not be included in the calculation of the Secured Leverage Ratio for purposes of the calculation to be made pursuant to such clause (xx)
on such date or clause (24) of the definition of Permitted Liens on such date (but shall, for the avoidance of doubt, be included in any and all subsequent calculations of the Secured Leverage Ratio to the extent then outstanding and secured)
to (ii) Consolidated Cash Flow of the Company for the most recent four consecutive full fiscal quarters for which internal financial statements are available ending on or prior to the transaction date. In addition, the “Secured Leverage
Ratio” will be calculated in a manner consistent with the definition of “Fixed Charge Coverage Ratio” to give effect to transactions that would require pro forma adjustments to such ratio. 

To the extent the Company elects pursuant to an Officers’ Certificate delivered to the Trustee to treat all or any portion of the
commitment under any Indebtedness as being incurred prior to the actual incurrence thereof pursuant to Section 4.9(e) hereof, the Company shall deem all or such portion of such commitment of such Indebtedness, as applicable, as having been
incurred and to be outstanding for purposes of calculating the Secured Leverage Ratio for any period in which the Company makes any such election and for any subsequent period until such commitments or such Indebtedness, as applicable, are no longer
outstanding. 
 “Securities Act” means the U.S. Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder, as in effect from time to time. 
 “Securitization Program Assets” means (i) all receivables
customarily transferred in connection with asset securitization transactions by the Company or any of its Restricted Subsidiaries pursuant to documents relating to any Qualified Securitization Transaction, (ii) all rights arising under the
documentation governing or related to receivables (including rights in respect of Liens securing such receivables and other credit support in respect of such receivables), any proceeds of such receivables and any lockboxes or accounts in which such
proceeds are deposited, spread accounts and other similar accounts (and any amounts on deposit therein) established in connection with a Qualified Securitization Transaction, any warranty, indemnity, dilution and other intercompany claim arising out
of the documents relating to such Qualified Securitization Transaction and other assets which are customarily transferred or in respect of which security interests are customarily granted in connection with asset securitizations involving accounts
receivable and (iii) all collections (including recoveries) and other proceeds of the assets described in the foregoing clauses (i) and (ii). 

“Securitization Special Purpose Entity” means a Person (including, without limitation, a Restricted Subsidiary) created in
connection with the transactions contemplated by a Qualified Securitization Transaction, which Person engages in no activities and holds no assets other than those incidental to such Qualified Securitization Transaction. 

“Significant Subsidiary” means any Subsidiary of the Company that would be a “significant subsidiary” as defined in
Article 1, Rule 1-02 of Regulation S-X, promulgated by the SEC, as such regulation is in effect on the date hereof. 

“Standard Securitization Undertakings” means all representations, warranties, covenants, indemnities, performance guarantees
and servicing obligations entered into by the Company or any Subsidiary (other than a Securitization Special Purpose Entity) which are customary in connection with any Qualified Securitization Transaction. 

“Stated Maturity” means, with respect to any installment of interest or principal on any series of Indebtedness, the date on
which the payment of interest or principal was scheduled to be paid in the original documentation governing such Indebtedness, and will not include any contingent obligations to repay, redeem or repurchase any such interest or principal prior to the
date originally scheduled for the payment thereof. 

  
 -23- 

 “Subsidiary” means, with respect to any specified Person: 

(1) any corporation, association or other business entity of which more than 50% of the total voting power of shares of Capital
Stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees of the corporation, association or other business entity is at the time owned or controlled, directly or indirectly, by
that Person or one or more of the other Subsidiaries of that Person (or a combination thereof); and 
 (2) any partnership
(a) the sole general partner or the managing general partner of which is such Person or a Subsidiary of such Person or (b) the only general partners of which are that Person or one or more Subsidiaries of that Person (or any combination
thereof). 
 Unless the context otherwise requires, references to “Subsidiary” herein refer to a subsidiary of the Company. 

“TIA” means the Trust Indenture Act of 1939, as amended, and the rules and regulations thereunder as in effect on the date of
this Indenture, except to the extent any amendment to the Trust Indenture Act expressly provides for application of the Trust Indenture Act as in effect on another date. 

“Total Consolidated Indebtedness” means Indebtedness consisting of Indebtedness for borrowed money, Capital Lease
Obligations, letters of credit (only to the extent of any unreimbursed drawings thereunder), debt obligations evidenced by promissory notes and similar instruments and Guarantees in respect of any of the foregoing. 

“Total Leverage Ratio” means the ratio of (i) Total Consolidated Indebtedness of the Company and its Restricted
Subsidiaries, after giving effect to all incurrences and repayments of Indebtedness on the transaction date (net of unrestricted cash and Cash Equivalents of the Company and its Restricted Subsidiaries as of such date), to (ii) Consolidated
Cash Flow of the Company and its Restricted Subsidiaries for the most recent four consecutive full fiscal quarters for which internal financial statements are available ending on or prior to the transaction date. In addition, the “Total
Leverage Ratio” will be calculated in a manner consistent with the definition of “Fixed Charge Coverage Ratio” to give effect to transactions that would require pro forma adjustments to such ratio. 

To the extent the Company elects pursuant to an Officers’ Certificate delivered to the Trustee to treat all or any portion of the
commitment under any Indebtedness as being incurred prior to the actual incurrence thereof pursuant to Section 4.9(e) hereof, the Company shall deem all or such portion of such commitment of such Indebtedness, as applicable, as having been
incurred and to be outstanding for purposes of calculating the Total Leverage Ratio for any period in which the Company makes any such election and for any subsequent period until such commitments or such Indebtedness, as applicable, are no longer
outstanding. 
 “Treasury Rate” means, (x) with respect to the 2028 Notes, the rate per annum equal to the yield to
maturity at the time of computation of U.S. Treasury securities with a constant maturity most nearly equal to the period from such date of redemption to January 15, 2023, provided, however, that if the period from such date of
redemption to January 15, 2023 is not equal to the constant maturity of a U.S. Treasury security for which a weekly average yield is given, the Treasury Rate shall be obtained by linear interpolation (calculated to the nearest one-twelfth of a year) from the weekly average yields of U.S. Treasury securities for which such yields are given, except that if the period from such date of redemption to January 15, 2023 is less than one
year, the weekly average yield on actually traded U.S. Treasury securities adjusted to a constant maturity of one year shall be used; and (y) with respect to the 2029 Notes, the rate per annum equal to the yield to maturity at the time of
computation of U.S. Treasury securities with a constant maturity most nearly equal to the period from such date of redemption to May 30, 2024, provided, however, that if the period from such date of redemption to May 30, 2024
is not equal to the constant maturity of a U.S. Treasury security for which a weekly average yield is given, the Treasury Rate shall be obtained by linear interpolation (calculated to the nearest one-twelfth
of a year) from the weekly average yields of U.S. Treasury securities for which such yields are given, except that if the period from such date of redemption to May 30, 2024 is less than one year, the weekly average yield on actually traded
U.S. Treasury securities adjusted to a constant maturity of one year shall be used. In each such instance, the Company shall obtain the Treasury Rate. 

  
 -24- 

 “Trust Officer” shall mean, when used with respect to the Trustee, any
officer within the corporate trust department of the Trustee, including any vice president, assistant secretary, associate, secretary, trust officer or any other officer of the Trustee who customarily performs functions similar to those performed by
the Persons who at the time shall be such officers, respectively, or to whom any corporate trust matter is referred because of such person’s knowledge of and familiarity with the particular subject and who shall have direct responsibility for
the administration of this Indenture. 
 “Trustee” means The Bank of New York Mellon, a New York banking corporation, until
a successor replaces it in accordance with the provisions of this Indenture, and thereafter means the successor. 
 “UCC”
or “Uniform Commercial Code” means the Uniform Commercial Code as the same may be in effect from time to time in the State of New York or the Uniform Commercial Code (or similar code or statute) of another jurisdiction. 

“Unrestricted Subsidiary” means (1) Closed Joint Stock Company Valeant Pharma, (2) Hythe Property Incorporated,
(3) Valeant Pharmaceuticals Nominee Bermuda, (4) 0938638 B.C. ULC, (5) Oceana Therapeutics Limited and (6) any other Subsidiary of the Company that is designated by the Board of Directors of the Company as an Unrestricted Subsidiary
pursuant to a board resolution, but only to the extent that such Subsidiary: 
 (1) has no Indebtedness other than Non-Recourse Debt; 
 (2) is not party to any agreement, contract, arrangement or
understanding with the Company or any Restricted Subsidiary of the Company unless the terms of any such agreement, contract, arrangement or understanding are not materially less favorable to the Company or such Restricted Subsidiary, in each case,
taken as a whole, than those that might be obtained at the time from Persons who are not Affiliates of the Company; 
 (3) is
a Person with respect to which neither the Company nor any of its Restricted Subsidiaries has any direct or indirect obligation (a) to subscribe for additional Equity Interests or (b) to maintain or preserve such Person’s financial
condition or to cause such Person to achieve any specified levels of operating results; and 
 (4) has not Guaranteed or
otherwise directly or indirectly provided credit support for any Indebtedness of the Company or any of its Restricted Subsidiaries. 
 Any
designation of a Subsidiary of the Company as an Unrestricted Subsidiary will be evidenced to the Trustee by filing with the Trustee a certified copy of the board resolution giving effect to such designation and an Officers’ Certificate
certifying that such designation complied with the preceding conditions and was permitted by Section 4.8 hereof. If, at any time, any Unrestricted Subsidiary would fail to meet the preceding requirements as an Unrestricted Subsidiary, it will
thereafter cease to be an Unrestricted Subsidiary for purposes of this Indenture and any Indebtedness of such Subsidiary will be deemed to be incurred by a Restricted Subsidiary of the Company as of such date, and, if such Indebtedness is not
permitted to be incurred as of such date under Section 4.9 hereof, the Company will be in default of such covenant. The Board of Directors of the Company may at any time designate any Unrestricted Subsidiary to be a Restricted Subsidiary;
provided, that such designation will be deemed to be an incurrence of Indebtedness and, if applicable, related Liens by a Restricted Subsidiary of the Company of any outstanding Indebtedness and, if applicable, related Liens of such
Unrestricted Subsidiary and such designation will only be permitted if (1) such Indebtedness and, if applicable, related Liens are permitted under Section 4.9 hereof and, if applicable, Section 4.11 hereof (other than clause
(3) under the definition of “Permitted Liens”), calculated, if applicable, on a pro forma basis as if such designation had occurred at the beginning of the four-quarter reference period; and (2) no Default or Event of Default
would be in existence following such designation. 
 “Upfront Payments” means any upfront or similar payments made in
connection with any drug or pharmaceutical product research and development or collaboration arrangements or the closing of any Drug Acquisition. 

  
 -25- 

 “Vice President” when used with respect to the Company or the Trustee,
means any vice president, whether or not designated by a number or a word or words added before or after the title “vice president.” 

“Voting Stock” of any Person as of any date means the Capital Stock of such Person that is at the time entitled to vote in
the election of the Board of Directors of such Person. 
 “Weighted Average Life to Maturity” means, when applied to any
Indebtedness at any date, the number of years obtained by dividing: 
 (1) the sum of the products obtained by multiplying
(a) the amount of each then remaining installment, sinking fund, serial maturity or other required payments of principal, including payment at final maturity, in respect of the Indebtedness, by (b) the number of years (calculated to the
nearest one-twelfth) that will elapse between such date and the making of such payment; by 

(2) the then outstanding principal amount of such Indebtedness. 

“WURA” means the Winding-Up and Restructuring Act (Canada). 

Section 1.2 Other Definitions. 
  

			
	 TERM
	  	DEFINED IN
SECTION
	 “Acceptable Commitment”
	  	4.14(b)
	 “Additional Amounts”
	  	4.21(a)
	 “Affiliate Transaction”
	  	4.13(a)
	 “Agent Members”
	  	2.1(b)
	 “Agreed Guarantee Principles”
	  	4.15
	 “Asset Sale Offer”
	  	4.14(c)/3.14
	 “Authorized Agent”
	  	11.16
	 “Benefited Party”
	  	10.1(b)
	 “Change in Tax Law”
	  	3.7(h)
	 “Change of Control Offer”
	  	3.8(b)
	 “Change of Control Purchase Date”
	  	3.8(b)(iii)
	 “Change of Control Purchase Notice”
	  	3.8(c)
	 “Change of Control Purchase Price”
	  	3.8(a)
	 “Company Notice”
	  	3.8(b)
	 “Company Order”
	  	2.2
	 “Covenant Defeasance”
	  	8.3
	 “Declined Asset Sale Proceeds”
	  	4.14(c)
	 “Event of Default”
	  	6.1
	 “Excess Proceeds”
	  	4.14(c)
	 “FATCA”
	  	4.21(b)(vii)
	 “Fixed Amounts”
	  	11.15(c)
	 “incur”
	  	4.9(a)
	 “Incurrence-Based Amounts”
	  	11.15(c)
	 “Judgment Currency”
	  	11.17
	 “Legal Defeasance”
	  	8.2
	 “Legal Holiday”
	  	11.7
	 “Legend”
	  	2.12(a)
	 “Offer Amount”
	  	3.14
	 “Offer Period”
	  	3.14
	 “Paying Agent”
	  	2.3
	 “Payment Default”
	  	6.1(e)
	 “Payor”
	  	4.21(a)

  
 -26- 

			
	 TERM
	  	DEFINED IN
SECTION
	 “Permitted Debt”
	  	4.9(b)
	 “Purchase Date”
	  	3.14
	 “Registrar”
	  	2.3
	 “Regulation 803 Reimbursement”
	  	4.21(d)
	 “Relevant Taxing Jurisdiction”
	  	4.21(a)
	 “Restricted Amount”
	  	4.14(b)
	 “Restricted Payments”
	  	4.8(a)
	 “Retained Asset Sale Proceeds”
	  	4.14(b)
	 “Tax”
	  	4.21(a)

 Section 1.3 [Reserved]. 

Section 1.4 Rules of Construction. Unless the context otherwise requires: 

(A) a term has the meaning assigned to it; 

(B) an accounting term not otherwise defined has the meaning assigned to it in accordance with GAAP; 

(C) words in the singular include the plural, and words in the plural include the singular; 

(D) provisions apply to successive events and transactions; 

(E) the term “merger” includes a statutory share exchange and the term “merged” has a correlative meaning;

 (F) the masculine gender includes the feminine and the neuter; 

(G) references to agreements and other instruments include subsequent amendments thereto; 

(H) “herein,” “hereof” and other words of similar import refer to this Indenture as a whole and not to any
particular Article, Section or other subdivision; 
 (I) references to ratings by Moody’s or S&P shall include any
successor equivalent ratings if either Moody’s or S&P changes its ratings scale subsequent to the date of this Indenture; 

(J) except as otherwise provided for herein, the Notes of each series will be treated as a single class for all purposes under
this Indenture, including, without limitation, waivers, amendments, redemptions and offers to purchase; and 
 (K) a
reference to a statute includes all regulations made pursuant to such statute and, unless otherwise specified, the provisions of any statute or regulation which amends, revises, restates, supplements or supersedes any such statute or any such
regulation. 
 ARTICLE 2 
 THE
SECURITIES 
 Section 2.1 Form and Dating. The Notes and the Trustee’s certificate of authentication with respect thereto
shall be substantially in the form set forth in Exhibit A-1, in the case of the 2028 Notes and Exhibit A-2, in the case of the 2029
Notes, which are incorporated in and made part of this Indenture. The Notes may have notations, legends or endorsements required by law, stock exchange rule or usage. The Company shall provide any 

  
 -27- 

 
such notations, legends or endorsements to the Trustee in writing. The Notes shall be in a minimum denomination of $2,000 and integral multiples of $1,000 in excess thereof. Each Note shall be
dated the date of its authentication. The Notes are being offered and sold by the Company in transactions exempt from, or not subject to, the registration requirements of the Securities Act. 

(a) Restricted Global Notes. All of the Notes are initially being offered and sold to (i) qualified institutional
buyers as defined in Rule 144A in reliance on Rule 144A under the Securities Act or (ii) outside the United States to persons other than U.S. persons in reliance upon Regulation S under the Securities Act, and shall be issued initially in the
form of one or more 144A Global Notes and Regulation S Global Notes, respectively, which shall be deposited on behalf of the purchasers of the Notes represented thereby with the Trustee, as custodian for the depositary, DTC, and registered in the
name of its nominee, Cede & Co., duly executed by the Company and authenticated by the Trustee as hereinafter provided. The aggregate principal amount of the Restricted Global Notes may from time to time be increased or decreased by
adjustments made on the records of the Notes Custodian as hereinafter provided, subject in each case to compliance with the Applicable Procedures. 

(b) Form of Notes. Notes issued in global form shall be substantially in the form of Exhibit A-1 attached hereto in the case of the 2028 Global Notes or Exhibit A-2 attached hereto in the case of the 2029 Global Notes (including the Global Note Legend
thereon and the “Schedule of Exchanges of Interests in the Global Note” attached thereto). Definitive Notes shall be substantially in the form of Exhibit A-1 or Exhibit A-2, as applicable, attached hereto (but without the Global Note Legend thereon and without the “Schedule of Exchanges of Interests in the Global Note” attached thereto). Each Global Note shall
represent such of the outstanding Notes of the applicable series as shall be specified therein and each shall provide that it shall represent the aggregate principal amount of outstanding Notes from time to time endorsed thereon and that the
aggregate principal amount of outstanding Notes represented thereby may from time to time be reduced or increased, as appropriate, to reflect exchanges and redemptions. Any endorsement of a Global Note to reflect the amount of any increase or
decrease in the aggregate principal amount of outstanding Notes represented thereby shall be made by the Trustee or the Notes Custodian, at the direction of the Trustee, in accordance with instructions given by the Holder thereof as required by
Section 2.12 hereof and shall be made on the records of the Trustee and the Depositary. 
 Members of, or participants
in, the Depositary (“Agent Members”) shall have no rights under this Indenture with respect to any Global Note held on their behalf by the Depositary or under the Global Note, and the Depositary (including, for this purpose, its
nominee) may be treated by the Company, the Trustee and any agent of the Company or the Trustee as the absolute owner and Holder of such Global Note for all purposes whatsoever. Notwithstanding the foregoing, nothing herein shall (A) prevent
the Company, the Trustee or any agent of the Company or the Trustee from giving effect to any written certification, proxy or other authorization furnished by the Depositary or (B) impair, as between the Depositary and its Agent Members, the
operation of customary practices governing the exercise of the rights of a Holder of any Note. 
 (c) Additional
Notes. Subject to compliance with the provisions of Section 4.9 hereof, the Company may issue Additional Notes of any series in an unlimited amount under this Indenture. 

(d) Regulation S Global Notes. Global Notes offered and sold in reliance on Regulation S shall initially be represented
by one or more Regulation S Global Notes, substantially in the form of Exhibit A-1 attached hereto in the case of the 2028 Regulation S Global Notes and Exhibit A-2 attached hereto in the case of the 2029 Regulation S Global Notes, with such applicable legends as are provided in Exhibit A-1 and Exhibit
A-2, respectively. The Regulation S Global Notes will be deposited, upon issuance, on behalf of the purchasers of the Notes represented thereby with the Trustee, as custodian for the Depositary and
registered in the name of the Depositary or the nominee of the Depositary, duly executed by the Company and authenticated by the Trustee as hereinafter provided. 

The aggregate principal amount of the Regulation S Global Notes may from time to time be increased or decreased by adjustments
made on the records of the Trustee and the Depositary or its nominee, as the case may be, in connection with transfers of interest as hereinafter provided. 

  
 -28- 

 (e) Book Entry Provisions. The Company shall execute and the Trustee
shall, in accordance with this Section 2.1(e), authenticate and deliver initially one or more Global Notes of each series that (i) shall be registered in the name of the applicable Depositary or its nominee, (ii) shall be delivered by
the Trustee to the applicable Depositary or pursuant to the applicable Depositary’s instructions and (iii) shall bear legends substantially in the form of the first paragraph of
Exhibit A-1 or Exhibit A-2 attached hereto. 

Section 2.2 Execution and Authentication. An Officer of the Company shall sign the Notes for the Company by manual or facsimile
signature. Typographic and other minor errors or defects in any such facsimile signature shall not affect the validity or enforceability of any Note which has been authenticated and delivered by the Trustee. 

If an Officer whose signature is on a Note no longer holds that office at the time the Trustee authenticates the Note, the Note shall be valid
nevertheless. 
 A Note shall not be valid until an authorized signatory of the Trustee manually signs the certificate of authentication on
the Note. The signature shall be conclusive evidence that the Note has been authenticated under this Indenture. 
 The Trustee shall
authenticate and make available for delivery the 2028 Notes for original issue in an initial aggregate principal amount of $750,000,000 and the 2029 Notes for original issue in an initial aggregate principal amount of $750,000,000 and Additional
Notes of either series, as contemplated by Section 2.1(c) hereof, in each case upon receipt of a written order of the Company signed by an Officer of the Company (a “Company Order”). The Company Order shall specify the amount
of Notes to be authenticated and shall provide that all such Notes will be represented by a Restricted Global Note and the date on which such issue of Notes is to be authenticated. For the avoidance of doubt, each of the 2028 Notes and the 2029
Notes shall constitute a separate series hereunder. The aggregate principal amount of any series of Notes outstanding at any time may not exceed the applicable amounts in the foregoing sentence, except as provided in Sections 2.1(c) and 2.7 hereof.

 The Trustee shall act as the initial authenticating agent. Thereafter, the Trustee may appoint an authenticating agent acceptable to the
Company to authenticate Notes. An authenticating agent may authenticate Notes whenever the Trustee may do so. Each reference in this Indenture to authentication by the Trustee includes authentication by such agent. An authenticating agent shall have
the same rights as an Agent to deal with the Company or an Affiliate of the Company. 
 The Notes shall be issuable only in registered form
without coupons and only in minimum denominations of $2,000 principal amount and integral multiples of $1,000 in excess thereof. 

Section 2.3 Registrar and Paying Agent. The Company shall maintain one or more offices or agencies where Notes may be presented
for registration of transfer or for exchange (each, a “Registrar”), one or more offices or agencies where Notes may be presented for payment (each, a “Paying Agent”) and one or more offices or agencies where notices
and demands to or upon the Company in respect of the Notes and this Indenture may be served. The Company will at all times maintain a Paying Agent, Registrar and an office or agency where notices and demands to or upon the Company in respect of the
Notes and this Indenture may be served in the Borough of Manhattan in the City of New York. 
 The Company shall enter into an appropriate
agency agreement with any Agent not a party to this Indenture. The agreement shall implement the provisions of this Indenture that relate to such Agent. The Company shall notify the Trustee of the name and address of any Agent not a party to this
Indenture. If the Company fails to maintain a Registrar, Paying Agent or agent for service of notices and demands in any place required by this Indenture, or fail to give the foregoing notice, the Trustee shall act as such. The Company or any
Affiliate of the Company may act as Paying Agent (except for the purposes of Section 4.1 and Article 8). 

  
 -29- 

 The Company hereby initially designates the Trustee as Paying Agent, Registrar and Notes
Custodian, and the office or agency of the Trustee in the Borough of Manhattan, The City of New York (which shall initially be the office located at 240 Greenwich Street, New York, NY 10286) as one such office or agency of the Company for each of
the aforesaid purposes. 
 The Company may change the Paying Agents or Registrar in its sole discretion without prior notice to the Holders.

 Section 2.4 Paying Agent to Hold Money in Trust. Prior to 11:00 a.m., New York City time, on each due date of the principal
of or interest on any Notes, the Company shall deposit with a Paying Agent a sum sufficient to pay such principal or interest, if any, so becoming due. A Paying Agent shall hold in trust for the benefit of Noteholders or the Trustee all money held
by the Paying Agent for the payment of principal of or interest on the Notes, and shall notify the Trustee of any default by the Company (or any other obligor on the Notes) in making any such payment. If the Company or an Affiliate of the Company
acts as Paying Agent, the Company or such Affiliate shall, before 11:00 a.m., New York City time, on each due date of the principal of or interest on any Notes, segregate the money and hold it as a separate trust fund. The Company at any time may
require a Paying Agent to pay all money held by it to the Trustee, and the Trustee may at any time during the continuance of any Default, upon written request to a Paying Agent, require such Paying Agent to pay forthwith to the Trustee all sums so
held in trust by such Paying Agent. Upon doing so, the Paying Agent (other than the Company) shall have no further liability for the money. For the avoidance of doubt, in no event shall any Paying Agent (unless the Company or an Affiliate of the
Company is acting as Paying Agent) be required to advance funds for any payment on the Notes of any series hereunder or to make any such payment until the Paying Agent has actually received such funds from the Company. 

Section 2.5 Noteholder Lists. The Trustee shall preserve in as current a form as is reasonably practicable the most recent list
available to it of the names and addresses of Noteholders. If the Trustee is not the Registrar, the Company shall furnish to the Trustee on or before each interest payment date, and at such other times as the Trustee may request in writing, a list
in such form and as of such date as the Trustee may reasonably require of the names and addresses of Noteholders. 
 Section 2.6
Transfer and Exchange. 
 (a) Subject to compliance with any applicable additional requirements contained in Section 2.12 hereof,
when a Note is presented to a Registrar with a request to register a transfer thereof or to exchange such Note for an equal principal amount of Notes of the same series of other authorized denominations, the Registrar shall register the transfer or
make the exchange as requested; provided, however, that every Note presented or surrendered for registration of transfer or exchange shall be duly endorsed or accompanied by an assignment form and, if applicable, a transfer certificate
in the form(s) included in Exhibit A-1 (in the case of the 2028 Notes), Exhibit A-2 (in the case of the 2029 Notes) and
Exhibit C, as applicable, and in form satisfactory to the Registrar, duly executed by the Holder thereof or its attorney duly authorized in writing. To permit registration of transfers and exchanges, upon surrender of any
Note for registration of transfer or exchange at an office or agency maintained pursuant to Section 2.3 hereof, the Company shall execute and the Trustee shall authenticate Notes of a like aggregate principal amount of the same series at the
Registrar’s request. Any exchange or transfer shall be without charge, except that the Company or the Registrar may require payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto, and
provided, that this sentence shall not apply to any exchange pursuant to Section 2.10, 2.12(a), 3.6, 3.11 or 9.5 hereof. 

Neither the Company, any Registrar nor the Trustee shall be required to exchange or register a transfer of any Notes of any series or portions
thereof in respect of which a Change of Control Purchase Notice or a notice in connection with an Asset Sale Offer has been delivered and not withdrawn by the Holder thereof (except, in the case of the purchase of a Note in part, the portion thereof
not to be purchased). 
 All Notes of any series issued upon any transfer or exchange of Notes shall be valid obligations of the Company,
evidencing the same debt and entitled to the same benefits under this Indenture, as the Notes of such series surrendered upon such transfer or exchange. 

  
 -30- 

 (b) Any Registrar appointed pursuant to Section 2.3 hereof shall provide to the Trustee
such information as the Trustee may reasonably require in connection with the delivery by such Registrar of Notes of any series upon transfer or exchange of Notes of such series. 

(c) Each Holder of a Note agrees to indemnify the Company and the Trustee against any liability that may result from the transfer, exchange or
assignment of such Holder’s Note in violation of any provision of this Indenture and/or applicable United States federal, state, Canadian federal, provincial or territorial securities law. 

Section 2.7 Replacement Notes. If any mutilated Note is surrendered to the Company, a Registrar or the Trustee, or the Company, a
Registrar and the Trustee receive evidence to their satisfaction of the destruction, loss or theft of any Note, and there is delivered to the Company, the applicable Registrar and the Trustee such security or indemnity as will be required by them to
save each of them harmless, then, in the absence of notice to the Company, such Registrar or the Trustee that such Note has been acquired by a bona fide purchaser, the Company shall execute, and upon its written request the Trustee shall
authenticate and deliver, in exchange for any such mutilated Note or in lieu of any such destroyed, lost or stolen Note, a new Note of like tenor, principal amount and series, bearing a number not contemporaneously outstanding. 

In case any such mutilated, destroyed, lost or stolen Note has become or is about to become due and payable, or is about to be purchased by
the Company pursuant to Article 3, the Company in its discretion may, instead of issuing a new Note, pay or purchase such Note, as the case may be. 

Upon the issuance of any new Notes under this Section 2.7, the Company may require the payment of a sum sufficient to cover any tax or
other governmental charge that may be imposed in relation thereto and any other reasonable expenses (including the reasonable fees and expenses of the Trustee or the Registrar) in connection therewith. 

Every new Note issued pursuant to this Section 2.7 in lieu of any mutilated, destroyed, lost or stolen Note shall constitute an original
additional contractual obligation of the Company, whether or not the mutilated, destroyed, lost or stolen Note shall be at any time enforceable by anyone, and shall be entitled to all benefits of this Indenture equally and proportionately with any
and all other Notes of such series duly issued hereunder. 
 The provisions of this Section 2.7 are (to the extent lawful) exclusive
and shall preclude (to the extent lawful) all other rights and remedies with respect to the replacement or payment of mutilated, destroyed, lost or stolen Notes. 

Section 2.8 Outstanding Notes. Notes of a series outstanding at any time are all Notes of such series authenticated by the
Trustee, except for those canceled by it, those delivered to it for cancellation or surrendered for transfer or exchange and those described in this Section 2.8 as not outstanding. 

If a Note is replaced pursuant to Section 2.7 hereof, it ceases to be outstanding unless the Company receives proof satisfactory to it
that the replaced Note is held by a bona fide purchaser. 
 If a Paying Agent (other than the Company or an Affiliate of the Company) holds
on a Redemption Date, Change of Control Purchase Date or the Final Maturity Date money sufficient to pay the principal of (including premium, if any) and interest on Notes (or portions thereof) payable on that date, then on and after such Redemption
Date, Change of Control Purchase Date or the Final Maturity Date, as the case may be, such Notes (or portions thereof, as the case may be) shall cease to be outstanding and interest on them shall cease to accrue. 

Subject to the restrictions contained in Section 2.9 hereof, a Note does not cease to be outstanding because the Company or an Affiliate
of the Company holds the Note. 
 Section 2.9 Treasury Notes. In determining whether the Holders of the required principal
amount of Notes of a series have concurred in any notice, direction, waiver or consent, Notes of such series owned by the Company or any other obligor on the Notes of such series or by any Affiliate of the Company or of such other obligor shall be
disregarded, except that, for purposes of determining whether the Trustee shall be protected in 

  
 -31- 

 
relying on any such notice, direction, waiver or consent, only Notes of such series which a Trust Officer of the Trustee actually knows are so owned shall be so disregarded. Notes of a series so
owned which have been pledged in good faith shall not be disregarded if the pledgee establishes to the satisfaction of the Trustee the pledgee’s right so to act with respect to the Notes of such series and that the pledgee is neither the
Company nor any other obligor on the Notes of such series or any Affiliate of the Company or of such other obligor. 
 Section 2.10
Temporary Notes. Until Definitive Notes are ready for delivery, the Company may prepare and execute, and, upon receipt of a Company Order, the Trustee shall authenticate and deliver, temporary Notes. Temporary Notes shall be substantially in
the form of Definitive Notes but may have variations that the Company with the consent of the Trustee considers appropriate for temporary Notes. Without unreasonable delay, the Company shall prepare and the Trustee shall authenticate and deliver
Definitive Notes in exchange for temporary Notes. 
 Section 2.11 Cancellation. The Company at any time may deliver Notes to the
Trustee for cancellation. The Registrar and the Paying Agent shall forward to the Trustee or its agent any Notes surrendered to them for transfer, exchange, payment or conversion. The Trustee and no one else shall cancel, in accordance with its
standard procedures, all Notes surrendered for transfer, exchange, payment, conversion or cancellation and shall deliver the canceled Notes to the Company. All Notes which are purchased or otherwise acquired by the Company or any of its Subsidiaries
prior to the Final Maturity Date of such Notes may be delivered to the Trustee for cancellation or resold. The Company may not hold or resell such Notes or issue any new Notes to replace any Notes delivered for cancellation 

Section 2.12 Legend; Additional Transfer and Exchange Requirements. 

(a) If Notes are issued upon the transfer, exchange or replacement of Notes subject to restrictions on transfer and bearing the legends set
forth on the form of Notes attached hereto as Exhibit A-1 (in the case of the 2028 Notes) and Exhibit A-2 (in the case of the 2029
Notes), as applicable (collectively, the “Legend”), or if a request is made to remove the Legend on a Note, the Notes so issued shall bear the Legend, or the Legend shall not be removed, as the case may be, unless there is delivered
to the Company such satisfactory evidence, which shall include an opinion of counsel if requested by the Company, as may be reasonably required by the Company, that neither the Legend nor the restrictions on transfer set forth therein are required
to ensure that transfers thereof comply with the provisions of Rule 144 under the Securities Act or that such Notes are not “restricted” within the meaning of Rule 144 under the Securities Act; provided, that no such evidence need
be supplied in connection with the sale of such Note pursuant to a registration statement that is effective at the time of such sale. Upon (i) provision of satisfactory evidence if requested, or (ii) notification by the Company to the
Trustee and Registrar of the sale of such Note pursuant to a registration statement that is effective at the time of such sale, the Trustee, at the written direction of the Company, shall authenticate and deliver a Note of the same series that does
not bear the Legend. If the Legend is removed from the face of a Note and the Note is subsequently held by an Affiliate of the Company, the Legend shall be reinstated. 

(b) A Global Note may not be transferred, in whole or in part, to any Person other than the Depositary or a nominee or any successor thereof,
and no such transfer to any such other Person may be registered; provided, that the foregoing shall not prohibit any transfer of a Note that is issued in exchange for a Global Note but is not itself a Global Note; provided
further, that in no event shall a beneficial interest in a Regulation S Global Note be transferred to a U.S. Person prior to the receipt by the Registrar of any certificates required pursuant to Regulation S, as determined by the Company. No
transfer of a Note to any Person shall be effective under this Indenture or the Notes unless and until such Note has been registered in the name of such Person. Notwithstanding any other provisions of this Indenture or the Notes, transfers of a
Global Note, in whole or in part, shall be made only in accordance with this Section 2.12. 
 (c) Subject to the succeeding paragraph,
every Note shall be subject to the restrictions on transfer provided in the Legend. Whenever any Restricted Note is presented or surrendered for registration of transfer or for exchange for a Note registered in a name other than that of the Holder,
such Note must be accompanied by a certificate in substantially the form set forth in Exhibit A-1 or Exhibit A-2, as applicable, dated
the date of such surrender and signed by the Holder of such Note, as to compliance with such restrictions on transfer. The Registrar shall not be required to accept for such registration of transfer or exchange any Note not so accompanied by a
properly completed certificate. 

  
 -32- 

 (d) The restrictions imposed by the Legend upon the transferability of any Note shall cease
and terminate when such Note has been sold pursuant to an effective registration statement under the Securities Act or transferred in compliance with Rule 144 under the Securities Act (or any successor provision thereto) or, if earlier, upon the
expiration of the holding period applicable to sales thereof under Rule 144(d)(1)(ii) under the Securities Act (or any successor provision). Any Note as to which such restrictions on transfer shall have expired in accordance with their terms or
shall have terminated may, upon a surrender of such Note for exchange to the Registrar in accordance with the provisions of this Section 2.12 (accompanied, in the event that such restrictions on transfer have terminated by reason of a transfer
in compliance with Rule 144 or any successor provision, by, if requested by the Company or the Registrar, an opinion of counsel reasonably acceptable to the Company and addressed to the Company to the effect that the transfer of such Note has been
made in compliance with Rule 144 or such successor provision), be exchanged for a new Note, of like tenor, series and aggregate principal amount, which shall not bear the restrictive Legend. The Company shall inform the Trustee of the effective date
of any registration statement registering any Notes under the Securities Act. The Trustee shall not be liable for any action taken or omitted to be taken by it in good faith in accordance with the aforementioned opinion of counsel or registration
statement. 
 (e) As used in this Section 2.12, the term “transfer” encompasses any sale, pledge, transfer, hypothecation or
other disposition of any Note. 
 (f) The provisions of clauses (iii), (iv) and (v) below shall apply only to Global Notes: 

(i) Notwithstanding any other provisions of this Indenture or the Notes, a Global Note shall not be exchanged in whole or in
part for a Note of such series registered in the name of any Person other than the Depositary or one or more nominees thereof, provided, that a Global Note of a series may be exchanged for Notes of such series registered in the names of any
person designated by the Depositary in the event that (A) the Depositary has notified the obligors that it is unwilling or unable to continue as Depositary for such Global Note and the Company fails to appoint a successor Depositary or
(B) an Event of Default has occurred and is continuing with respect to the Notes of such series. Any Global Note exchanged pursuant to clause (A) above shall be so exchanged in whole and not in part, and any Global Note exchanged pursuant
to clause (B) above may be exchanged in whole or from time to time in part as directed by the applicable Depositary. Any Note issued in exchange for a Global Note or any portion thereof shall be a Global Note; provided, that any such
Note so issued that is registered in the name of a Person other than the Depositary or a nominee thereof shall not be a Global Note. 

(ii) Notes issued in exchange for a Global Note of a series or any portion thereof shall be issued in definitive, fully
registered form, without interest coupons, shall be of the same series, shall have an aggregate principal amount equal to that of such Global Note or portion thereof to be so exchanged, shall be registered in such names and shall be in such
authorized denominations as the Depositary shall designate and shall bear the applicable legends provided for herein. Any Global Note to be exchanged in whole shall be surrendered by the Depositary to the Trustee, as Registrar. With regard to any
Global Note to be exchanged in part, either such Global Note shall be so surrendered for exchange or, if the Trustee is acting as custodian for the Depositary or its nominee with respect to such Global Note, the principal amount thereof shall be
reduced, by an amount equal to the portion thereof to be so exchanged, by means of an appropriate adjustment made on the records of the Trustee. Upon any such surrender or adjustment, the Trustee shall authenticate and deliver Notes of the same
series issuable on such exchange to or upon the order of the Depositary or an authorized representative thereof. 
 (iii)
Subject to the provisions of clause (v) below, the registered Holder may grant proxies and otherwise authorize any Person, including Agent Members and persons that may hold interests through Agent Members, to take any action which a Holder is
entitled to take under this Indenture or the Notes. 

  
 -33- 

 (iv) In the event of the occurrence of any of the events specified in clause
(i) above, the obligors will promptly make available to the Trustee a reasonable supply of applicable Definitive Notes in definitive, fully registered form, without interest coupons. 

(v) Neither Agent Members nor any other Persons on whose behalf Agent Members may act shall have any rights under this
Indenture with respect to any Global Note registered in the name of the Depositary or any nominee thereof, or under any such Global Note, and the Depositary or such nominee, as the case may be, may be treated by the Company, the Trustee and any
agent of the Company or the Trustee as the absolute owner and holder of such Global Note for all purposes whatsoever. Notwithstanding the foregoing, nothing herein shall prevent the Company, the Trustee or any agent of the Company or the Trustee
from giving effect to any written certification, proxy or other authorization furnished by the Depositary or such nominee, as the case may be, or impair, as between the Depositary, its Agent Members and any other Person on whose behalf an Agent
Member may act, the operation of customary practices of such Persons governing the exercise of the rights of a holder of any Note. 

(vi) The Trustee shall have no obligation or duty to monitor, determine or inquire as to compliance with any restrictions on
transfer imposed under this Indenture or under applicable law with respect to any transfer of any interest in any Note (including any transfers between or among Agent Members or beneficial owners in any Global Note) other than to require delivery of
such certificates and other documentation or evidence as are expressly required by, and to do so as and when expressly required by, the terms or this Indenture, and to examine the same to determine substantial compliance as to form with the express
requirements hereof. 
 (g) Euroclear and Clearstream Procedures Applicable. The provisions of the “Operating Procedures of the
Euroclear System” and “Terms and Conditions Governing Use of Euroclear” and the equivalent procedures of Clearstream shall be applicable to transfers of beneficial interests in Global Notes that are held by Participants through
Euroclear or Clearstream. 
 Section 2.13 CUSIP, Common Code and ISIN Numbers. The Company in issuing the Notes of any series
may use one or more “CUSIP” and “ISIN” numbers (if then generally in use), and, if so, the Trustee shall use “CUSIP” and “ISIN” numbers in notices of purchase as a convenience to Holders; provided that
any such notice may state that no representation is made as to the correctness of such numbers either as printed on the Notes or as contained in any notice of a purchase and that reliance may be placed only on the other identification numbers
printed on the Notes, and any such purchase shall not be affected by any defect in or omission of such numbers. The Company will promptly notify the Trustee of any change in the “CUSIP” and “ISIN” numbers applicable to any series
of the Notes. 
 ARTICLE 3 

REDEMPTION AND PURCHASES 

Section 3.1 Right to Redeem. The Company, at its option, may redeem the Notes of a series in accordance with the provisions of
Sections 3.7 and 3.8(g) hereof. 
 If the Company elects to redeem the Notes of a series, it shall notify the Trustee at least 45 days prior
to the Redemption Date (unless a shorter notice period shall be satisfactory to the Trustee) of the Redemption Date, the aggregate principal amount of the Notes and series of such Notes to be redeemed and the Section of this Indenture pursuant to
which such Notes are being redeemed. 
 Section 3.2 Selection of Notes to Be Redeemed. The Company will give not less than 15
days’ nor more than 60 days’ notice of any redemption. If the Company elects to redeem less than all of the outstanding Notes of a series, the Notes of that series will be selected for redemption as follows: 

  
 -34- 

 (i) in accordance with the procedures of The Depository Trust Company and in
compliance with the requirements of the applicable stock exchange to the extent the Notes of such series are held in the form of Global Notes; or 

(ii) on a pro rata basis, by lot or by such method as the Trustee deems fair and appropriate to the extent the Notes of
such series are held in the form of Definitive Notes. 
 In the event of a partial redemption by lot, the particular Notes to be redeemed
will be selected, unless otherwise provided herein, not less than 15 nor more than 60 days prior to the Redemption Date from the outstanding Notes of the applicable series not previously called for redemption. 

The Notes and portions of the Notes selected for redemption will be in amounts of $2,000 or whole multiples of $1,000 except that if all of
the Notes of a series of a Holder are to be redeemed, the entire outstanding amount of Notes of such series held by such Holder, even if not a multiple of $1,000, shall be redeemed. Except as provided in the preceding sentence, provisions of this
Indenture that apply to Notes called for redemption also apply to portions of Notes called for redemption. 
 Section 3.3 Notice of
Redemption. At least 15 days but not more than 60 days before a Redemption Date, the Company shall mail, or shall cause to be mailed, a notice of redemption by first-class mail, postage prepaid, (or otherwise transmit in accordance with
applicable procedures of DTC) to the Trustee and to each Holder of Notes of the applicable series to be redeemed. 
 The notice shall
identify the Notes to be redeemed and shall state: 
  

	 	•	 	 the aggregate principal amount of the Notes to be redeemed; 

 

	 	•	 	 the series of Notes to be redeemed; 

 

	 	•	 	 the Redemption Date (which shall be a Business Day); 

 

	 	•	 	 the redemption price; 

  

	 	•	 	 the name and address of the Paying Agent; 

 

	 	•	 	 that Notes called for redemption must be surrendered to the Paying Agent to collect the redemption price;

  

	 	•	 	 if fewer than all the outstanding Notes of a series are to be redeemed, the certificate numbers, if any, and
principal amounts of the particular Notes of such series to be redeemed; 

  

	 	•	 	 that, unless the Company defaults in the deposit of the redemption price, interest on Notes called for redemption
will cease to accrue on and after the Redemption Date; 

  

	 	•	 	 the Section of this Indenture pursuant to which the Notes are being redeemed; 

 

	 	•	 	 the CUSIP numbers of the Notes; and 

 

	 	•	 	 any conditions precedent to such redemption. 

At the Company’s request, the Trustee shall give the notice of redemption in the Company’s name and at the Company’s expense, provided,
that the Company makes such request at least three Business Days prior to the date by which such notice of redemption must be given to Holders in accordance with this Section 3.3. Redemption notices may be given more than 60 days prior to a
Redemption Date if the notice is issued in connection with a defeasance of the Notes of such series pursuant to Sections 8.3 or 8.4 or a satisfaction and discharge of this 

  
 -35- 

 
Indenture with respect to such series of Notes pursuant to Section 8.1. If a redemption is subject to satisfaction of one or more conditions precedent, the applicable redemption notice shall
describe such condition, and if applicable, shall state that, in the Company’s discretion, the Redemption Date may be delayed until such time as any or all such conditions shall be satisfied, without the requirement of an additional notice
period to the Holders, or such redemption may not occur and such notice may be rescinded in the event that any or all such conditions shall not have been satisfied by the Redemption Date, or by the Redemption Date as so delayed. The Trustee shall
have no responsibility for calculating the redemption price. 
 Section 3.4 Effect of Notice of Redemption. Once notice of
redemption is given and any conditions set forth therein have been satisfied, Notes called for redemption become due and payable on the Redemption Date and at the redemption price stated in the notice. Upon surrender to the Paying Agent, such Notes
shall be paid at the redemption price stated in the notice. 
 On and after the Redemption Date, unless the Company defaults in the deposit
of the redemption price and subject to satisfaction of any conditions precedent, interest will cease to accrue on the Notes or any portion of the Notes called for redemption, and all other rights of the Holder will terminate other than the right to
receive the redemption price, without interest from the Redemption Date, on surrender of the Notes. 
 Section 3.5 Deposit of
Redemption Price. Prior to 11:00 a.m. (New York City time) on the Redemption Date, the Company shall deposit with the Paying Agent (or the Trustee) money sufficient to pay the redemption price (as calculated by the Company) on all Notes to be
redeemed on that date. 
 Section 3.6 Notes Redeemed in Part. Upon surrender of a Note that is redeemed in part, the Company
shall execute and the Trustee shall authenticate and deliver to the Holder, without service charge, a new Note in an authorized denomination equal in principal amount to, and in exchange for, the unredeemed portion of the Note surrendered. 

Section 3.7 Optional Redemption. 

(a) At any time prior to July 15, 2022, the Company may on any one or more occasions redeem up to 40% of the aggregate principal amount of
2028 Notes (including 2028 Notes issued after the Issue Date, if any) issued under this Indenture at a redemption price of 107.000% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the redemption date, with
the net cash proceeds of one or more Equity Offerings; provided that: 
 (1) at least 60% of the aggregate principal
amount of 2028 Notes (including 2028 Notes issued after the Issue Date, if any) issued under this Indenture remains outstanding immediately after the occurrence of such redemption (excluding 2028 Notes held by the Company and its Subsidiaries); and

 (2) the redemption occurs within 180 days of the date of the closing of such Equity Offering. 

(b) On or after January 15, 2023, the Company may redeem all or a part of the 2028 Notes upon not less than 15 nor more than 60 days’
notice, at the redemption prices (expressed as percentages of principal amount) set forth below plus accrued and unpaid interest on the 2028 Notes redeemed, to, but not including, the applicable redemption date, if redeemed during the twelve-month
period beginning on January 15 of the years indicated below: 
  

					
	 Year
	  	Percentage	 
	 2023
	  	 	103.500	% 
	 2024
	  	 	101.750	% 
	 2025 and thereafter
	  	 	100.000	% 

 (c) In addition, at any time prior to January 15, 2023, the Company may redeem the 2028 Notes, in whole or
in part, at a redemption price equal to the principal amount of the 2028 Notes redeemed plus the Applicable Premium plus accrued and unpaid interest to, but not including, the date of redemption. The Company shall calculate the redemption price,
including any Applicable Premium. 

  
 -36- 

 (d) At any time prior to May 30, 2022, the Company may on any one or more occasions
redeem up to 40% of the aggregate principal amount of 2029 Notes (including 2029 Notes issued after the Issue Date, if any) issued under this Indenture at a redemption price of 107.250% of the principal amount thereof, plus accrued and unpaid
interest to, but not including, the redemption date, with the net cash proceeds of one or more Equity Offerings; provided that: 

(1) at least 60% of the aggregate principal amount of 2029 Notes (including 2029 Notes issued after the Issue Date, if any)
issued under this Indenture remains outstanding immediately after the occurrence of such redemption (excluding 2029 Notes held by the Company and its Subsidiaries); and 

(2) the redemption occurs within 180 days of the date of the closing of such Equity Offering. 

(e) On or after May 30, 2024, the Company may redeem all or a part of the 2029 Notes upon not less than 15 nor more than 60 days’
notice, at the redemption prices (expressed as percentages of principal amount) set forth below plus accrued and unpaid interest on the 2029 Notes redeemed, to, but not including, the applicable redemption date, if redeemed during the twelve-month
period beginning on May 30 of the years indicated below: 
  

					
	 Year
	  	Percentage	 
	 2024
	  	 	103.625	% 
	 2025
	  	 	101.813	% 
	 2026 and thereafter
	  	 	100.000	% 

 (f) In addition, at any time prior to May 30, 2024, the Company may redeem the 2029 Notes, in whole or in
part, at a redemption price equal to the principal amount of the 2029 Notes redeemed plus the Applicable Premium plus accrued and unpaid interest to, but not including, the date of redemption. The Company shall calculate the redemption price,
including any Applicable Premium. 
 (g) In connection with any optional redemption of a series of Notes, any such redemption may, at the
Company’s discretion, be subject to one or more conditions precedent. If a redemption is subject to satisfaction of one or more conditions precedent, the applicable redemption notice shall describe such condition, and if applicable, shall state
that, in the Company’s discretion, the redemption date may be delayed until such time as any or all such conditions shall be satisfied, without the requirement of an additional notice period to the Holders, or such redemption may not occur and
such notice may be rescinded in the event that any or all such conditions shall not have been satisfied by the Redemption Date, or by the Redemption Date as so delayed. 

(h) If the Company or any Note Guarantor becomes obligated to pay, on the next date on which any amount will be payable with respect to a
series of Notes, any Additional Amounts as a result of (i) any amendment to, or change in, the laws or regulations of a Relevant Taxing Jurisdiction (as defined in Section 4.21 herein) which amendment or change is publicly announced and
becomes effective after May 9, 2019 (or, if the applicable Relevant Taxing Jurisdiction became a Relevant Taxing Jurisdiction on a date after May 9, 2019, after such later date) or (ii) any amendment to, or change in, an official
written interpretation or application of such laws or regulations (including by virtue of a holding by a court of competent jurisdiction) which amendment or change is publicly announced and becomes effective after May 9, 2019 (or, if the
applicable Relevant Taxing Jurisdiction became a Relevant Taxing Jurisdiction on a date after May 9, 2019, after such later date) (each of the foregoing clauses (i) and (ii), a “Change in Tax Law”) and the Company or the
applicable Note Guarantor cannot avoid any such payment obligation by taking reasonable measures available to it (including making payment through a paying agent located in another jurisdiction, but not including the substitution of an obligor if
the Company would be required to pay Additional Amounts), the Company may, at its option, redeem the Notes of such series then outstanding, in whole but not in part, at a redemption price equal to 100% of the principal amount thereof, plus accrued
and unpaid interest, if any, to, but not including, the redemption date (subject to the right of Holders of record on the relevant record date to receive interest due on the relevant interest payment date), provided, however, that if such right to
redeem is triggered by the obligation of a Note Guarantor to pay 

  
 -37- 

 
Additional Amounts, such right to redeem will apply only if the payment giving rise to such obligation cannot be made by the Company or another Note Guarantor without the obligation to pay
Additional Amounts. Notice of the Company’s intent to redeem the Notes of such series shall not be given until the Company delivers to the Trustee an opinion of tax counsel to the effect that there has been such Change in Tax Law which would
entitle the Company to redeem the Notes of such series hereunder and an Officers’ Certificate to the effect that the Company or the applicable Note Guarantor cannot avoid its obligation to pay Additional Amounts by taking reasonable measures
available to it. The foregoing provisions shall apply mutatis mutandis to any successor Person to the Company or the applicable Note Guarantor, after such successor Person becomes a party to this Indenture, with respect to a Change in Tax Law that
is publicly announced and becomes effective after such successor Person becomes a party to this Indenture. 
 (i) Any redemption pursuant to
this Section 3.7 shall be made pursuant to the provisions of Sections 3.1 through 3.6 hereof. 
 (j) In connection with any redemption
under this Section 3.7, the Company shall deliver to the Trustee an Officers’ Certificate and Opinion of Counsel to the effect that all conditions precedent in this Indenture to the redemption have been complied with. 

Section 3.8 Purchase of Notes at Option of the Holder Upon Change of Control. 

(a) If at any time that Notes of any series remain outstanding there shall occur a Change of Control with respect to a series of Notes, such
series of Notes shall be purchased by the Company at the option of the Holders of such series, as of the Change of Control Purchase Date, at a purchase price equal to 101% of the principal amount of the Notes of such series, together with accrued
and unpaid interest, including interest on any unpaid overdue interest, if any, to, but excluding, the Change of Control Purchase Date (the “Change of Control Purchase Price”), subject to satisfaction by or on behalf of any Holder
of the requirements set forth in subsection (c) of this Section 3.8. 
 (b) Within 30 days after the occurrence of a Change of
Control with respect to either series of Notes, the Company shall transmit a written notice (“Company Notice”) of the Change of Control to the Trustee and to each Holder of such series of Notes (and to beneficial owners as required
by applicable law) pursuant to which the Company shall make an offer (a “Change of Control Offer”) to each Holder to repurchase all or any part (equal to $2,000 or an integral multiple of $1,000 in excess thereof) of each
Holder’s Notes of such series at the Change of Control Purchase Price. The notice shall include the form of a Change of Control Purchase Notice to be completed by the Holder, shall describe the transaction or transactions that constitute the
Change of Control and shall state: 
 (i) that the Change of Control Offer is being made pursuant to this Section 3.8
and that all Notes of the applicable series tendered will be accepted for payment; 
 (ii) the date by which the Change of
Control Purchase Notice pursuant to this Section 3.8 must be given; 
 (iii) the purchase date, which date shall be no
earlier than 30 days and no later than 60 days after the date the Company Notice is mailed (the “Change of Control Purchase Date”); 

(iv) the Change of Control Purchase Price; 

(v) the Holder’s right to require the Company to purchase the Notes of such series; 

(vi) the name and address of the Paying Agent; 

(vii) that, unless the Company defaults in making such payment, any Note of such series accepted for payment pursuant to the
Change of Control Offer will cease to accrue interest after the Change of Control Purchase Date; 

  
 -38- 

 (viii) the procedures that the Holder must follow to exercise rights under
this Section 3.8; and 
 (ix) the procedures for withdrawing a Change of Control Purchase Notice, including a form of
notice of withdrawal. 
 If any of the Notes of such series is in the form of a Global Note, then the Company shall modify such notice to
the extent necessary to accord with the procedures of the Depositary applicable to the repurchase of Global Notes of such series. 
 (c) A
Holder may exercise its rights specified in subsection (a) of this Section 3.8 upon delivery of a written notice (which shall be in substantially the form included in Exhibit A hereto, as applicable, and which may
be delivered by letter, overnight courier, hand delivery, facsimile transmission or in any other written form and, in the case of Global Notes, may be delivered electronically or by other means in accordance with the Depositary’s customary
procedures) of the exercise of such rights (a “Change of Control Purchase Notice”) to any Paying Agent at any time prior to the close of business on the Business Day next preceding the Change of Control Purchase Date. 

The delivery of such Note to any Paying Agent (together with all necessary endorsements) at the office of such Paying Agent shall be a
condition to the receipt by the Holder of the Change of Control Purchase Price therefor. 
 The Company shall purchase from the Holder
thereof, pursuant to this Section 3.8, a portion of a Note of the applicable series if the principal amount of such portion is $2,000 or an integral multiple of $1,000 in excess thereof. Provisions of this Indenture that apply to the purchase
of all of a Note pursuant to Sections 3.8 through 3.13 also apply to the purchase of such portion of such Note. 
 Notwithstanding anything
herein to the contrary, any Holder delivering to a Paying Agent the Change of Control Purchase Notice contemplated by this subsection (c) shall have the right to withdraw such Change of Control Purchase Notice in whole or in a portion thereof
that is a principal amount of $2,000 or an integral multiple of $1,000 in excess thereof at any time prior to the close of business on the Business Day next preceding the Change of Control Purchase Date by delivery of a written notice of withdrawal
to the Paying Agent in accordance with Section 3.9 hereof. 
 A Paying Agent shall promptly notify the Company of the receipt by it of
any Change of Control Purchase Notice or written withdrawal thereof. 
 Anything herein to the contrary notwithstanding, in the case of
Global Notes, any Change of Control Purchase Notice may be delivered or withdrawn and such Notes may be surrendered or delivered for purchase in accordance with the Applicable Procedures as in effect from time to time. 

(d) The Company will not be required to make a Change of Control Offer upon a Change of Control with respect to a series of Notes if (1) a
third party makes the Change of Control Offer with respect to such series of Notes in the manner, at the times and otherwise in compliance with the requirements applicable to a Change of Control Offer made by the Company set forth in subsection
(b) of this Section 3.8 and purchases all Notes of such series properly tendered and not withdrawn under the Change of Control Offer, (2) notice of redemption with respect to such series of Notes has been given pursuant to Sections
3.1 or 3.7 hereof, unless and until there is a default in payment of the applicable redemption price, or (3) after giving effect to such Change of Control, (i) no Default or Event of Default has occurred and is continuing, (ii) the
Change of Control transaction has been approved by the Board of Directors of the Company, and (iii) the Notes of such series have received an Investment Grade Rating. In addition, a Change of Control Offer may be made in advance of a Change of
Control, conditional upon such Change of Control, if a definitive agreement is in place for the Change of Control at the time of launching the Change of Control Offer. 

(e) The Company will publicly announce the results of the Change of Control Offer on or as soon as practicable after the Change of Control
Purchase Date. 

  
 -39- 

 (f) The provisions under this Indenture relative to the Company’s obligation to make an
offer to repurchase the Notes of a series as a result of a Change of Control (including any required notice period) may be waived or modified with respect to a series of Notes with the written consent of the Holders of a majority in principal amount
of the Notes of that series, including after the entry into an agreement that would result in the need to make a Change of Control Offer. 

(g) With respect to a series of Notes, in the event that Holders of not less than 90% in aggregate principal amount of the outstanding Notes of
such series validly tender and do not withdraw such Notes in a Change of Control Offer and the Company purchases all of the Notes of that series validly tendered and not withdrawn by such Holders, within 60 days of such purchase, the Company will
have the right, upon not less than 15 days’ nor more than 60 days’ prior notice, to redeem all of the Notes of that series that remain outstanding following such purchase at a redemption price in cash equal to 101% of the principal amount
thereof plus accrued and unpaid interest on the Notes of that series to, but excluding, the date of redemption. Any redemption pursuant to this Section 3.8(g) shall be made pursuant to the provisions of Sections 3.1 through 3.6 hereof. 

Section 3.9 Effect of Change of Control Purchase Notice. Upon receipt by any Paying Agent of the Change of Control Purchase Notice
specified in Section 3.8(c) hereof, the Holder of the Note in respect of which such change of Control Purchase Notice was given shall (unless such Change of Control Purchase Notice is withdrawn as specified below) thereafter be entitled to
receive the Change of Control Purchase Price with respect to such Note. Such Change of Control Purchase Price shall be paid to such Holder promptly following the later of (a) the Change of Control Purchase Date with respect to such Note
(provided the conditions in Section 3.8(c) hereof have been satisfied) and (b) the time of delivery of such Note to a Paying Agent by the Holder thereof in the manner required by Section 3.8(c) hereof. 

A Change of Control Purchase Notice may be withdrawn by means of a written notice (which may be delivered by mail, overnight courier, hand
delivery, facsimile transmission or in any other written form and, in the case of Global Notes, may be delivered electronically or by other means in accordance with the Depositary’s customary procedures) of withdrawal delivered by the Holder to
a Paying Agent at any time prior to the close of business on the Business Day immediately preceding the Change of Control Purchase Date, specifying the principal amount of the Note or portion thereof (which must be a principal amount of $2,000 or an
integral multiple of $1,000 in excess thereof) with respect to which such notice of withdrawal is being submitted. 
 Section 3.10
Deposit of Change of Control Purchase Price. On or before 11:00 a.m., New York City time on the Change of Control Purchase Date, the Company shall deposit with the Trustee or with a Paying Agent (other than the Company or an Affiliate of the
Company) an amount of money (in immediately available funds if deposited on such Change of Control Purchase Date) sufficient to pay the aggregate Change of Control Purchase Price of all the Notes of such series or portions thereof that are to be
purchased as of such Change of Control Purchase Date. The manner in which the deposit required by this Section 3.10 is made by the Company shall be at the option of the Company, provided that such deposit shall be made in a manner such
that the Trustee or a Paying Agent shall have immediately available funds on the Change of Control Purchase Date. 
 If a Paying Agent
holds, in accordance with the terms hereof, money sufficient to pay the Change of Control Purchase Price of any Note of such series for which a Change of Control Purchase Notice has been tendered and not withdrawn in accordance with this Indenture
then, on the Change of Control Purchase Date, interest will cease to accrue on such Notes or any portion of such Notes as to which a Change of Control Purchase Notice has been tendered and not withdrawn in accordance with this Indenture and all
other rights of the Holder of such Notes will terminate other than the right to receive the Change of Control Purchase Price, without interest from the Change of Control Purchase Date, on surrender of such Notes. 

Section 3.11 Notes Purchased in Part. Any Note that is to be purchased only in part shall be surrendered at the office of a Paying
Agent, and promptly after the Change of Control Purchase Date the Company shall execute and the Trustee shall authenticate and deliver to the Holder of such Note, without service charge, a new Note or Notes of the applicable series, of such
authorized denomination or denominations as may be requested by such Holder, in aggregate principal amount equal to, and in exchange for, the portion of the principal amount of the Note so surrendered that is not purchased. 

  
 -40- 

 Section 3.12 Compliance with Securities Laws upon Purchase of Notes. In
connection with any offer to purchase or purchase of Notes under Section 3.8 hereof, the Company shall (a) comply with Rule 14e-1 (or any successor to such Rule), if applicable, under the Exchange
Act, and (b) otherwise comply with all United States federal and state securities laws and Canadian federal, provincial and territorial securities laws in connection with such offer to purchase or purchase of Notes, all so as to permit the
rights of the Holders and obligations of the Company under Sections 3.8 through 3.11 hereof to be exercised in the time and in the manner specified therein. To the extent that the provisions of any securities laws or regulations conflict with the
Change of Control provisions of this Article 3, the Company will comply with the applicable securities laws and regulations and will not be deemed to have breached its obligations under this Article 3 by virtue of such conflict. 

Section 3.13 Repayment to the Company. To the extent that the aggregate amount of cash deposited by the Company pursuant to
Section 3.10 with respect to any series of Notes hereof exceeds the aggregate Change of Control Purchase Price (including interest thereon) of the Notes of such series or portions thereof that the Company is obligated to purchase, then promptly
after the Change of Control Purchase Date, and upon request, the Trustee or a Paying Agent, as the case may be, shall return any such excess cash to the Company. 

Section 3.14 Offer to Purchase by Application of Excess Proceeds. In the event that, pursuant to Section 4.14 hereof, the
Company is required to commence an offer to all Holders to purchase Notes of a series (“Asset Sale Offer”), it shall follow the procedures specified below. 

The Asset Sale Offer shall be made to all Holders of each series of Notes and all holders of other Indebtedness that is pari passu with
the Notes (including Notes of the other series) containing provisions similar to those set forth in this Indenture with respect to offers to purchase or redeem with the proceeds of sales of assets. The Asset Sale Offer shall remain open for a period
of at least 20 Business Days following its commencement and not more than 30 Business Days, except to the extent that a longer period is required by applicable law (the “Offer Period”). No later than three Business Days after the
termination of the Offer Period (the “Purchase Date”), the Company shall apply a portion of the Excess Proceeds as calculated pursuant to Section 4.14 hereof (the “Offer Amount”) to the purchase of Notes of any
series and such other pari passu Indebtedness (on a pro rata basis, if applicable) or, if less than the Offer Amount has been tendered, all of such Notes of the applicable series and other pari passu Indebtedness tendered in response
to the Asset Sale Offer. Payment for any Notes so purchased shall be made in the same manner as interest payments are made. 
 Upon the
commencement of an Asset Sale Offer, the Company shall send, by first-class mail, a notice to the Trustee and each of the applicable Holders. The notice will contain all instructions and materials necessary to enable such Holders to tender such
series of Notes pursuant to the Asset Sale Offer. The notice, which will govern the terms of the Asset Sale Offer, will state: 

(1) that the Asset Sale Offer is being made pursuant to this Section 3.14 and Section 4.14 hereof and the length of
time the Asset Sale Offer will remain open; 
 (2) the Offer Amount, the purchase price and the Purchase Date; 

(3) that with respect to any series of Notes, any Note not tendered or accepted for payment will continue to accrue interest;

 (4) that, unless the Company defaults in making such payment, any Note accepted for payment pursuant to the Asset Sale
Offer shall cease to accrue interest after the Purchase Date; 
 (5) that, with respect to any series of Notes, Holders
electing to have a Note purchased pursuant to an Asset Sale Offer may elect to have such series of Notes purchased in a principal amount of $2,000 (or in integral multiples of $1,000 in excess thereof) only; 

(6) that Holders electing to have a Note purchased pursuant to any Asset Sale Offer shall be required to surrender the Note,
with the form entitled “Option of Holder to Elect Purchase” on the reverse of the Note completed, or transfer by book-entry transfer, to the Company, the Depositary, if appointed by the Company, or a Paying Agent at the address specified
in the notice at least three days before the Purchase Date; 

  
 -41- 

 (7) that Holders shall be entitled to withdraw their election if the Company
or the Paying Agent, as the case may be, receives, not later than the expiration of the Offer Period, a facsimile transmission or letter setting forth the name of the Holder, the principal amount of the Note the Holder delivered for purchase and a
statement that such Holder is withdrawing his election to have such Note purchased; 
 (8) that, if the aggregate principal
amount of any Notes of such series and other pari passu Indebtedness surrendered in connection with the Asset Sale Offer exceeds the Offer Amount, the Company shall select Notes of such series and other pari passu Indebtedness to be
purchased on a pro rata basis based on the principal amount of the applicable series of Notes and such other pari passu Indebtedness surrendered (with such adjustments as may be deemed appropriate by the Company so that only such Notes in
denominations of $2,000 (or integral multiples of $1,000 in excess thereof), will be purchased); and 
 (9) that Holders of
any Notes whose Notes were purchased only in part will be issued new Notes of such series equal in principal amount to the unpurchased portion of such Notes surrendered (or transferred by book-entry transfer). 

On or before the Purchase Date, the Company shall, to the extent lawful, accept for payment, on a pro rata basis to the extent necessary, the
Offer Amount of the applicable Notes of such series or portions thereof tendered pursuant to the Asset Sale Offer, or if less than the Offer Amount has been tendered, all such Notes of such series tendered, and shall deliver to the Trustee an
Officers’ Certificate stating that such Notes or portions thereof were accepted for payment by the Company in accordance with the terms of this Section 3.14. The Company, the Depositary or the Paying Agent, as the case may be, shall
promptly (but in any case not later than five days after the Purchase Date) mail or deliver to each tendering Holder an amount equal to the purchase price of the applicable series of Notes tendered by such Holder and accepted by the Company for
purchase, and the Company shall promptly issue a new Note of such series, and the Trustee, upon written request from the Company, shall authenticate and mail or deliver such new Note to such Holder, in a principal amount equal to any unpurchased
portion of the Note surrendered. Any Note not so accepted shall be promptly mailed or delivered by the Company to the Holder thereof. The Company shall publicly announce the results of the Asset Sale Offer on or as soon as practicable after the
Purchase Date. 
 Other than as specifically provided in this Section 3.14, any purchase pursuant to this Section 3.14 shall be
made pursuant to the provisions of Sections 3.1 through 3.6 hereof. 
 ARTICLE 4 

COVENANTS 
 Section 4.1
Payment of Notes. The Company shall promptly make all payments in respect of the Notes of each series on the dates and in the manner provided in the Notes and this Indenture. An installment of principal or interest shall be considered paid on
the date it is due if the Paying Agent (other than the Company) holds by 11:00 a.m., New York City time, on that date money, deposited by the Company or an Affiliate thereof, sufficient to pay the installment. Except in the case of a redemption, a
Change of Control Offer or an Asset Sale Offer, accrued and unpaid interest on any Note that is payable, and is punctually paid or duly provided for, on any interest payment date shall be paid to the Person in whose name that Note is registered at
the close of business on the record date for such interest at the office or agency of the Company maintained for such purpose. The Company shall (in immediately available funds), to the fullest extent permitted by law, pay interest on overdue
principal (including premium, if any) and overdue installments of interest from the original due date to the date paid, at the rate applicable to the Note, which interest shall be payable on demand. 

The Company will make payments in respect of the Notes represented by the Global Notes (including principal, premium, if any, and interest) by
wire transfer of immediately available funds to the accounts specified by the Holder of the Global Note. The Company will make all payments of principal, interest and premium, if any, 

  
 -42- 

 
with respect to Definitive Notes by wire transfer of immediately available funds to the accounts specified by the Holders of the Definitive Notes, in the case of a Holder holding an aggregate
principal amount of Notes of any series of $1,000,000 or more, or, if no such account is specified or in the case of a Holder holding an aggregate principal amount of Notes of any series of less than $1,000,000, by mailing a check to each such
Holder’s registered address. All payments shall be made in immediately available funds in U.S. dollars. Payments to any Holder holding an aggregate principal amount of Notes of any series in excess of $1,000,000 shall be made by wire transfer
in immediately available funds to an account maintained by such Holder in the United States, if such Holder has provided wire transfer instructions to the Company at least 10 Business Days prior to the payment date. Any wire transfer instructions
received by the Trustee will remain in effect until revoked by the Holder. 
 Section 4.2 Maintenance of Office or Agency. 

(a) The Company shall maintain in the United States of America, an office or agency (which may be an office of the Trustee or an affiliate of
the Trustee, Registrar or co registrar) where Notes may be surrendered for payment, registration of transfer or for exchange and where notices and demands to or upon the Company in respect of the Notes and this Indenture may be served. The Company
shall give prompt written notice to the Trustee of the location, and any change in the location, of such office or agency. If at any time the Company shall fail to maintain any such required office or agency or shall fail to furnish the Trustee with
the address thereof, such presentations, surrenders, notices and demands may be made or served at the Corporate Trust Office of the Trustee. 

(b) The Company may also from time to time designate one or more other offices or agencies where the Notes may be presented or surrendered for
any or all such purposes and may from time to time rescind such designations; provided, however, that no such designation or rescission shall in any manner relieve the Company of its obligation to maintain an office or agency in the
United States of America, for such purposes. The Company shall give prompt written notice to the Trustee of any such designation or rescission and of any change in the location of any such other office or agency. 

(c) The Company hereby designates the offices of the Trustee set forth in Section 2.3 hereof as one such office or agency of the Company.

 Section 4.3 Reports. 

(a) Whether or not required by the SEC’s rules and regulations, so long as any Notes are outstanding, the Company shall furnish (to the
extent not publicly available on the SEC’s EDGAR system) to the Trustee and the Holders of Notes and post on the Company’s website (in a format that is accessible to Holders of Notes as well as prospective Holders of Notes), within the
time periods specified in the SEC’s rules and regulations: 
 (i) all quarterly and annual reports that would be
required to be filed with the SEC on Forms 10-Q and 10-K if the Company were required to file such reports; and 

(ii) all current reports that would be required to be filed with the SEC on Form 8-K if
the Company were required to file such reports. 
 All such reports shall be prepared in all material respects in accordance with all of the
rules and regulations applicable to such reports (other than consolidating financial information required by Rule 3-10 or 3-16 of Regulation S-X or any comparable provision so long as the Company complies with Section 4.3(d)). Each annual report on Form 10-K shall include a report on the Company’s
consolidated financial statements by the Company’s independent registered public accountants. In addition, the Company shall file a copy of each of the reports referred to in clauses (i) and (ii) above with the SEC for public availability
within the time periods specified in the rules and regulations applicable to such reports (unless the SEC will not accept such a filing or the Company is no longer subject to the periodic reporting requirements of the Exchange Act for any reason)
and make such information available to securities analysts and prospective investors upon request. 

  
 -43- 

 (b) If, at any time, the Company is no longer subject to the periodic reporting requirements
of the Exchange Act for any reason, and regardless of whether it continues to file reports with the SEC, the Company shall nevertheless continue making the reports specified in Section 4.3(a) hereof available to the Holders of the Notes,
prospective investors and securities analysts by posting such information on its website. While the Company remains subject to the periodic reporting requirements of the Exchange Act, the Company agrees that it shall not take any action for the
purpose of causing the SEC not to accept any such filings. If, notwithstanding the foregoing, the SEC will not accept the Company’s filings for any reason, the Company shall post the reports referred to in Section 4.3(a) hereof on its
website within the time periods that would apply if the Company were required to file those reports with the SEC. 
 (c) The Company further
agrees that, for so long as any Notes remain outstanding, at any time it is not required to file the reports required by Section 4.3(a) or (b) hereof with the SEC, it shall furnish to the Holders and to securities analysts and prospective
investors, upon their request, the information required to be delivered pursuant to Rule 144A(d)(4) under the Securities Act. 
 (d) The
quarterly and annual financial information required by Sections 4.3(a) and (b) hereof shall include a reasonably detailed presentation, either on the face of the financial statements, in the footnotes of the financial statements or in
Management’s Discussion and Analysis of Financial Condition and Results of Operations that discloses the total assets, liabilities, revenues and income from operations of Subsidiaries of the Company that do not Guarantee the Notes. The Trustee
shall not be responsible for determining whether this clause 4.3(d) has been satisfied, nor shall it have any liability in connection therewith. 

(e) Delivery of such reports, information and documents to the Trustee is for informational purposes only and the Trustee’s receipt of
such shall not constitute constructive notice of any information contained therein or determinable from information contained therein, including the Company’s compliance with any of its covenants hereunder (as to which the Trustee is entitled
to rely exclusively on Officers’ Certificates). 
 (f) Notwithstanding anything herein to the contrary, in the event that the Company
fails to comply with its obligation to file or provide such information, documents and reports as required by this Section 4.3, the Company will be deemed to have cured such Default with respect to any series of Notes for purposes of
Section 6.1(d) upon the filing or provision of all such information, documents and reports required hereunder prior to the expiration of 90 days after written notice to the Company of such failure from the Trustee or the Holders of at least 25%
of the principal amount of such series of Notes. 
 Section 4.4 Compliance Certificates. The Company shall deliver to the
Trustee, within 90 days after the end of each fiscal year of the Company (beginning with the fiscal year ending December 31, 2019), an Officers’ Certificate as to the signer’s knowledge of the Company’s compliance with all
conditions and covenants on their part contained in this Indenture and stating whether or not the signer knows of any Default or Event of Default. If such signer knows of such a Default or Event of Default, the Officers’ Certificate shall
describe the Default or Event of Default and the efforts to remedy the same. For the purposes of this Section 4.4, compliance shall be determined without regard to any grace period or requirement of notice provided pursuant to the terms of this
Indenture. 
 Section 4.5 Further Instruments and Acts. Upon request of the Trustee, the Company will execute and deliver such
further instruments and do such further acts as may be reasonably necessary or proper to carry out more effectively the purposes of this Indenture. 

Section 4.6 Maintenance of Corporate Existence. Subject to Article 5 hereof, the Company will do or cause to be done all things
necessary to preserve and keep in full force and effect its corporate existence and the corporate existence of each Restricted Subsidiary; provided, however, that the Company shall not be required to preserve the corporate existence of
any Restricted Subsidiary if (a) the Board of Directors or management of the Company shall determine that the preservation thereof is no longer desirable in the conduct of the business of the Company and the Restricted Subsidiaries, taken as a
whole, and that the loss thereof is not adverse in any material respect to the Holders of the Notes, (b) if a Subsidiary is to be dissolved or merged or consolidated in compliance with this Indenture or (c) such Subsidiary has no assets.

  
 -44- 

 Section 4.7 Changes in Covenants When Notes Rated Investment Grade. In the event
of the occurrence of a Fall Away Event with respect to the Notes of a series (and notwithstanding the failure of the Company subsequently to maintain an Investment Grade Rating with respect to such series of Notes), the provisions of Sections 4.8,
4.9, 4.12, 4.13 and 4.14 hereof and clause (iv) of Section 5.1(a) hereof will no longer be applicable to the Notes of the applicable series. 

Section 4.8 Restricted Payments. 

(a) The Company shall not, and shall not permit any of its Restricted Subsidiaries to, directly or indirectly: 

(i) declare or pay any dividend or make any other payment or distribution on account of the Company’s or any of its
Restricted Subsidiaries’ Equity Interests (including, without limitation, any payment in connection with any merger or consolidation involving the Company or any of its Restricted Subsidiaries) or to the direct or indirect holders of the
Company’s or any of its Restricted Subsidiaries’ Equity Interests in their capacity as such (other than dividends or distributions payable in Equity Interests (other than Disqualified Stock) of the Company or to the Company or a Restricted
Subsidiary of the Company); 
 (ii) purchase, redeem or otherwise acquire or retire for value (including, without limitation,
in connection with any merger or consolidation involving the Company) any Equity Interests of the Company or any direct or indirect parent of the Company; 

(iii) purchase, redeem, defease or otherwise acquire or retire for value, prior to scheduled maturity, scheduled repayment or
scheduled sinking fund payment, any Indebtedness of the Company or any Note Guarantor that is contractually subordinated in right of payment to the Notes or a Note Guarantee, except (i) from the Company or a Restricted Subsidiary of the Company
or (ii) the purchase, redemption, defeasance or other acquisition or retirement of any such Indebtedness made in anticipation of satisfying a sinking fund obligation, principal installment or final maturity, in each case due within one year of
the date of such purchase, redemption, defeasance or other acquisition or retirement; or 
 (iv) make any Restricted
Investment 
 (all such payments and other actions set forth in clauses (i) through (iv) above being collectively referred to as “Restricted
Payments”), unless, at the time of and after giving effect to such Restricted Payment: 
 (1) no Default or Event of
Default has occurred and is continuing or would occur as a consequence of such Restricted Payment; 
 (2) the Company would,
at the time of such Restricted Payment and after giving pro forma effect thereto as if such Restricted Payment had been made at the beginning of the applicable four-quarter period, have been permitted to incur at least $1.00 of additional
Indebtedness pursuant to the Fixed Charge Coverage Ratio test or Total Leverage Ratio test set forth in Section 4.9(a) hereof; and 

(3) such Restricted Payment, together with the aggregate amount of all other Restricted Payments made by the Company and its
Restricted Subsidiaries after January 30, 2015 (excluding Restricted Payments permitted by clauses (ii) through (ix), (xi), (xii) and (xiii) of Section 4.8(b)), is less than the sum, without duplication, of: 

(A) an amount (which shall not be less than zero) equal to 50% of the Consolidated Net Income of the Company for the period
(taken as one accounting period) from October 1, 2014 to the end of the Company’s most recently ended fiscal quarter for which internal financial statements are available at the time of such Restricted Payment, plus 

  
 -45- 

 (B) 100% of the aggregate net cash proceeds (or the fair market value of
assets) received by the Company since January 30, 2015 as a contribution to its common equity capital or from the issue or sale of Equity Interests of the Company (other than Excluded Contributions or Disqualified Stock) or from the issue or
sale of convertible or exchangeable Disqualified Stock or convertible or exchangeable debt securities of the Company that have been converted into or exchanged for such Equity Interests (other than Equity Interests (or Disqualified Stock or debt
securities) sold to a Subsidiary of the Company), plus 
 (C) to the extent that any Restricted Investment that was
made after January 30, 2015 is sold for cash or otherwise liquidated or repaid for cash, the lesser of (i) the cash return of capital with respect to such Restricted Investment (less the cost of disposition, if any) or (ii) the
initial amount of such Restricted Investment, plus 
 (D) to the extent that any Unrestricted Subsidiary of the
Company is redesignated as a Restricted Subsidiary after January 30, 2015, the lesser of (i) the Fair Market Value of the Company’s Investment in such Subsidiary as of the date of such redesignation or (ii) such Fair Market Value
as of the date on which such Subsidiary was originally designated as an Unrestricted Subsidiary, plus 
 (E)
$3.7 billion; plus 
 (F) Declined Asset Sale Proceeds or Retained Asset Sale Proceeds. 

(b) The preceding provisions shall not prohibit: 

(i) the payment of any dividend within 60 days after the date of declaration of the dividend, if at the date of declaration the
dividend payment would have complied with the provisions of this Indenture (it being understood that the amount of any such dividend shall be included in the aggregate amount of Restricted Payments determined in Section 4.8(a)(3) only once and
not as separate Restricted Payments made at both declaration and payment); 
 (ii) any Restricted Payment made in exchange
for, or in an amount equal to the net cash proceeds of, the substantially concurrent sale (other than to the Company or a Restricted Subsidiary of the Company) of, Equity Interests of the Company (other than Disqualified Stock); provided,
that an amount equal to such Restricted Payment will be excluded from clause (3)(B) of Section 4.8(a) hereof; 
 (iii)
the defeasance, redemption, repurchase or other acquisition or retirement of subordinated Indebtedness of the Company or any Note Guarantor with the net cash proceeds from, or in exchange for, an incurrence of Permitted Refinancing Indebtedness;

 (iv) the payment of any dividend or any other payment or distribution by a Restricted Subsidiary of the Company to the
holders of its Equity Interests of any class on a pro rata basis to the holders of such class; 
 (v) so long as no Default
or Event of Default has occurred and is continuing, the repurchase, redemption or other acquisition or retirement for value of Equity Interests of the Company or any Restricted Subsidiary of the Company held by any present or former employee,
director, officer or consultant of, or service provider to, the Company or any of its Restricted Subsidiaries pursuant to any management equity plan or stock option plan or any other management or employee benefit plan or agreement (including, for
the avoidance of doubt, any principal and interest payable on any notes issued by the Company in connection with any such repurchase, retirement or other acquisition), or any stock subscription or shareholder agreement; provided that the
aggregate amount of Restricted Payments made under this clause (v) shall not exceed in any calendar year $25.0 million (with unused amounts for any year being carried over to the next succeeding year, but not to any subsequent year, with
the permitted amount for each year being used prior to any amount carried over from the previous year); provided further, that such amount in any calendar year may be increased by an amount not to exceed: 

  
 -46- 

 (i) the cash proceeds of key man life insurance policies received by the
Company or its Restricted Subsidiaries after the Issue Date; less 
 (ii) the amount of any Restricted Payments previously
made with the cash proceeds described in subclause (i) of this clause (v); 
 (vi) payments to holders of Equity
Interests (or to the holders of Indebtedness that is convertible into or exchangeable for Equity Interests upon such conversion or exchange) in lieu of the issuance of fractional shares; 

(vii) repurchases of Equity Interests deemed to occur in connection with the exercise or vesting of stock options or similar
instruments to the extent necessary to pay withholding or similar taxes related to such exercise or vesting of stock options or similar instruments; 

(viii) the making of additional Restricted Payments in an amount not to exceed the portion, if any, of the Excluded
Contributions on such date that the Company elects to apply to this clause (viii) (plus, without duplication of amounts referred to in this clause (viii), in an amount equal to the Net Proceeds from a disposition of property or assets acquired after
the Issue Date, if the acquisition of such property or assets was financed with Excluded Contributions up to the amount of such Excluded Contributions); 

(ix) repurchases or retirement for value of Equity Interests deemed to occur upon exercise of stock options or warrants if such
Equity Interests represent a portion of the exercise price of such options or warrants; 
 (x) the repurchase, redemption or
other acquisition or retirement for value of any subordinated Indebtedness or Disqualified Stock pursuant to provisions similar to those described under Section 3.8 and Section 4.14; provided that, prior thereto, all Notes tendered
by Holders in connection with a Change of Control Offer or Asset Sale Offer, as applicable, have been repurchased, redeemed or acquired for value; 

(xi) so long as no Default or Event of Default has occurred and is continuing, the declaration and payment of dividends to
holders of any class or series of Disqualified Stock of the Company or its Restricted Subsidiaries issued in accordance with Section 4.9; 

(xii) so long as no Default or Event of Default has occurred and is continuing, other Restricted Payments; provided,
however, that if the Total Leverage Ratio as of the date of any Restricted Payment to be made pursuant to this clause (xii) is greater than or equal to 3.50 to 1.0, such Restricted Payment shall be permitted to be made pursuant to this
clause (xii) only if the amount of such Restricted Payment, when taken together with the amount of all other Restricted Payments previously made pursuant to this clause (xii) when the Total Leverage Ratio was greater than or equal to 3.50
to 1.0, does not exceed the greater of (x) $750.0 million and (y) 2.5% of Consolidated Total Assets in the aggregate; 

(xiii) the distribution, as a dividend or otherwise, of shares of Capital Stock of, or Indebtedness owed to the Company or a
Restricted Subsidiary by, Unrestricted Subsidiaries; and 
 (xiv) any payments or deliveries in connection with (a) a
Permitted Bond Hedge Transaction or (b) Permitted Warrant Transaction or Packaged Rights (i) by delivery of shares of the Company’s Equity Interests (other than Disqualified Stock) or (ii) otherwise, to the extent of a payment or
delivery received from a Permitted Bond Hedge Transaction (whether such payment or delivery on the Permitted Warrant Transaction is effected by netting, set-off or otherwise). 

  
 -47- 

 (c) The amount of all Restricted Payments (other than cash) shall be the Fair Market Value
(determined, for purposes of this Section 4.8, by the Company or, in the case of any asset(s) valued in excess of $750.0 million, by the Board of Directors of the Company) on the date of the Restricted Payment of the asset(s) or securities
proposed to be transferred or issued by the Company or such Restricted Subsidiary, as the case may be, pursuant to the Restricted Payment. For purposes of determining compliance with this Section 4.8, in the event that a Restricted Payment
meets the criteria of more than one of the categories described in clauses (i) through (xiv) of clause (b) of this Section 4.8, including Section 4.8(a) or the definition of “Permitted Investment,” the Company will be
permitted to classify such Restricted Payment and later reclassify all or a portion of such Restricted Payment in any manner that complies with this Section 4.8. In addition, a Restricted Payment need not be permitted solely by reference to one
provision permitting such Restricted Payment but may be permitted in part by one such provision and in part by one or more other provisions of this Section 4.8 permitting such Restricted Payment. 

Section 4.9 Incurrence of Indebtedness and Issuance of Preferred Stock. 

(a) The Company shall not, and shall not permit any of its Restricted Subsidiaries to, directly or indirectly, create, incur, issue, assume,
guarantee or otherwise become directly or indirectly liable, contingently or otherwise (collectively, “incur”), with respect to any Indebtedness (including Acquired Debt), and the Company shall not issue any Disqualified Stock and
shall not permit any of its Restricted Subsidiaries to issue any Disqualified Stock or preferred stock; provided, however, that the Company or any Restricted Subsidiary may incur Indebtedness (including Acquired Debt) or issue
Disqualified Stock and any Restricted Subsidiary may issue preferred stock if (x) the Fixed Charge Coverage Ratio for the Company’s most recently ended four full fiscal quarters for which internal financial statements are available
immediately preceding the date on which such additional Indebtedness is incurred or such Disqualified Stock or preferred stock is issued would have been at least 2.0 to 1.0, determined on a pro forma basis (including a pro forma application of the
net proceeds therefrom), as if the additional Indebtedness had been incurred or the Disqualified Stock or preferred stock had been issued, as the case may be, at the beginning of such four-quarter period or (y) the Total Leverage Ratio on the
date on which such additional Indebtedness is incurred or such Disqualified Stock or preferred stock is issued would have been no higher than 6.5 to 1.0, determined on a pro forma basis (including a pro forma application of the net proceeds
therefrom), giving effect to the incurrence of the additional Indebtedness, Disqualified Stock or preferred stock. 
 (b) Subsection
(a) of this Section 4.9 shall not prohibit the incurrence of any of the following items of Indebtedness (collectively, “Permitted Debt”): 

(i) the incurrence by the Company and its Restricted Subsidiaries of Indebtedness under Credit Facilities in an aggregate
principal amount at any one time outstanding under this clause (i) not to exceed $2,500.0 million; 
 (ii) the
incurrence by the Company and its Restricted Subsidiaries of the Existing Indebtedness, including the Existing Notes; 

(iii) the incurrence by the Company and the Note Guarantors of Indebtedness represented by the Initial Notes (including the
Note Guarantees and any future Note Guarantees); 
 (iv) the incurrence by the Company or any of its Restricted Subsidiaries
of Indebtedness represented by Capital Lease Obligations, in an aggregate amount, including all Permitted Refinancing Indebtedness incurred to refund, refinance or replace any Indebtedness incurred pursuant to this clause (iv), not to exceed the
greater of (x) $275.0 million and (y) 1.0% of Consolidated Total Assets at any time outstanding; 
 (v) mortgage
financings or purchase money obligations, in each case, incurred for the purpose of financing all or any part of the purchase price or cost of construction or improvement of property, plant or equipment used in the business of the Company or any
Restricted Subsidiary of the Company, in an aggregate principal amount, including all Permitted Refinancing Indebtedness incurred to refund, refinance or replace any Indebtedness incurred pursuant to this clause (v), not to exceed the greater of (x)
$675.0 million and (y) 2.5% of Consolidated Total Assets at any time outstanding; 

  
 -48- 

 (vi) the incurrence by the Company or any of its Restricted Subsidiaries of
Permitted Refinancing Indebtedness in exchange for, or the net proceeds of which are used to refund, refinance or replace, Indebtedness (other than intercompany Indebtedness) that was permitted by this Indenture to be incurred under
Section 4.9(a) hereof or clauses (ii), (iii), (xii), (xiv) or (xxi) of this Section 4.9(b) or this clause (vi) or, solely to the extent of the excess (if any) of the amount of Indebtedness incurred and outstanding under clause
(xx) of this Section 4.9(b) prior to the applicable refinancing over the maximum aggregate amount permitted to be incurred and outstanding under clause (xx) of this Section 4.9(b) at the time of such refinancing, clause
(xx) of this Section 4.9(b); 
 (vii) the incurrence by the Company or any of its Restricted Subsidiaries of
intercompany Indebtedness between or among the Company and any of its Restricted Subsidiaries; provided, however, that: 

(A) if a Note Guarantor is the obligor on such Indebtedness and the obligee is not the Company or another Note Guarantor, such
Indebtedness must be expressly subordinated (without regard to security interest) to the prior payment in full in cash of all Obligations with respect to the Notes; and 

(B) (i) any subsequent issuance or transfer of Equity Interests that results in any such Indebtedness being held by a
Person other than the Company or a Restricted Subsidiary of the Company and (ii) any sale or other transfer of any such Indebtedness to a Person that is not either the Company or a Restricted Subsidiary of the Company shall be deemed, in each
case, to constitute an incurrence of such Indebtedness by the Company or such Restricted Subsidiary, as the case may be, that is not permitted by this clause (vii); 

(viii) (i) the incurrence by the Company or any of its Restricted Subsidiaries of Hedging Obligations that are incurred
and not for speculative purposes and (ii) the incurrence by a Securitization Special Purpose Entity of Indebtedness in a Qualified Securitization Transaction that is without recourse to the Company or to any other Restricted Subsidiary of the
Company or their assets (other than Standard Securitization Undertakings); 
 (ix) the Guarantee by the Company or any
Restricted Subsidiary of the Company of Indebtedness of the Company or any Restricted Subsidiary that was permitted to be incurred under this Section 4.9 (other than the Note Guarantees); provided that if the Indebtedness being
guaranteed is subordinated to or pari passu with the Notes or any Note Guarantee, then the Guarantee shall be subordinated to the same extent as the Indebtedness guaranteed (without regard to security interest); 

(x) the accrual of interest, the accretion or amortization of original issue discount, the payment of interest on any
Indebtedness in the form of additional Indebtedness with the same terms, and the payment of dividends on Disqualified Stock in the form of additional shares of the same class of Disqualified Stock will not be deemed to be an incurrence of
Indebtedness or an issuance of Disqualified Stock for purposes of this Section 4.9; provided, in each such case, that the amount thereof is included in Fixed Charges of the Company as accrued; 

(xi) obligations in respect of performance and surety bonds and completion guarantees or similar obligations provided by the
Company or any Restricted Subsidiary of the Company in each case in the normal course of business (whether or not consistent with past practice); 

(xii) the incurrence by the Company or any of its Restricted Subsidiaries of Acquired Debt; provided, however,
that on the date of acquisition and after giving effect thereto on a pro forma basis, (i) the Fixed Charge Coverage Ratio of the Company (A) would be at least 2.0 to 1.0 or (B) would be equal to or greater than such Fixed Charge
Coverage Ratio immediately prior to such acquisition or (ii) the Total Leverage Ratio of the Company (A) would be no higher than 6.5 to 1.0 or (B) would be equal to or lower than such Total Leverage Ratio immediately prior to such
acquisition; 

  
 -49- 

 (xiii) the incurrence by any Foreign Subsidiary or other Non-Guarantor Subsidiary of Indebtedness in an aggregate principal amount at any time outstanding, including all Permitted Refinancing Indebtedness incurred to refund, refinance or replace any Indebtedness incurred
pursuant to this clause (xiii), not to exceed the greater of (x) $675.0 million or (y) 2.5% of Consolidated Total Assets; 

(xiv) Indebtedness of the Company or any Restricted Subsidiary incurred in connection with or in contemplation of, or to
provide all or any portion of the funds or credit support utilized to consummate, the acquisition by the Company or any Restricted Subsidiary of the Company of property used or useful in a Permitted Business (whether through the direct purchase of
assets or the purchase of Capital Stock of, or merger or consolidation with, any Person owning such assets); provided, however, on the date of such incurrence and after giving effect thereto on a pro forma basis, (i) the Fixed
Charge Coverage Ratio of the Company (A) would be at least 2.0 to 1.0 or (B) would be equal to or greater than such Fixed Charge Coverage Ratio immediately prior to such incurrence or (ii) the Total Leverage Ratio of the Company
(A) would be no higher than 6.5 to 1.0 or (B) would be equal to or lower than such Total Leverage Ratio immediately prior to such incurrence; 

(xv) Indebtedness incurred by the Company or any of its Restricted Subsidiaries constituting reimbursement obligations with
respect to letters of credit issued in the ordinary course of business, including letters of credit in respect of workers’ compensation claims, death, disability or other employee benefits or property, casualty or liability insurance or
self-insurance, or other Indebtedness with respect to reimbursement-type obligations regarding workers’ compensation claims; provided, however, that upon the drawing of such letters of credit or the incurrence of such
Indebtedness, such obligations are reimbursed within 30 days following such drawing or incurrence; 
 (xvi) Indebtedness
arising from the honoring by a bank or other financial institution of a check, draft or similar instrument drawn against insufficient funds, provided that such Indebtedness is extinguished within five Business Days of notice of its
incurrence; 
 (xvii) Indebtedness of the Company or any of its Restricted Subsidiaries supported by a letter of credit
issued pursuant to the Credit Facilities, in a principal amount not in excess of the stated amount of such letter of credit; 

(xviii) Indebtedness of the Company or any of its Restricted Subsidiaries consisting of (i) the financing of insurance
premiums or (ii) take-or-pay or similar obligations contained in supply arrangements, in each case, incurred in the ordinary course of business; 

(xix) the incurrence by the Company or any of its Restricted Subsidiaries of additional Indebtedness in an aggregate principal
amount (or accreted value, as applicable) at any time outstanding, including all Permitted Refinancing Indebtedness incurred to refund, refinance or replace any Indebtedness incurred pursuant to this clause (xix), not to exceed the greater of (x)
$1,000.0 million and (y) 3.75% of Consolidated Total Assets; 
 (xx) the incurrence by the Company or any of its
Restricted Subsidiaries of Indebtedness secured by a Lien under Credit Facilities in an aggregate principal amount such that, on a pro forma basis (including a pro forma application of the proceeds therefrom), the Secured Leverage Ratio would not
exceed 3.50 to 1.00; 
 (xxi) the incurrence by the Company or any of its Restricted Subsidiaries of Indebtedness of the
Company and/or any Restricted Subsidiary in an aggregate outstanding principal amount not to exceed 100% of the amount of any capital contributions or other proceeds received by the Company or any Restricted Subsidiary (a) from the issuance or
sale of its Equity Interests (other than Disqualified Stock) or (b) in the form of any cash contribution, plus the fair market value, as determined by the Company in good faith, of Cash Equivalents, marketable securities or other property
received by the Company or any Restricted Subsidiary from the issuance and sale of its Equity Interests (other than Disqualified Stock) or a contribution to the capital of the Company or any Restricted Subsidiary (including through consolidation,
amalgamation or merger), in each case after the Issue Date, and in each case other than (x) any proceeds received from the sale of Equity Interests to, or contributions from, the Company or any of its Restricted Subsidiaries, (y) to the
extent the relevant proceeds have otherwise been applied to make Restricted Payments hereunder and (z) any Excluded Contribution; and 

  
 -50- 

 (xxii) the incurrence of Indebtedness of any joint venture or Indebtedness
of the Company or any Restricted Subsidiary incurred on behalf of any joint venture or any guarantees by the Company or any Restricted Subsidiary of Indebtedness of any joint venture in an aggregate outstanding principal amount for all such
Indebtedness not to exceed at any time the greater of $350.0 million and 1.25% of Consolidated Total Assets. 
 (c) The Company shall
not, and shall not permit any Note Guarantor to, incur any Indebtedness (including Permitted Debt) that is contractually subordinated in right of payment to any other Indebtedness of the Company or the Note Guarantors unless such Indebtedness is
also contractually subordinated in right of payment to the Notes on substantially identical terms; provided, however, that no Indebtedness of the Company or the Note Guarantors shall be deemed to be contractually subordinated in right
of payment to any other Indebtedness of the Company or any Note Guarantor solely by virtue of being unsecured or having a junior lien priority. 

(d) For purposes of determining compliance with this Section 4.9, in the event that an item of proposed Indebtedness meets the criteria of
more than one of the categories of Permitted Debt described in clauses (i) through (xxii) of Section 4.9(b) hereof, or is entitled to be incurred pursuant to subsection (a) of this Section 4.9, the Company shall be permitted to
classify such item of Indebtedness on the date of its incurrence, or later reclassify from time to time all or a portion of such item of Indebtedness, in any manner that complies with this Section 4.9. Indebtedness permitted by this
Section 4.9 need not be permitted solely by reference to one clause permitting such Indebtedness but may be permitted in part by one such clause and in part by one or more other clauses of this Section 4.9 permitting such Indebtedness.
Indebtedness under Credit Facilities outstanding on the Issue Date will be deemed to have been incurred on such date in reliance on the exception provided by clause (xx) of Section 4.9(b) hereof. 

(e) In addition, for purposes of determining compliance with this Section 4.9, the Company or the applicable Restricted Subsidiary may,
pursuant to an Officers’ Certificate delivered to the Trustee, elect to treat all or any portion of the commitment under any Indebtedness (including with respect to any revolving loan commitment) as being incurred at the time of such
commitment, in which case any subsequent incurrence of Indebtedness under such commitment shall not be deemed to be an incurrence at such subsequent time. 

Section 4.10 [Reserved]. 

Section 4.11 Liens. 

(a) The Company shall not, and shall not permit any of its Restricted Subsidiaries to, directly or indirectly, create, incur, assume or suffer
to exist any Lien securing Indebtedness of any kind on any asset now owned or hereafter acquired, except Permitted Liens, unless contemporaneously therewith: 

(i) in the case of any Lien securing Indebtedness that ranks pari passu with the Notes of a series or a Note Guarantee
of such series, effective provision is made to secure the Notes of such series or such Note Guarantee, as the case may be, equally and ratably with or prior to such obligation with a Lien on the same assets of the Company or such Restricted
Subsidiary, as the case may be; and 
 (ii) in the case of any Lien securing Indebtedness that is subordinated in right of
payment to the Notes of a series or a Note Guarantee of such series, effective provision is made to secure the Notes of such series or such Note Guarantee, as the case may be, with a Lien on the same assets of the Company or such Restricted
Subsidiary, as the case may be, that is prior to the Lien securing such subordinated obligation. 

  
 -51- 

 Any Lien created for the benefit of Holders pursuant to this Section 4.11 shall provide
by its terms that such Lien shall be automatically and unconditionally released and discharged, without any action on the part of the Holders, upon the release and discharge of each Lien described in clauses (i) and (ii) in this
Section 4.11. 
 Section 4.12 Dividend and Other Payment Restrictions Affecting Restricted Subsidiaries. 

(a) The Company shall not, and shall not permit any of its Restricted Subsidiaries to, directly or indirectly, create or permit to exist or
become effective any consensual encumbrance or restriction on the ability of any such Restricted Subsidiary to: 
 (i) pay
dividends or make any other distributions on its Capital Stock to the Company or any of its Restricted Subsidiaries or pay any indebtedness owed to the Company or any of its Restricted Subsidiaries; 

(ii) make loans or advances to the Company or any of its Restricted Subsidiaries; or 

(iii) transfer any of its properties or assets to the Company or any of its Restricted Subsidiaries. 

(b) The restrictions set forth in Section 4.12(a) hereof shall not apply to encumbrances or restrictions existing under or by reason of:

 (i) agreements, including agreements governing Existing Indebtedness as in effect on the date of this Indenture and any
amendments, modifications, restatements, renewals, increases, supplements, refundings, replacements or refinancings of those agreements, provided that the amendments, modifications, restatements, renewals, increases, supplements, refundings,
replacements or refinancings are, in the good faith judgment of the Company, not materially more restrictive, taken as a whole, with respect to such dividend and other payment restrictions than those contained in those agreements on the date of this
Indenture; 
 (ii) this Indenture, the Notes and the Note Guarantees; 

(iii) any encumbrance or restriction pursuant to Credit Facilities incurred under clause (i) or (xx) of
Section 4.9(b) hereof; 
 (iv) applicable law, rule, regulation or order, approval, license, permit or similar
restriction, including under contracts with foreign governments or agencies thereof entered into in the ordinary course of business; 

(v) any instrument governing Indebtedness, Capital Stock or assets of a Person acquired by the Company or any of its Restricted
Subsidiaries as in effect at the time of such acquisition (except to the extent such Indebtedness was incurred, or such Capital Stock was issued, in connection with or in contemplation of such acquisition), which encumbrance or restriction is not
applicable to any Person, or the properties or assets of any Person, other than the Person, or the property or assets of the Person, so acquired and any amendments, modifications, restatements, renewals, increases, supplements, refundings,
replacements or refinancings of those agreements provided that the amendments, modifications, restatements, renewals, increases, supplements, refundings, replacements or refinancings are, in the good faith judgment of the Company, not materially
more restrictive, taken as a whole, with respect to such dividend and other payment restrictions than those contained in those agreements on the date of the acquisition, provided that, in the case of Indebtedness, such Indebtedness was
permitted to be incurred under Section 4.9 hereof; 
 (vi) customary
non-assignment provisions in leases, contracts and licenses entered into in the ordinary course of business; 

  
 -52- 

 (vii) purchase money obligations for property that impose restrictions on
that property of the nature described in clause (iii) of Section 4.12(a) hereof; 
 (viii) any agreement for the
sale or other disposition of a Restricted Subsidiary that restricts distributions, transfers, loans or advances by that Restricted Subsidiary pending its sale or other disposition; 

(ix) Permitted Refinancing Indebtedness; provided that the restrictions contained in the agreements governing such
Permitted Refinancing Indebtedness are not, in the good faith judgment of the Company, materially more restrictive, taken as a whole, than those contained in the agreements governing the Indebtedness being refinanced; 

(x) Permitted Liens securing Indebtedness that limit the right of the debtor to dispose of the assets subject to such Liens;

 (xi) customary provisions in joint venture agreements, asset sale agreements, stock sale agreements and other similar
agreements entered into with the approval of the Board of Directors of the Company or otherwise in the ordinary course of business; 

(xii) restrictions on cash or other deposits or net worth imposed by customers under contracts entered into in the ordinary
course of business; 
 (xiii) restrictions in agreements or instruments which prohibit the payment or making of dividends or
other distributions other than on a pro rata basis; 
 (xiv) contractual requirements of a Securitization Special Purpose
Entity in connection with a Qualified Securitization Transaction; provided, that such restrictions apply only to such Securitization Special Purpose Entity; and 

(xv) any agreement or instrument governing Indebtedness or preferred stock permitted to be incurred subsequent to the Issue
Date pursuant to Section 4.9 hereof which encumbrances or restrictions (x) are not, in the good faith judgment of the Company, materially more restrictive, taken as a whole, than those contained in this Indenture or (y) will not, in
the good faith judgment of the Company, affect the ability of the Company to make anticipated payments of principal, interest or premium on the Notes. 

Section 4.13 Transactions with Affiliates. 

(a) The Company shall not, and shall not permit any of its Restricted Subsidiaries to, make any payment to, or sell, lease, transfer or
otherwise dispose of any of its properties or assets to, or purchase any property or assets from, or enter into or make or amend any transaction, contract, agreement, understanding, loan, advance or guarantee with, or for the benefit of, any
Affiliate (each, an “Affiliate Transaction”) involving aggregate payments or consideration in excess of $100.0 million, unless: 

(i) the Affiliate Transaction is on terms that are no less favorable, taken as a whole, to the Company or the relevant
Restricted Subsidiary than those that would have been obtained in a comparable transaction by the Company or such Restricted Subsidiary with an unrelated Person, as determined by the Company in good faith; and 

(ii) with respect to any Affiliate Transaction or series of related Affiliate Transactions involving aggregate consideration in
excess of $750.0 million, such Affiliate Transaction has been approved by a majority of the disinterested members of the Board of Directors of the Company. 

(b) The following items shall be deemed not to be Affiliate Transactions and, therefore, will not be subject to the provisions of
Section 4.13(a) hereof: 

  
 -53- 

 (i) any employment agreement or benefit or similar plan entered into by the
Company or any of its Restricted Subsidiaries in the ordinary course of business of the Company or such Restricted Subsidiary; 

(ii) transactions between or among the Company and/or its Restricted Subsidiaries; 

(iii) transactions with a Person that is an Affiliate of the Company solely because the Company owns, directly or through a
Restricted Subsidiary, an Equity Interest in, or controls, such Person; 
 (iv) the payment of reasonable compensation and
fees to, and the provision of customary indemnities to, current or former officers, directors, employees or consultants of the Company or any of its Restricted Subsidiaries; 

(v) issuances or sales of Equity Interests (other than Disqualified Stock) of the Company to Affiliates or employees of or
consultants to the Company; 
 (vi) Restricted Payments that are permitted by the provisions of Section 4.8 hereof and
Permitted Investments; 
 (vii) transactions effected pursuant to agreements in effect on the date of this Indenture and any
amendment, modification or replacement to such agreement (so long the as amendment, modification or replacement is not, in the good faith judgment of the Company, materially more disadvantageous to the Company or such Restricted Subsidiary, taken as
a whole, than the terms of those agreements in effect on the date of this Indenture); 
 (viii) [reserved]; 

(ix) transactions with a Permitted Joint Venture in which the Company or any Restricted Subsidiary holds or acquires an
ownership interest (whether by way of Capital Stock or otherwise) so long as the terms of any such transactions, in the good faith judgment of the Company, are not materially less favorable, taken as a whole, to Company or such Restricted Subsidiary
than they are to other joint venture partners; 
 (x) any agreement that grants registration and other customary rights in
connection therewith or otherwise to the direct or indirect security holders of the Company or any Restricted Subsidiary (and the performance of such agreements); 

(xi) transactions with Affiliates solely in their capacity as Holders of Indebtedness or Capital Stock of the Company or any of
its Restricted Subsidiaries, where such Affiliates receive the same consideration as non-Affiliates in such transactions; 

(xii) transactions affected as part of a Qualified Securitization Transaction; and 

(xiii) transactions in which the Company or any Restricted Subsidiary, as the case may be, delivers to the Trustee a copy of a
letter from an accounting, appraisal or investment banking firm of national standing addressed to the Company stating that such transaction meets the requirements of Section 4.13(a)(i). 

Section 4.14 Asset Sales. 

(a) The Company shall not, and shall not permit any of its Restricted Subsidiaries to, consummate an Asset Sale unless: 

(i) The Company (or its Restricted Subsidiary, as the case may be) receives consideration at the time of the Asset Sale at
least equal to the Fair Market Value (determined, for purposes of this clause (i), by the Company or, in the case of any asset(s) valued in excess of $750.0 million, by the Board of Directors of the Company) of the assets or Equity Interests
issued or sold or otherwise disposed of; and 

  
 -54- 

 (ii) except in the case of a Permitted Asset Swap, at least 75% of the
consideration received in the Asset Sale by the Company or such Restricted Subsidiary is in the form of cash or Cash Equivalents. For purposes of this provision, each of the following will be deemed to be cash: 

(A) any liabilities, as shown on the Company’s most recent consolidated balance sheet, of the Company or any Restricted
Subsidiary (other than contingent liabilities and liabilities that are by their terms subordinated to the Notes and the Note Guarantees) (i) that are assumed by the transferee of any such assets pursuant to an agreement that releases the
Company or such Restricted Subsidiary from further liability or (ii) that are discharged by the transferee in a transaction pursuant to which neither the Company nor any Restricted Subsidiary has any liability following such Asset Sale; 

(B) any securities, notes or other obligations received by the Company or any such Restricted Subsidiary from such transferee
that are converted by the Company or such Restricted Subsidiary into cash within 180 days after the consummation of the applicable Asset Sale, to the extent of the cash received in that conversion; 

(C) any Designated Noncash Consideration having an aggregate Fair Market Value that, when taken together with all other
Designated Noncash Consideration previously received and then outstanding, does not exceed at the time of the receipt of such Designated Noncash Consideration (with the Fair Market Value of each item of Designated Noncash Consideration being
measured at the time received and without giving effect to subsequent changes in value) the greater of $800.0 million or 3.0% of Consolidated Total Assets; and 

(D) future payments to be made in cash or Cash Equivalents owed to the Company or a Restricted Subsidiary in the form of
licensing, royalty, earnout or Milestone Payment (or similar deferred cash payments). 
 (b) Within 450 days after the receipt of any Net
Proceeds from an Asset Sale, the Company or the applicable Restricted Subsidiary may apply an amount equal to those Net Proceeds: 

(i) to repay (w) Indebtedness and other Obligations under the Credit Agreement and, if the Indebtedness repaid under the
Credit Agreement is revolving credit Indebtedness, to correspondingly reduce commitments with respect thereto, (x) other secured indebtedness, (y) other Indebtedness which ranks pari passu in right of payment with the Notes
(provided in the case of this clause (y) the Company shall equally and ratably reduce obligations under each series of Notes in accordance with Section 3.7 hereof, through privately negotiated transactions or open market purchases (in each
case, provided that such purchases are at or above 100% of the principal amount thereof), or by making an offer (in accordance with Section 4.14(c)) to all Holders to purchase, at a purchase price equal to 100% of the principal amount
thereof, plus accrued and unpaid interest, the pro rata principal amount of such series of Notes) or (z) other Indebtedness of a Subsidiary that does not Guarantee the Notes, so long as the relevant assets were assets of such Subsidiary; 

(ii) to acquire all or substantially all of the assets of, or a majority of the Voting Stock of, another Permitted Business or
the minority interest in any Permitted Business; 
 (iii) to make payments with respect to the acquisition or license of
intellectual property rights that are used in a Permitted Business; 
 (iv) to make a capital expenditure in or that is
useful in a Permitted Business; 

  
 -55- 

 (v) to retire Notes (x) pursuant to Section 3.7 hereof,
(y) through privately negotiated transactions or open market purchases or (z) by making an offer to purchase Notes in accordance with Section 4.14(c); or 

(vi) to acquire other assets (other than cash and Cash Equivalents) that are used or useful in a Permitted Business; 

provided that (1) a binding commitment to apply any Net Proceeds from an Asset Sale as set forth in clauses (ii), (iii), (iv) or (vi) of this
Section 4.14(b) shall be treated as a permitted application of the Net Proceeds from the date of such commitment so long as the Company or such Restricted Subsidiary enters into such commitment with the good faith expectation that such Net
Proceeds will be applied to satisfy such commitment within 180 days of the end of such 450-day period (an “Acceptable Commitment”) and, in the event any Acceptable Commitment is later
cancelled or terminated for any reason before the Net Proceeds are applied in connection therewith, then the Company or such Restricted Subsidiary shall be permitted to apply the Net Proceeds in any manner set forth above before the expiration of
such 180-day period and, in the event the Company or such Restricted Subsidiary fails to do so, then such Net Proceeds shall constitute Excess Proceeds and (2) the Company may elect to deem certain
expenditures that would otherwise be permissible reinvestments but that occurred prior to the receipt of the applicable Net Proceeds as having been reinvested in accordance with the provisions of this Section 4.14, but only to the extent such
deemed expenditure shall have been made no earlier than the earlier of the execution of a definitive agreement with respect to such Asset Sale or the consummation thereof. 

Notwithstanding anything in this Section 4.14 to the contrary, the Company shall not be required to apply any amount that would otherwise
be required to be applied pursuant to this Section 4.14 to the extent that the Asset Sale (x) is consummated by any Foreign Subsidiary for so long as the Company determines in good faith that the repatriation to the Company of any such
amount would be prohibited or delayed (beyond the time period during which such application is otherwise required to be made pursuant hereto) under any requirement of law or conflict with the fiduciary duties of such Foreign Subsidiary’s
directors, or result in, or could reasonably be expected to result in, a material risk of personal or criminal liability for any officer, director, employee, manager, member of management or consultant of such Foreign Subsidiary (including on
account of financial assistance, corporate benefit, thin capitalization, capital maintenance or similar considerations); it being understood and agreed that (i) solely within 365 days following the event giving rise to the relevant Net
Proceeds, the Company shall take all commercially reasonable actions required by applicable requirements of law to permit such repatriation and, to the extent applicable, would no longer conflict with the fiduciary duties of such director, or result
in, or be reasonably expected to result in, a material risk of personal or criminal liability for the Persons described above, in either case, and (ii) if such repatriation is permitted or would no longer so conflict, within 365 days following
the event giving rise to the relevant Net Proceeds, the relevant Foreign Subsidiary will promptly repatriate the relevant Net Proceeds, and the repatriated Net Proceeds will be promptly (and in any event not later than two Business Days after such
repatriation) applied (net of additional taxes payable or reserved against such Net Proceeds, as a result thereof, in each case by the Company or the Company’s subsidiaries, and any Affiliates or indirect or direct equity owners of the
foregoing) as required above, or (y) generates Net Proceeds that are received by any joint venture for so long as the Company determines in good faith that the distribution of such Net Proceeds would be prohibited under the organizational
documents (or any relevant shareholders’ or similar agreement) governing such joint venture; it being understood that if the relevant prohibition ceases to exist within the 365-day period following the
event giving rise to the relevant Net Proceeds, the relevant joint venture will promptly distribute the Net Proceeds, as the case may be, and the Net Proceeds, as the case may be, will be promptly (and in any event not later than ten Business Days
after such distribution) applied (net of additional taxes payable or reserved against as a result thereof) as set forth above. In addition, if the Company determines in good faith that the repatriation (or other intercompany distribution) to the
Company of any amounts required to be applied as set forth above would result in material and adverse tax consequences for the Company or any of its subsidiaries, Affiliates or indirect or direct equity owners, taking into account any foreign tax
credit or benefit actually realized in connection with such repatriation (such amount, a “Restricted Amount”), as determined by the Company in good faith, the amount the Company shall be required to apply as set forth above shall be
reduced by the Restricted Amount; provided that to the extent that the repatriation (or other intercompany distribution) of any Net Proceeds from the relevant Foreign Subsidiary would no longer have a material and adverse tax consequence within the 365-day period following the event giving rise to the Net Proceeds, an amount equal to the Net Proceeds not previously applied pursuant to this Section 4.14 shall be so applied. 

  
 -56- 

 Notwithstanding Sections 4.14(a) and 4.14(b), the Company and its Restricted Subsidiaries
will not be required to apply an amount equal to any Net Proceeds in accordance with this Section 4.14 except to the extent that the aggregate Net Proceeds from all Asset Sales which are not applied in accordance with this Section 4.14 in
any calendar year exceeds the greater of $200.0 million or 1.0% of Consolidated Total Assets at the time of receipt of such Net Proceeds (any amount less than such threshold, “Retained Asset Sale Proceeds”). Pending application
of an amount equal to Net Proceeds pursuant to this Section 4.14, the Company or a Restricted Subsidiary may temporarily reduce revolving credit borrowings or otherwise invest the Net Proceeds in any manner that is not prohibited by this
Indenture. 
 (c) Any Net Proceeds from Asset Sales that are not applied or invested as provided in Section 4.14(b) hereof shall
constitute “Excess Proceeds.” When the aggregate amount of Excess Proceeds in any calendar year exceeds the greater of $200.0 million or 1.0% of Consolidated Total Assets with respect to a series of Notes, the Company shall
make an offer (an “Asset Sale Offer”) to all Holders of such series of Notes and all holders of other Indebtedness that is pari passu with the Notes (including Notes of the other series) containing provisions similar to those
set forth in this Indenture with respect to offers to purchase or redeem with the proceeds of sales of assets to purchase the maximum principal amount of Notes such series of and such other pari passu Indebtedness (including Notes of the
other series) that may be purchased out of the amount of such Excess Proceeds. The offer price in any Asset Sale Offer shall be equal to 100% of principal amount plus accrued and unpaid interest to, but not including, the date of purchase, and shall
be payable in cash. If any Excess Proceeds remain after consummation of an Asset Sale Offer (“Declined Asset Sale Proceeds”), the Company and its Restricted Subsidiaries may use the amount of such Excess Proceeds for any purpose not
otherwise prohibited by this Indenture. If the aggregate principal amount of Notes of a series and other pari passu Indebtedness tendered into such Asset Sale Offer exceeds the amount of Excess Proceeds, the Company shall select the Notes of
such series and such other pari passu Indebtedness to be purchased on a pro rata basis. Upon completion of each Asset Sale Offer, the amount of Excess Proceeds shall be reset at zero. 

(d) The Company shall comply with the requirements of Rule 14e-1 under the Exchange Act and any other
securities laws and regulations thereunder to the extent those laws and regulations are applicable in connection with each repurchase of Notes pursuant to an Asset Sale Offer. To the extent that the provisions of any securities laws or regulations
conflict with the Asset Sale provisions of this Indenture, the Company shall comply with the applicable securities laws and regulations and shall not be deemed to have breached its obligations under the Asset Sale provisions of this Indenture by
virtue of such compliance. 
 Section 4.15 Additional Note Guarantees. If any one of the Company’s Subsidiaries that is not
a Note Guarantor Guarantees any Indebtedness of the Company or any Guarantor under any syndicated Credit Facility or Capital Markets Indebtedness, that Subsidiary shall (i) execute and deliver to the Trustee a supplemental indenture in form
reasonably satisfactory to the Trustee and a notation of Note Guarantee substantially in the form of Exhibit B hereto or, in the case that such Subsidiary of the Company is a Canadian Note Guarantor, a Canadian Note
Guarantee, pursuant to which such Subsidiary shall unconditionally Guarantee, on a senior unsecured basis, all of the Company’s obligations under the Notes and this Indenture on the terms set forth in this Indenture and, if applicable, the
Canadian Note Guarantee, and (ii) deliver to the Trustee an Opinion of Counsel that such supplemental indenture and notation of Note Guarantee or, if applicable, Canadian Note Guarantee, has been duly authorized, executed and delivered by such
Subsidiary and constitutes a legal, valid, binding and enforceable obligation of such Subsidiary. Thereafter, such Subsidiary shall be a Note Guarantor for all purposes hereof until such Note Guarantee is released in accordance herewith. 

Notwithstanding the foregoing, the supplemental indenture and notation of Note Guarantee may be modified in respect of any Note Guarantor
organized outside the United States of America as necessary or appropriate to (1) comply with applicable law, (2) avoid any general legal limitations such as general statutory limitations, financial assistance, corporate benefit,
“thin capitalization” rules, retention of title claims or similar matters or (3) avoid a conflict with the fiduciary duties of such company’s directors, contravention of any legal prohibition or regulatory condition, or the
material risk of personal or criminal liability for any officers or directors (collectively referred to as “Agreed Guarantee Principles”), in each case as determined by the Company in its sole discretion. 

  
 -57- 

 Section 4.16 Designation of Restricted and Unrestricted Subsidiaries. The
Company’s Board of Directors may designate any Restricted Subsidiary (other than BHA) to be an Unrestricted Subsidiary if that designation would not cause a Default. Any designation of a Subsidiary as an Unrestricted Subsidiary will be deemed
to be a designation of each of such entity’s Subsidiaries as Unrestricted Subsidiaries. Following the Issue Date, if a Restricted Subsidiary is designated as an Unrestricted Subsidiary, the aggregate Fair Market Value of all outstanding
Investments owned by the Company and its Restricted Subsidiaries in the Subsidiary designated as an Unrestricted Subsidiary shall be deemed to be an Investment made as of the time of the designation and will reduce the amount available for
Restricted Payments under Section 4.8 hereof or under one or more of the clauses of the definition of “Permitted Investments,” as determined by the Company. That designation will only be permitted if the Investment would be permitted
at that time and if the Restricted Subsidiary otherwise meets the definition of an Unrestricted Subsidiary. The Company’s Board of Directors may redesignate any Unrestricted Subsidiary to be a Restricted Subsidiary if the redesignation would
not cause a Default; provided, that such redesignation will be deemed to be an incurrence of Indebtedness and, if applicable, an incurrence of related Liens by a Restricted Subsidiary of the Company of any outstanding Indebtedness and, if
applicable, related Liens of such Unrestricted Subsidiary and such redesignation will only be permitted if such Indebtedness and, if applicable, related Liens are permitted under Section 4.9 hereof and, if applicable, Section 4.11 hereof
(other than clause (3) under the definition of “Permitted Liens”), calculated, if applicable, on a pro forma basis as if such designation had occurred at the beginning of the four-quarter reference period. 

Section 4.17 Business Activities. The Company shall not, and shall not permit any of its Restricted Subsidiaries to, engage in any
business other than Permitted Businesses, except to such extent as would not be material to the Company and its Restricted Subsidiaries, taken as a whole. 

Section 4.18 [Reserved]. 

Section 4.19 Stay, Extension and Usury Laws. The Company covenants (to the extent that it may lawfully do so) that it shall not at
any time insist upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law or other law which would prohibit or forgive the Company from paying all or any portion of the principal of,
premium, if any, or interest on the Notes as contemplated herein, wherever enacted, now or at any time hereafter in force, or which may affect the covenants or the performance of this Indenture, and the Company (to the extent it may lawfully do so)
hereby expressly waives all benefit or advantage of any such law and covenant that it will not, by resort to any such law, hinder, delay or impede the execution of any power herein granted to the Trustee, but will suffer and permit the execution of
every such power as though no such law had been enacted. 
 Section 4.20 Notice of Default. In the event that any Default or
Event of Default under Section 6.1 hereof shall occur, the Company shall give prompt written notice of such Default or Event of Default to the Trustee after it becomes aware of the same. 

Section 4.21 Payment of Additional Amounts. 

(a) All payments made by or on behalf of the Company under or with respect to the Notes, or by or on behalf of any Note Guarantor, under or
with respect to any Note Guarantee (each such Person, a “Payor”) will be made free and clear of any withholding or deduction for or on account of any tax, duty, levy, impost, assessment or other governmental charge of whatever
nature (collectively, “Tax”) imposed or levied by or on behalf of any jurisdiction in which such Payor is organized, resident or carrying on business for tax purposes or from or through which such Payor makes any payment on the
Notes or its Note Guarantee or any department or political subdivision of any of the foregoing (each, a “Relevant Taxing Jurisdiction”), unless the Payor (or an applicable withholding agent) is required to withhold or deduct Taxes
by law. If the Payor (or an applicable withholding agent) is required by law to withhold or deduct any amount for or on account of Taxes of a Relevant Taxing Jurisdiction from any payment made under or with respect to any Notes or Note Guarantee,
the Payor, subject to the exceptions listed below, will pay additional amounts (“Additional Amounts”) as may be necessary to ensure that the net amount received by each Holder or beneficial owner of the Notes after such withholding
or deduction (including withholding or deduction attributable to Additional Amounts payable hereunder) will not be less than the amount the Holder or beneficial owner would have received if such Taxes had not been required to be so withheld or
deducted. 

  
 -58- 

 (b) A Payor will not, however, pay Additional Amounts to a Holder or beneficial owner of
Notes: 
 (i) to the extent the Taxes giving rise to such Additional Amounts would not have been imposed but for the
existence of any present or former connection between the Holder or beneficial owner (or between a fiduciary, settler, beneficiary, member or shareholder of, or possessor of a power over, such Holder or beneficial owner, if such Holder or beneficial
owner is an estate, trust, partnership or corporation) and the Relevant Taxing Jurisdiction (other than any connection resulting solely from the acquisition, ownership, holding or disposition of Notes, the receipt of payments thereunder or under any
Note Guarantee and/or the exercise or enforcement of rights under any Notes or any Note Guarantee); 
 (ii) to the extent the
Taxes giving rise to such Additional Amounts would not have been imposed but for the failure of the Holder or beneficial owner of Notes, following the Company’s or the Payor’s written request addressed to the Holder, to the extent such
Holder or beneficial owner is legally eligible to do so, to comply with any certification, identification, information or other reporting requirements, whether required by statute, treaty, regulation or administrative practice of a Relevant Taxing
Jurisdiction, as a precondition to exemption from, or reduction in the rate of deduction or withholding of, Taxes imposed by the Relevant Taxing Jurisdiction (including, without limitation, a certification that the Holder or beneficial owner is not
resident in the Relevant Taxing Jurisdiction); 
 (iii) with respect to any estate, inheritance, gift, sales, transfer,
capital gains, excise or personal property tax or any similar Taxes; 
 (iv) to the extent the Taxes giving rise to such
Additional Amounts would not have been imposed but for the presentation by the Holder or beneficial owner of any Note, where presentation is required, for payment on a date more than 30 days after the date on which payment became due and
payable or the date on which payment thereof is duly provided for, whichever occurs later; 
 (v) to the extent the Taxes
giving rise to such Additional Amounts would not have been imposed but for the Holder or beneficial owner not dealing at arm’s length, within the meaning of the Income Tax Act (Canada), with such Payor; 

(vi) to the extent the Taxes giving rise to such Additional Amounts would not have been imposed but for such Holder or
beneficial owner being, or not dealing at arm’s length (within the meaning of the Income Tax Act (Canada)) with, a “specified shareholder” of the Company as defined in subsection 18(5) of the Income Tax Act (Canada) for purposes of
the thin capitalization rules in the Income Tax Act (Canada); 
 (vii) to the extent the Taxes giving rise to such Additional
Amounts are U.S. federal withholding taxes imposed pursuant to Sections 1471 through 1474 of the Internal Revenue Code of 1986, as amended (the “Code”), as in effect on the date hereof (or any amended or successor version that is
substantively comparable and not materially more onerous to comply with), any current or future regulations, official interpretations or administrative authority promulgated thereunder and any agreements entered into pursuant to
Section 1471(b)(1) of the Code as in effect on the date hereof (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), and, for the avoidance of doubt, any intergovernmental
agreement (and related legislation, rules or practices) implementing the foregoing (taken together, “FATCA”), except to the extent that such Taxes result from a failure of any Paying Agent to comply with FATCA; or 

(viii) any combination of items (i), (ii), (iii), (iv), (v), (vi) and (vii). 

Additional Amounts also shall not be paid with respect to any payment on a Note to a beneficial owner who is a fiduciary, a partnership (or
entity treated as a partnership for tax purposes) or anyone other than the sole beneficial owner of that payment to the extent that payment would be required by the laws of the Relevant Taxing Jurisdiction to be included in the income, for tax
purposes, of a beneficiary or settlor with respect to the fiduciary, a member of that partnership or a beneficial owner who would not have been entitled to the Additional Amounts had that beneficiary, settlor, member or interest holder been the
beneficial owner. 

  
 -59- 

 (c) The Payor or applicable withholding agent will (i) make any such withholding or
deduction required by applicable law and (ii) timely remit the full amount deducted or withheld to the relevant authority in accordance with applicable law. The Payor, or the applicable withholding agent, will make reasonable efforts to obtain
certified copies of tax receipts evidencing the payment of any Taxes so deducted or withheld from each Relevant Taxing Jurisdiction imposing such Taxes. The Payor, or the applicable withholding agent, will provide to the Trustee, within a reasonable
time after the date the payment of any Taxes so deducted or withheld are due pursuant to applicable law, either a certified copy of tax receipts evidencing such payment, or, if such tax receipts are not reasonably available to the Payor, such other
documentation that provides reasonable evidence of such payment by the Payor. 
 (d) Where Tax is payable pursuant to Regulation 803 of the
Income Tax Act (Canada) by a Holder or beneficial owner of the Notes in respect of any amount payable under the Notes or any Note Guarantee to the Holder (other than by reason of a transfer of the Notes to a person resident in Canada with
whom the transferor does not deal at arm’s length for the purposes of such Act), but no Additional Amount is paid in respect of such Tax, the Payor will pay as or on account of interest to the Holder an amount equal to such Tax (a
“Regulation 803 Reimbursement”) plus an amount equal to any Tax required to be paid by the Holder or beneficial owner as a result of such Regulation 803 Reimbursement within 45 days after receiving from the Holder a notice
containing reasonable particulars of the Tax so payable, provided such Holder or beneficial owner would have been entitled to receive Additional Amounts on account of such Tax (and only to the extent of such Additional Amounts that such
Holder or beneficial owner would have been entitled to receive) but for the fact that it is payable otherwise than by deduction or withholding from payments made under or with respect to the Notes or any Note Guarantee. 

(e) Prior to the date on which the payment of any Additional Amounts are due, the Payor will deliver to the Trustee an Officers’
Certificate stating that such Additional Amounts will be payable on the applicable payment date and setting forth the amounts so payable, and will set forth such other information necessary to enable the Trustee (or applicable paying agent) to pay
such Additional Amounts to Holders on the payment date. Any such Officers’ Certificate will be delivered at least two Business Days in advance of when the payments in question are required to be made (unless a shorter period of time is
acceptable to the Trustee in its reasonable discretion). The Payor will promptly publish a notice in accordance with Section 11.2 hereof stating that such Additional Amounts will be payable and describing the obligation to pay such amounts.

 (f) The Payors, jointly and severally, will reimburse the Holders or beneficial owners of Notes, upon written request of such Holder or
beneficial owner of Notes and certified proof of payment for the amount of (i) any Taxes levied or imposed by a Relevant Taxing Jurisdiction and payable by such Holder or beneficial owner in connection with payments made under or with respect
to the Notes or under or with respect to any Note Guarantee; and (ii) any Taxes levied or imposed with respect to any reimbursement under the foregoing clause (i) or this clause (ii), so that the net amount received by such Holder or
beneficial owner after such reimbursement will not be less than the net amount such Holder or beneficial owner would have received if the Taxes giving rise to the reimbursement described in clauses (i) and/or (ii) had not been imposed,
provided, however, that the indemnification obligation provided for in this Section 4.21(f) shall not extend to Taxes imposed for which the Holder or beneficial owner of the Notes would not have been eligible to receive payment of
Additional Amounts hereunder by virtue of clauses (i) through (viii) of Section 4.21(b) hereof, or to the extent such Holder or beneficial owner received Additional Amounts with respect to such payments. 

(g) In addition, the Payor will pay any stamp, issue, registration, court, documentary, excise or other similar taxes, charges and duties,
including interest and penalties with respect thereto, imposed by any Relevant Taxing Jurisdiction at any time in respect of the execution, issuance, registration or delivery of the Notes or any Note Guarantee or any other document or instrument
referred to thereunder and any such taxes, charges or duties imposed by any Relevant Taxing Jurisdiction at any time as a result of, or in connection with, (i) any payments made pursuant to the Notes or any Note Guarantee or any other such
document or instrument referred to thereunder and/or (ii) the enforcement of the Notes or any Note Guarantee or any other such document or instrument referred to thereunder. 

  
 -60- 

 (h) The obligations described under this Section 4.21 will survive any termination,
defeasance or discharge of this Indenture and will apply mutatis mutandis to any successor Person, to any Payor and to any jurisdiction in which such successor is organized, carrying on business or is otherwise resident for Tax purposes or
any jurisdiction from or through which payment is made by such successor or its respective agents. 
 (i) Whenever this Indenture refers to,
in any context, the payment of principal, premium, if any, interest or any other amount payable under or with respect to any Note or under any Note Guarantee, such reference includes the payment of Additional Amounts or other payments that would be
payable pursuant to this Section 4.21, if applicable. 
 ARTICLE 5 

MERGER, CONSOLIDATION OR SALE OF ASSETS 

Section 5.1 Merger, Consolidation or Sale of Assets. 

(a) The Company shall not, directly or indirectly: (1) consolidate, amalgamate or merge with or into another Person (whether or not the
Company is the surviving Person) or (2) sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company and its Restricted Subsidiaries, taken as a whole, in one or more related
transactions, to another Person, unless: 
 (i) either (x) the Company is the surviving Person; or (y) the Person
formed by or surviving any such consolidation, amalgamation or merger (if other than the Company) or to which such sale, assignment, transfer, conveyance or other disposition has been made is organized and validly existing under the laws of the
U.S., any state of the U.S. or the District of Columbia or under the laws of Canada or any province thereof, any member state of the European Union as in effect on the Issue Date, Bermuda, Cayman Islands, any Channel Island or Switzerland
(provided that, if such entity is not a corporation, a co-obligor of the Notes is a corporation); 

(ii) the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company) or the Person
to which such sale, assignment, transfer, conveyance or other disposition has been made expressly assumes all the obligations of the Company, under the Notes of the applicable series and this Indenture pursuant to agreements reasonably satisfactory
to the Trustee; 
 (iii) immediately after such transaction, no Default or Event of Default exists; 

(iv) either (a) the Company or the Person formed by or surviving any such consolidation, amalgamation or merger (if other
than the Company), or to which such sale, assignment, transfer, conveyance or other disposition has been made shall, on the date of such transaction after giving pro forma effect thereto and any related financing transactions as if the same had
occurred at the beginning of the applicable four-quarter period, be permitted to incur at least $1.00 of additional Indebtedness pursuant to the Fixed Charge Coverage Ratio test or Total Leverage Ratio test set forth in Section 4.9(a) hereof or
(b) the Company or the Person formed by or surviving any such consolidation, amalgamation or merger (if other than the Company) or to which such sale, assignment, transfer, conveyance or other disposition has been made would, on the date of
such transaction after giving pro forma effect thereto and any related financing transactions as if the same had occurred at the beginning of the applicable four-quarter period, have a Fixed Charge Coverage Ratio for such Person and its
Restricted Subsidiaries that would be equal to or greater than such ratio for such Person and its Restricted Subsidiaries immediately prior to such action or have a Total Leverage Ratio for such Person and its Restricted Subsidiaries that would be
equal to or lower than such ratio for such Person and its Restricted Subsidiaries immediately prior to such action; and 

(v) the Company has delivered to the Trustee an Officers’ Certificate stating that such consolidation, amalgamation,
merger, conveyance, transfer or lease and, if a supplemental indenture is required in connection with such transaction, such supplemental indenture, complies with this Article and that all conditions precedent herein provided for relating to such
transaction have been complied with. 

  
 -61- 

 (b) The Company may not, directly or indirectly, lease all or substantially all of its
properties or assets, in one or more related transactions, to any other Person. 
 (c) The Company will not permit any Note Guarantor to,
directly or indirectly, (1) consolidate, amalgamate or merge with or into another Person; or (2) sell, assign, transfer, convey or otherwise dispose (collectively, “dispose”) of all or substantially all of its properties
or assets, in one or more related transactions, to another Person unless: 
 (i) except in the case of a Note Guarantor
(x) that has disposed of all or substantially all of its assets, whether through a merger, amalgamation, consolidation or sale of Capital Stock or assets or (y) that, as a result of the disposition of all or a portion of its Capital Stock,
ceases to be a Subsidiary of the Company, in both cases in compliance with Section 4.14 hereof, the resulting, surviving or transferee Person (if not such Note Guarantor) shall expressly assume, by a guarantee agreement in a form reasonably
satisfactory to the Trustee, all the obligations of such Note Guarantor under its Note Guarantee; and 
 (ii) immediately
after such transaction, no Default or Event of Default exists. 
 Notwithstanding the foregoing: (A) any Restricted Subsidiary may
consolidate or amalgamate with, merge into or transfer all or part of its properties and assets to the Company or any Note Guarantor and (B) the Company may merge or amalgamate with an Affiliate of the Company solely for the purpose of
reincorporating the Company in another jurisdiction within the United States of America, any state thereof or the District of Columbia, or Canada or any province thereof, any member state of the European Union as in effect on the Issue Date,
Bermuda, Cayman Islands, any Channel Island, Singapore or Switzerland or converting the Company into a limited liability company organized under the United States of America, any state thereof or the District of Columbia, or Canada or any province
thereof, any member state of the European Union as in effect on the Issue Date, Bermuda, Cayman Islands, any Channel Island, Singapore or Switzerland (provided that a co-obligor of the Notes is a
corporation). 
 Section 5.2 Successor Substituted. Upon any consolidation of the Company with, or merger or amalgamation of the
Company into, any other Person or any conveyance, transfer or lease of all or substantially all of the properties and assets of the Company in accordance with Section 5.1 hereof, the successor Person formed by such consolidation or into which
the Company is merged or to which such conveyance, transfer or lease is made shall succeed to, and be substituted for, and may exercise every right and power of, the Company under this Indenture with the same effect as if such successor Person had
been named as the Company herein, and thereafter, except in the case of a lease, the predecessor Person shall be relieved of all obligations and covenants under this Indenture and the Notes. 

ARTICLE 6 
 DEFAULT AND REMEDIES

 Section 6.1 Events of Default. Each of the following is an “Event of Default” with respect to any series of
Notes: 
 (a) default in the payment of any principal of (including, without limitation, any premium, if any, on) of the
Notes of such series when the same becomes due and payable (whether at maturity, upon a Redemption Date, Change of Control Purchase Date, Purchase Date or otherwise); 

(b) default in the payment of any interest payable on Notes of such series when the same becomes due and payable and the
Default continues for a period of 30 days; 
 (c) failure by the Company or any of its Restricted Subsidiaries 

(i) to comply with any of the provisions of Sections 3.8, 3.14 or 4.14 of this Indenture with respect to the Notes of such
series, which failure remains uncured for 30 days after written notice to the Company from the Trustee or to the Company and the Trustee from the Holders of at least 25% in principal amount of the Notes of the applicable series; or 

  
 -62- 

 (ii) to comply with the provisions described in Section 5.1 of this
Indenture; 
 (d) the Company or any of its Restricted Subsidiaries fails to comply with any of the other covenants contained
in such series of Notes or this Indenture and the Default continues for 60 days (or 90 days in the case of the provisions of Section 4.3) after written notice to the Company from the Trustee or to the Company and the Trustee from the Holders of
at least 25% in aggregate principal amount of the Notes of the applicable series then outstanding; 
 (e) default under any
mortgage, indenture or instrument under which there may be issued or by which there may be secured or evidenced any Indebtedness for money borrowed by the Company or any of its Restricted Subsidiaries (or the payment of which is Guaranteed by the
Company or any of its Restricted Subsidiaries) whether such Indebtedness or Guarantee now exists, or is created after the date of this Indenture, if that default: 

(i) is caused by a failure to pay principal when due on such Indebtedness within any applicable grace period provided in such
Indebtedness (a “Payment Default”); or 
 (ii) results in the acceleration of such Indebtedness prior to its
express maturity, and, in each case, the principal amount of any such Indebtedness, together with the principal amount of any other such Indebtedness under which there has been a Payment Default or the maturity of which has been so accelerated,
aggregates $250.0 million or more; 
 (f) failure by the Company or any of its Restricted Subsidiaries to pay final non-appealable judgments aggregating in excess of $250.0 million, which judgments are not paid, discharged, stayed or subject to insurance for a period of 60 days after becoming final; 

(g) any Note Guarantee by a Significant Subsidiary ceases to be in full force and effect in all material respects (except as
contemplated by the terms thereof) or any Note Guarantor that is a Significant Subsidiary denies or disaffirms such Note Guarantor’s obligations under this Indenture or any Note Guarantee and such Default continues for 10 days after receipt of
the notice as specified in this Indenture; 
 (h) the Company, any Restricted Subsidiary that is a Significant Subsidiary or
any group of Restricted Subsidiaries that, taken together, would constitute a Significant Subsidiary, pursuant to or within the meaning of any Bankruptcy Law: 

(i) commences a voluntary case or proceeding; 

(ii) consents to the entry of an order for relief against it in an involuntary case or proceeding; 

(iii) consents to the appointment of a Custodian of it or for all or substantially all of its property; or 

(iv) makes a general assignment for the benefit of its creditors; and 

(i) a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that: 

(i) is for relief against the Company, any Restricted Subsidiary that is a Significant Subsidiary or any group of Restricted
Subsidiaries that, taken together, would constitute a Significant Subsidiary in an involuntary case or proceeding; 

  
 -63- 

 (ii) appoints a Custodian of the Company, any Restricted Subsidiary that is
a Significant Subsidiary or any group of Restricted Subsidiaries that, taken together, would constitute a Significant Subsidiary or for all or substantially all of the property of the Company, any Restricted Subsidiary that is a Significant
Subsidiary or any group of Restricted Subsidiaries that, taken together, would constitute a Significant Subsidiary; or 

(iii) orders the liquidation of the Company, any Restricted Subsidiary that is a Significant Subsidiary or any group of
Restricted Subsidiaries that, taken together, would constitute a Significant Subsidiary; 
 and in each case the order or decree described in this clause
(i) remains unstayed and in effect for 60 consecutive days. 
 Any notice given pursuant to Section 6.1(d) hereof must be in
writing and must specify the Default, demand that it be remedied and state that the notice is a “Notice of Default.” When any Default under this Section 6.1 is cured, it ceases. 

Section 6.2 Acceleration. If an Event of Default (other than an Event of Default specified in clause (h) or (i) of
Section 6.1 hereof with respect to the Company) with respect to a particular series of Notes occurs and is continuing, the Trustee may, by notice to the Company, or the Holders of at least 25% in aggregate principal amount of such series of
Notes then outstanding may, by notice to the Company and the Trustee, declare all unpaid principal to the date of acceleration on the Notes of such series then outstanding (if not then due and payable) to be due and payable upon any such
declaration, and the same shall become and be immediately due and payable. If an Event of Default specified in clause (h) or (i) of Section 6.1 hereof with respect to the Company occurs, all unpaid principal (including, without limitation,
any premium, if any, then outstanding), and accrued interest, if any, on the Notes of such series then outstanding shall ipso facto become and be immediately due and payable without any declaration or other act on the part of the Trustee or any
Holder. The Holders of a majority in aggregate principal amount of Notes of such series then outstanding by notice to the Trustee may rescind an acceleration and its consequences with respect to that series if (a) all existing Events of
Default, other than the nonpayment of the principal of such series of Notes which has become due solely by such declaration of acceleration, have been cured or waived; (b) the rescission would not conflict with any judgment or decree of a court
of competent jurisdiction; and (c) all payments due to the Trustee and any predecessor Trustee under Section 7.7 hereof in respect of the Notes of such series have been made. No such rescission shall affect any subsequent default or impair
any right consequent thereto. 
 Section 6.3 Other Remedies. If an Event of Default occurs and is continuing in respect of a
series of Notes, the Trustee may, but shall not be obligated to, pursue any available remedy by proceeding at law or in equity to collect the payment of the principal of or interest on such series of Notes or to enforce the performance of any
provision of such series of Notes or this Indenture. 
 The Trustee may maintain a proceeding even if it does not possess any of such series
of Notes or does not produce any of them in the proceeding. A delay or omission by the Trustee or any Noteholder in exercising any right or remedy accruing upon an Event of Default shall not impair the right or remedy or constitute a waiver of or
acquiescence in the Event of Default. No remedy is exclusive of any other remedy. All available remedies are cumulative to the extent permitted by law. 

Section 6.4 Waiver of Defaults and Events of Default. Subject to Sections 6.7 and 9.2 hereof, the Holders of a majority in
aggregate principal amount of the Notes of a series then outstanding by notice to the Trustee may waive an existing Default or Event of Default with respect to such series and its consequences, except a Default or Event of Default in the payment of
the principal of, premium, if any, or interest on any Notes of such series when due or any Default or Event of Default in respect of any provision of this Indenture or the Notes of such series which, under Section 9.2 hereof, cannot be modified
or amended without the consent of the Holder of each Note of such series affected (with respect to any Notes held by a non-consenting Holder). When a Default or Event of Default is waived, it is cured and
ceases with respect to such series. 

  
 -64- 

 Section 6.5 Control by Majority. The Holders of a majority in aggregate
principal amount of the Notes of a series then outstanding may direct the time, method and place of conducting any proceeding for exercising any remedy or power available to the Trustee or exercising any trust or power conferred on it with respect
to such series. However, the Trustee may refuse to follow any direction that it determines, in consultation with its counsel conflicts with law or this Indenture, that the Trustee determines may be unduly prejudicial to the rights of another Holder
of Notes of such series or the Trustee, or that may involve the Trustee in personal liability unless the Trustee is offered indemnity satisfactory to it; provided, however, that the Trustee may take any other action deemed proper by
the Trustee which is not inconsistent with such direction. 
 Section 6.6 Limitations on Suits. A Holder may not pursue any
remedy with respect to this Indenture or a series of Notes (except actions for payment of overdue principal, premium, if any, or interest) unless: 

(a) the Holder gives to the Trustee written notice of a continuing Event of Default; 

(b) the Holders of at least 25% in aggregate principal amount of the then outstanding Notes of such series make a written
request to the Trustee to pursue the remedy; 
 (c) such Holder or Holders offer to the Trustee reasonable indemnity
satisfactory to the Trustee against any loss, liability or expense; 
 (d) the Trustee does not comply with the request
within 60 days after receipt of the request and the offer of indemnity; and 
 (e) no direction inconsistent with such
written request has been given to the Trustee during such 60-day period by the Holders of a majority in aggregate principal amount of the Notes of the applicable series. 

Section 6.7 Rights of Holders to Receive Payment. Notwithstanding any other provision of this Indenture, with respect to each
series of Notes, the contractual right of any Holder of a Note to receive payment of the principal of, or interest on such Note, on or after the respective due dates expressed in such Note and this Indenture and to bring suit for the enforcement of
any such payment on or after such respective dates, is absolute and unconditional and shall not be impaired or affected without the consent of the Holder. 

Section 6.8 Collection Suit by Trustee. If an Event of Default in the payment of principal or interest specified in clause
(a) or (b) of Section 6.1 hereof occurs and is continuing with respect to any series of Notes, the Trustee may recover judgment in its own name and as trustee of an express trust against the Company or another obligor on the Notes of such
series for the whole amount of principal and accrued interest remaining unpaid, together with, to the extent that payment of such interest is lawful, interest on overdue principal and overdue installments of interest, in each case at a rate equal to
the interest rate then in effect on such Note and such further amount as shall be sufficient to cover the costs and expenses of collection, including the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and
counsel. 
 Section 6.9 Trustee May File Proofs of Claim. The Trustee may file such proofs of claim and other papers or
documents as may be necessary or advisable in order to have the claims of the Trustee (including any claim for the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel) and the Holders allowed in any
judicial proceedings relative to the Company (or any other obligor on the applicable series of Notes), its creditors or its property and shall be entitled and empowered to collect and receive any money or other property payable or deliverable on any
such claims and to distribute the same, and any Custodian in any such judicial proceeding is hereby authorized by each Holder to make such payments to the Trustee and, in the event that the Trustee shall consent to the making of such payments
directly to the Holders, to pay to the Trustee any amount due to it for the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, and any other amounts due the Trustee under Section 7.7 hereof,
and to the extent that such payment of the reasonable compensation, expenses, disbursements and advances in any such proceedings shall be denied for any reason, payment of the same shall be secured by a lien on, and shall be paid out of, any and all
distributions, dividends, money, securities and other property which the Holders may be entitled to receive in such proceedings, 

  
 -65- 

 
whether in liquidation or under any plan of reorganization or arrangement or otherwise. Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to, or, on behalf
of any Holder, to authorize, accept or adopt any plan of reorganization, arrangement, adjustment or composition affecting the Notes of the applicable series or the rights of any Holder thereof, or to authorize the Trustee to vote in respect of the
claim of any Holder in any such proceeding. 
 Section 6.10 Priorities. If the Trustee collects any money pursuant to this
Article 6, it shall pay out the money in the following order: 
 First, to the Trustee for amounts due under
Section 7.7 hereof; 
 Second, to Holders for amounts due and unpaid on the Notes of the applicable series for
principal and interest ratably, without preference or priority of any kind, according to the amounts due and payable on such Notes for principal and interest respectively; and 

Third, the balance, if any, to the Company. 

The Trustee may fix a record date and payment date for any payment to Holders pursuant to this Section 6.10. 

Section 6.11 Undertaking for Costs. In any suit for the enforcement of any right or remedy under this Indenture or in any suit
against the Trustee for any action taken or omitted by it as Trustee, a court in its discretion may require the filing by any party litigant in the suit of an undertaking to pay the costs of the suit, and the court in its discretion may assess
reasonable costs, including reasonable attorneys’ fees and expenses, against any party litigant in the suit, having due regard to the merits and good faith of the claims or defenses made by the party litigant. This Section 6.11 does not
apply to a suit made by the Trustee, a suit by a Holder pursuant to Section 6.7 hereof, or a suit by Holders of more than 10% in aggregate principal amount of the Notes of a series then outstanding. 

ARTICLE 7 
 TRUSTEE 

Section 7.1 Duties of Trustee. 

(a) If an Event of Default has occurred and is continuing, the Trustee shall exercise such of the rights and powers vested in it by this
Indenture and use the same degree of care and skill in its exercise as a prudent person would exercise or use under the circumstances in the conduct of his or her own affairs. 

(b) Except during the continuance of an Event of Default: 

(A) the Trustee need perform only those duties as are specifically set forth in this Indenture and no others; and 

(B) in the absence of bad faith on its part, the Trustee may conclusively rely, as to the truth of the statements and the
correctness of the opinions expressed therein, upon certificates or opinions furnished to the Trustee and conforming to the requirements of this Indenture. The Trustee, however, shall examine any certificates and opinions which by any provision
hereof are specifically required to be delivered to the Trustee to determine whether or not they conform to the requirements of this Indenture (but need not confirm or investigate the accuracy of mathematical calculations or other facts stated
therein). 
 (c) The Trustee may not be relieved from liability for its own negligent action, its own negligent failure to act, or its own
willful misconduct, except that: 
 (A) this paragraph does not limit the effect of subsection (b) of this
Section 7.1; 

  
 -66- 

 (B) the Trustee shall not be liable for any error of judgment made in good
faith by a Trust Officer, unless it is proved that the Trustee was negligent in ascertaining the pertinent facts; and 
 (C)
the Trustee shall not be liable with respect to any action it takes or omits to take in good faith in accordance with a direction received by it pursuant to Section 6.5 hereof. 

(d) No provision of this Indenture shall require the Trustee to expend or risk its own funds or otherwise incur any financial liability in the
performance of any of its duties hereunder or in the exercise of any of its rights or powers unless the Trustee shall have received satisfactory indemnity in its opinion against potential costs and liabilities incurred by it relating thereto. 

(e) Every provision of this Indenture that in any way relates to the Trustee is subject to subsections (a), (b), (c) and (d) of this
Section 7.1. 
 (f) The Trustee shall not be liable for interest on any money received by it except as the Trustee may agree in writing
with the Company. Money held in trust by the Trustee need not be segregated from other funds except to the extent required by law. 

Section 7.2 Rights of Trustee. Subject to Section 7.1 hereof: 

(a) The Trustee may rely conclusively on any document believed by it to be genuine and to have been signed or presented by the
proper person. The Trustee need not investigate any fact or matter stated in the document. 
 (b) Before the Trustee acts or
refrains from acting, it may require an Officers’ Certificate or an Opinion of Counsel (or both), which shall conform to Section 11.4(b) hereof. The Trustee shall not be liable for any action it takes or omits to take in good faith in
reliance on such Officers’ Certificate or Opinion of Counsel. 
 (c) The Trustee may act through its agents and shall
not be responsible for the misconduct or negligence of any agent appointed with due care. 
 (d) The Trustee shall not be
liable for any action it takes or omits to take in good faith which it believes to be authorized or within its rights or powers. 

(e) The Trustee may consult with counsel of its selection, and the advice or opinion of such counsel as to matters of law shall
be full and complete authorization and protection in respect of any such action taken, omitted or suffered by it hereunder in good faith and in accordance with the advice or opinion of such counsel. 

(f) The Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the
request or direction of any of the Holders pursuant to this Indenture, unless such Holders shall have offered to the Trustee security or indemnity satisfactory to the Trustee against the costs, expenses and liabilities which might be incurred by it
in compliance with such request or direction. 
 (g) The Trustee shall not be bound to make any investigation into the facts
or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other evidence of indebtedness or other paper or document, but the Trustee, in its
discretion, may make such further inquiry or investigation into such facts or matters as it may see fit, and, if the Trustee shall determine to make such further inquiry or investigation, it shall be entitled to examine the books, records and
premises of the Company, personally or by agent or attorney at the sole cost of the Company and shall incur no liability or additional liability of any kind by reason of such inquiry or investigation. 

  
 -67- 

 (h) The Trustee shall not be deemed to have notice of any Default or Event
of Default unless written notice of any event which is in fact such a default is received by a responsible Trust Officer of the Trustee at the Corporate Trust Office, and such notice references the applicable series of Notes and this Indenture. 

(i) The rights, privileges, protections, immunities and benefits given to BNY Mellon as Trustee, including, without limitation,
its right to be indemnified, are extended to, and shall be enforceable by, BNY Mellon in each of its capacities hereunder, and to each agent, custodian and other Person employed to act hereunder. 

(j) In no event shall the Trustee be responsible or liable for special, punitive, indirect, or consequential loss or damage of
any kind whatsoever (including, but not limited to, loss of profit) irrespective of whether the Trustee has been advised of the likelihood of such loss or damage and regardless of the form of action. 

(k) In no event shall the Trustee be responsible or liable for any failure or delay in the performance of its obligations
hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural catastrophes or
acts of God, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services; it being understood that the Trustee shall use reasonable efforts which are consistent with accepted practices in the
banking industry to resume performance as soon as practicable under the circumstances. 
 Section 7.3 Individual Rights of
Trustee. The Trustee in its individual or any other capacity may become the owner or pledgee of Notes of a series and may otherwise deal with the Company or an Affiliate of the Company with the same rights it would have if it were not Trustee.
Any Agent may do the same with like rights. However, the Trustee is subject to Sections 7.10 and 7.11 hereof. 
 Section 7.4
Trustee’s Disclaimer. The Trustee makes no representation as to the validity or adequacy of this Indenture or the Notes, it shall not be accountable for the Company’s use of the proceeds from the Notes, and it shall
not be responsible for any statement in the Notes other than its certificate of authentication. 
 Section 7.5 Notice of Default or
Events of Default. If a Default or an Event of Default occurs and is continuing and if a Trust Officer of the Trustee has received written notice of such Default or Event of Default at its Corporate Trust Office and such notice references the
Notes and this Indenture, the Trustee shall notify each Noteholder of the applicable series of the Default or Event of Default within 90 days after it is known by the Trustee. However, the Trustee may withhold the notice if and so long as a
committee of its Trust Officers in good faith determines that withholding notice is in the interests of Noteholders of such series, except in the case of a Default or an Event of Default in payment of the principal (including premium, if any) of or
interest on any Note of such series. 
 Section 7.6 [Reserved]. 

Section 7.7 Compensation and Indemnity. The Company shall pay to the Trustee from time to time such compensation (as agreed to
from time to time by the Company and the Trustee in writing) for its services (which compensation shall not be limited by any provision of law in regard to the compensation of a trustee of an express trust). The Company shall reimburse the Trustee
upon request for all reasonable disbursements, expenses and advances incurred or made by it. Such expenses may include the reasonable compensation, disbursements and expenses of the Trustee’s agents and counsel. 

Each of the Company and each Guarantor, jointly and severally, shall indemnify the Trustee or any predecessor Trustee (which for purposes of
this Section 7.7 shall include its officers, directors, employees and agents) for, and hold it harmless against, any and all loss, liability or expense including taxes (other than taxes based upon, measured by or determined by the income of the
Trustee), (including reasonable legal fees and expenses) incurred by it in connection with the acceptance or administration of its duties under this Indenture or any action or 

  
 -68- 

 
failure to act as authorized or within the discretion or rights or powers conferred upon the Trustee hereunder or thereunder including the reasonable costs and expenses of the Trustee and its
counsel in defending itself against any claim or liability in connection with the exercise or performance of any of its powers or duties hereunder or thereunder. The Trustee shall notify the Company promptly of any claim asserted against the Trustee
for which it may seek indemnity. The Company need not pay for any settlement effected without its prior written consent, which shall not be unreasonably withheld. 

The Company need not reimburse the Trustee for any expense or indemnify it against any loss or liability determined by a court of competent
jurisdiction to have been caused by its own gross negligence or willful misconduct. 
 To secure the Company’s payment obligations in
this Section 7.7, the Trustee shall have a senior claim to which the Notes are hereby made subordinate on all money or property held or collected by the Trustee, except such money or property held in trust to pay the principal of and interest
on the Notes. The obligations of the Company under this Section 7.7 shall survive the satisfaction and discharge of this Indenture or the resignation or removal of the Trustee. 

When the Trustee incurs expenses or renders services after an Event of Default specified in clause (h) or (i) of Section 6.1 hereof
occurs, the expenses and the compensation for the services are intended to constitute expenses of administration under any Bankruptcy Law to the extent permitted by law. The provisions of this Section shall survive the termination of this Indenture.

 Section 7.8 Replacement of Trustee. The Trustee may resign by so notifying the Company. The Holders of a majority in
aggregate principal amount of the Notes of a series then outstanding may remove the Trustee with respect to such series by so notifying the Trustee. The Company may remove the Trustee if: 

(a) the Trustee fails to comply with Section 7.10 hereof; 

(b) the Trustee is adjudged a bankrupt or an insolvent; 

(c) a Custodian or other public officer takes charge of the Trustee or its property; or 

(d) the Trustee becomes incapable of acting. 

If the Trustee resigns or is removed or if a vacancy exists in the office of the Trustee for any reason, the Company shall promptly appoint a
successor Trustee. The resignation or removal of a Trustee shall not be effective until a successor Trustee shall have delivered the written acceptance of its appointment as described below. 

If a successor Trustee does not take office within 45 days after the retiring Trustee resigns or is removed, the retiring Trustee, the Company
or the Holders of 10% in principal amount of the Notes of the applicable series then outstanding may petition any court of competent jurisdiction for the appointment of a successor Trustee with respect to such series at the expense of the Company.

 If the Trustee fails to comply with Section 7.10 hereof, any Holder of the applicable series may petition any court of competent
jurisdiction for the removal of the Trustee with respect to such series and the appointment of a successor Trustee of such series. 
 A
successor Trustee shall deliver a written acceptance of its appointment to the retiring Trustee and to the Company. Immediately after that, the retiring Trustee, upon payment of its charges hereunder, shall transfer all property held by it as
Trustee in respect of such series of Notes to the successor Trustee and be released from its obligations (exclusive of any liabilities that the retiring Trustee may have incurred while acting as Trustee) hereunder, the resignation or removal of the
retiring Trustee shall become effective, and the successor Trustee shall have all the rights, powers and duties of the Trustee in respect of such series of Notes under this Indenture. A successor Trustee shall mail notice of its succession to each
affected Holder. 

  
 -69- 

 A retiring Trustee shall not be liable for the acts or omissions of any successor Trustee
after its succession. 
 Notwithstanding replacement of the Trustee pursuant to this Section 7.8, the Company’s obligations under
Section 7.7 hereof shall continue for the benefit of the retiring Trustee. 
 Section 7.9 Successor Trustee by Merger, Etc.
If the Trustee consolidates with, merges or converts into, or transfers all or substantially all of its corporate trust assets (including the administration of this Indenture) to, another corporation, the resulting, surviving or transferee
corporation, without any further act, shall be the successor Trustee, provided such transferee corporation shall qualify and be eligible under Section 7.10 hereof. Such successor Trustee shall promptly mail notice of its succession to
the Company and each affected Holder. 
 Section 7.10 Eligibility; Disqualification. The Trustee shall always satisfy the
requirements of paragraphs (1), (2) and (5) of TIA Section 310(a). The Trustee (or its parent holding company) shall have a combined capital and surplus of at least $50,000,000. If at any time the Trustee shall cease to satisfy any such
requirements, it shall resign immediately in the manner and with the effect specified in this Article 7. The Trustee shall be subject to the provisions of TIA Section 310(b). 

Section 7.11 Preferential Collection of Claims Against the Company. The Trustee shall comply with TIA Section 311(a),
excluding any creditor relationship listed in TIA Section 311(b). A Trustee who has resigned or been removed shall be subject to TIA Section 311(a) to the extent indicated therein. 

ARTICLE 8 
 DEFEASANCE;
SATISFACTION AND 
 DISCHARGE OF INDENTURE 

Section 8.1 Satisfaction and Discharge of Indenture. This Indenture shall cease to be of further effect with respect to the Notes
of a series and all Note Guarantees with respect to the Notes of such series will be released, and the Trustee, on demand of and at the expense of the Company, shall execute proper instruments acknowledging satisfaction and discharge of this
Indenture and release of such Guarantees with respect to such series of Notes, when 
 (a) either 

(i) all Notes of such series theretofore authenticated and delivered (other than (i) Notes which have been destroyed, lost
or stolen and which have been replaced or paid as provided in Section 2.7 hereof and (ii) Notes of such series for whose payment money has theretofore been deposited in trust and thereafter repaid to the Company as provided in
Section 8.5 hereof) have been delivered to the Trustee for cancellation; or 
 (ii) all Notes of such series not
theretofore delivered to the Trustee for cancellation have become due and payable by reason of the mailing of a notice of redemption or otherwise or will become due and payable within one year and the Company has irrevocably deposited or caused to
be irrevocably deposited cash in U.S. dollars, non-callable Government Securities or a combination thereof with the Trustee or a Paying Agent (other than the Company or any of their Affiliates) as trust funds
in trust for the purpose of and in an amount sufficient, without consideration of any reinvestment of interest, to pay and discharge the entire indebtedness on the Notes of such series not theretofore delivered to the Trustee for cancellation, for
principal, premium, if any, and accrued interest to the date of maturity or redemption, provided that with respect to any redemption that requires the payment of the Applicable Premium, the amount deposited shall be sufficient for purpose of
this Indenture to the extent that an amount is deposited with the Trustee equal to the Applicable Premium calculated by the Company as of the date of the notice of redemption, with any Applicable Premium deficit only required to be deposited with
the Trustee on or prior to the date of redemption; 

  
 -70- 

 (b) no Default or Event of Default has occurred and is continuing with
respect to such series of Notes on the date of the deposit or will occur as a result of the deposit and the deposit will not result in a breach or violation of or constitute a default under, any other instrument to which the Company is a party or by
which the Company is bound, and as to which the rights of the other parties thereto are senior to those of the Holders; 

(c) the Company has paid or caused to be paid all other sums payable hereunder with respect to such series of Notes by the
Company; 
 (d) the Company has delivered irrevocable instructions to the Trustee to apply the deposited money toward payment
of the Notes of such series at maturity or Redemption Date, as the case may be; and 
 (e) the Company has delivered to the
Trustee an Officers’ Certificate and an Opinion of Counsel, each stating that all conditions precedent herein relating to the satisfaction and discharge of this Indenture with respect to such series of Notes have been complied with. 

Notwithstanding the satisfaction and discharge of this Indenture, the obligations of the Company to the Trustee under Section 7.7 hereof
shall survive and, if cash in U.S. dollars, non-callable Government Securities or a combination thereof shall have been deposited with the Trustee pursuant to subclause (ii) of clause (a) of this
Section, the provisions of Sections 2.3, 2.4, 2.5, 2.6, 2.7, 2.12, 4.2 and 7.8, this Article 8 and Section 11.5, shall survive until the Notes of such series have been paid in full. 

Section 8.2 Legal Defeasance. The Company and the Note Guarantors shall be deemed to have paid and will be discharged from any and
all obligations in respect of this Indenture (with respect to the applicable series of Notes) and the Notes of a series and the related Note Guarantees released on the date of the deposit referred to in clause (a) of this Section 8.2, and
the provisions of this Indenture shall no longer be in effect with respect to such series of Notes (“Legal Defeasance”), and the Trustee, at the expense of the Company, shall execute proper instruments acknowledging the same, except
for the following provisions, which shall survive until otherwise terminated or discharged hereunder: (i) the rights of Holders of outstanding Notes of such series to receive solely from the trust fund described in clause (a) below
payments in respect of the principal of, premium, if any, and interest on such series of Notes when such payments are due, (ii) the Company’s obligations with respect to such series of Notes under Article 2 and Section 4.2 hereof,
(iii) the rights, powers, trusts, duties, indemnities and immunities of the Trustee hereunder, including, without limitation, Section 7.7 hereof and the Company’s obligations in connection therewith and (iv) this
Section 8.2. Subject to compliance with this Section 8.2, the Company may exercise its option under this Section 8.2 notwithstanding the prior exercise of its option under Section 8.3 hereof. The following conditions shall apply
to Legal Defeasance: 
 (a) the Company shall have irrevocably deposited with the Trustee, in trust, for the benefit of the
Holders of the Notes of the applicable series, cash in U.S. dollars, Government Securities, or a combination thereof, in such amounts as shall be sufficient, in the opinion of a nationally recognized firm of independent public accountants, to pay
the principal of, or interest and premium, if any, on the outstanding Notes of such series on the Stated Maturity or on the applicable Redemption Date, as the case may be, and the Company must specify whether such Notes of such series are being
defeased to their Stated Maturity or to a particular Redemption Date; 
 (b) the Company shall have delivered to the Trustee
an Opinion of Counsel (based on a ruling received from or published by the United States Internal Revenue Service or a change in the applicable U.S. federal income tax law since the date of this Indenture) in the United States reasonably acceptable
to the Trustee to the effect that the beneficial owners of the outstanding Notes of such series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of such Legal Defeasance and will be subject to U.S. federal
income tax on the same amounts, in the same manner and at the same times as would have been the case if such Legal Defeasance had not occurred; 

(c) the Company shall have delivered to the Trustee either (i) an Opinion of Counsel in Canada reasonably acceptable to
the Trustee to the effect that, based upon Canadian law then in effect and having regard to any applicable proposed amendments thereto which have been publicly announced prior to 

  
 -71- 

 
the date of such defeasance, the beneficial owners of the outstanding Notes of such series will not recognize income, gain or loss for Canadian federal, provincial or territorial or other tax
purposes, as a result of such Legal Defeasance and will be subject to Canadian taxes on the same amounts and in the same manner and at the same time as would have been the case if such Legal Defeasance had not occurred or (ii) a ruling directed
to the Trustee received from tax authorities of Canada to the same effect as the Opinion of Counsel described in clause (b) above; 

(d) no Default or Event of Default shall have occurred and be continuing on the date of such deposit (other than a Default or
an Event of Default resulting from the borrowing of funds to be applied to such deposit); 
 (e) the Legal Defeasance shall
not result in a breach or violation of, or constitute a default under, any material agreement or instrument (other than this Indenture with respect to such series of Notes) to which the Company or any of its Subsidiaries is a party or by which the
Company or any of its Subsidiaries is bound; and 
 (f) the Company must deliver to the Trustee an Officers’ Certificate
and an Opinion of Counsel, each stating that all conditions precedent relating to the Legal Defeasance have been complied with. 
 After any
such irrevocable deposit, the Trustee upon request shall acknowledge in writing the discharge of the Company’s obligations under the applicable series of Notes and this Indenture with respect to such series of Notes except for those surviving
obligations in the immediately preceding paragraph. 
 Notwithstanding the foregoing, the Opinion of Counsel required by Section 8.2(b)
hereof with respect to a Legal Defeasance need not be delivered if all Notes of such series not theretofore delivered to the Trustee for cancellation (1) have become due and payable or (2) shall become due and payable upon maturity or
redemption within one year under arrangements satisfactory to the Trustee for the giving of notice of redemption by the Trustee in the name, and at the expense, of the Company. 

Section 8.3 Covenant Defeasance. The Company may omit to comply with any term, provision or condition set forth in clause
(iv) of Section 5.1(a) hereof, and the Company and its Restricted Subsidiaries may omit to comply with any term, provision or condition set forth in Section 3.8, Section 4.3, Sections 4.8 through 4.17 hereof and any breach of
clauses (c), (d),(e), (f) or (g) of Section 6.1 hereof, or with respect to Significant Subsidiaries only, clauses (h) or (i) under Section 6.1 hereof shall be deemed not to be an Event of Default and all Guarantees and Liens
shall be released on the date of deposit referred to in clause (a) of this Section 8.3 (“Covenant Defeasance”), if in each case: 

(a) the Company shall have irrevocably deposited with the Trustee, in trust, for the benefit of the Holders of the applicable
series of Notes, cash in U.S. dollars, Government Securities, or a combination thereof, in such amounts as shall be sufficient, in the opinion of a nationally recognized firm of independent public accountants, to pay the principal of, or interest
and premium, if any, on the outstanding Notes of such series on the Stated Maturity or on the applicable Redemption Date, as the case may be, and the Company must specify whether such Notes of such series are being defeased to their Stated Maturity
or to a particular Redemption Date; 
 (b) the Company shall have delivered to the Trustee an Opinion of Counsel in the
United States reasonably acceptable to such Trustee confirming that the beneficial owners of the outstanding Notes of such series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of such Covenant Defeasance
and will be subject to U.S. federal income tax on the same amounts, in the same manner and at the same times as would have been the case if the Covenant Defeasance had not occurred; 

(c) the Company shall have delivered to the Trustee either (i) an Opinion of Counsel in Canada reasonably acceptable to
the Trustee to the effect that, based upon Canadian law then in effect and having regard to any applicable proposed amendments thereto which have been publicly announced prior to 

  
 -72- 

 
the date of such defeasance, the beneficial owners of the outstanding Notes of such series will not recognize income, gain or loss for Canadian federal, provincial or territorial or other tax
purposes, as a result of such Covenant Defeasance, and will be subject to Canadian taxes on the same amounts and in the same manner and at the same time as would have been the case if such Covenant Defeasance, had not occurred or (ii) a ruling
directed to the Trustee received from tax authorities of Canada to the same effect as the Opinion of Counsel described in clause (b) above; 

(d) no Default or Event of Default shall have occurred and be continuing with respect to such series of Notes on the date of
such deposit (other than a Default or Event of Default resulting from the borrowing of funds to be applied to such deposit); 

(e) the Covenant Defeasance shall not result in a breach or violation of, or constitute a default under any material agreement
or instrument (other than this Indenture with respect to such series of Notes) to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries is bound; and 

(f) the Company must deliver to the Trustee an Officers’ Certificate and an Opinion of Counsel, each stating that all
conditions precedent relating to the Covenant Defeasance have been complied with. 
 If the funds deposited with the Trustee to effect
Covenant Defeasance are insufficient to pay the principal of and interest on the applicable series of Notes when due, then the obligations of the Company and the Note Guarantors under this Indenture will be revived and no such defeasance will be
deemed to have occurred. 
 Notwithstanding the foregoing, the Opinion of Counsel required by Section 8.3(b) hereof with respect to a
Covenant Defeasance need not be delivered if all Notes of the applicable series not theretofore delivered to the Trustee for cancellation (1) have become due and payable or (2) shall become due and payable upon maturity or redemption
within one year under arrangements satisfactory to the Trustee for the giving of notice of redemption by the Trustee in the name, and at the expense, of the Company. 

Section 8.4 Application of Trust Money. Subject to the provisions of Section 8.5 hereof, the Trustee or a Paying Agent shall
hold in trust, for the benefit of the Holders of the applicable series of Notes, all money deposited with it pursuant to Section 8.1, 8.2 or 8.3 hereof and shall apply the deposited money in accordance with this Indenture and the applicable
series of Notes to the payment of the principal of and interest on such series of Notes. 
 Section 8.5 Repayment to the
Company. The Trustee and each Paying Agent shall promptly pay to the Company upon request any excess money (i) deposited with them pursuant to Section 8.1, 8.2 or 8.3 hereof and (ii) held by them at any time. 

The Trustee and each Paying Agent shall pay to the Company upon request any money held by them for the payment of principal or interest that
remains unclaimed for two years after a right to such money has matured; provided, however, that the Trustee or such Paying Agent, before being required to make any such payment, may at the expense of the Company cause to be mailed to
each Holder entitled to such money notice that such money remains unclaimed and that after a date specified therein, which shall be at least 30 days from the date of such mailing, any unclaimed balance of such money then remaining will be repaid to
the Company. After payment to the Company, Holders entitled to money must look to the Company for payment as general creditors unless an applicable abandoned property law designates another person. 

Section 8.6 Reinstatement. If the Trustee or any Paying Agent is unable to apply any money in accordance with Section 8.5
hereof by reason of any legal proceeding or by reason of any order or judgment of any court or governmental authority enjoining, restraining or otherwise prohibiting such application, then the Company’s obligations under this Indenture and the
applicable series of Notes shall be revived and reinstated as though no deposit had occurred pursuant to Section 8.1, 8.2 or 8.3 hereof until such time as the Trustee or such Paying Agent is permitted to apply all such money or Government
Securities in accordance with Section 8.4 hereof; provided, 

  
 -73- 

 
however, that if the Company has made any payment of the principal of or interest on any Notes of any series because of the reinstatement of its obligations, the Company shall be
subrogated to the rights of the Holders of such Notes to receive any such payment from the money or Government Securities held by the Trustee or such Paying Agent. 

ARTICLE 9 
 AMENDMENTS,
SUPPLEMENTS AND WAIVERS 
 Section 9.1 Without Consent of Holders. The Company and the Trustee may amend or supplement this
Indenture with respect to Notes of a series without notice to or consent of any Holder of Notes of such series: 
 (a) to
comply with Section 5.1 hereof; 
 (b) to cure any ambiguity, defect or inconsistency; 

(c) to provide for uncertificated Notes in addition to or in place of certificated Notes of such series; 

(d) to provide for the assumption of the Company’s or any Note Guarantor’s obligations to Holders of Notes of such
series in the case of a consolidation or merger or sale of all or substantially all of the Company’s or a Note Guarantor’s assets; 

(e) to make any change that would provide any additional rights or benefits to the Holders of Notes of such series or that does
not adversely affect the legal rights under this Indenture of any such Holder of Notes of such series; 
 (f) to comply with
requirements of the SEC in order to effect or maintain the qualification of this Indenture under the TIA; 
 (g) to conform
the text of this Indenture, the Notes of such series or the Note Guarantees of such series to any provision of the section of the Offering Memorandum dated May 9, 2019 captioned “Description of the Notes”; 

(h) to provide for the issuance of Additional Notes of such series in accordance with the limitations set forth in this
Indenture as of the date hereof; 
 (i) to add additional Note Guarantees with respect to the Notes of such series or to
confirm and evidence the release, termination or discharge of any Note Guarantee with respect to Notes of such series when such release, termination or discharge is permitted under this Indenture; or 

(j) to appoint a successor Trustee. 

Section 9.2 With Consent of Holders. The Company and the Trustee may amend or supplement this Indenture and the Notes of a series
with the written consent of the Holders of at least a majority in aggregate principal amount of the Notes of such series then outstanding (including, without limitation, consents obtained in connection with a purchase of, or tender offer or exchange
offer for, Notes). The Holders of at least a majority in aggregate principal amount of the Notes of a series then outstanding may waive compliance in a particular instance by the Company with any provision of this Indenture, or Notes of such series
without notice to any Holder (including, without limitation, consents obtained in connection with a purchase of, or tender offer or exchange offer for, the Notes of such series). However, notwithstanding the foregoing but subject to Section 9.4
hereof, without the written consent of each Holder of Notes a series affected hereby, an amendment, supplement or waiver, including a waiver pursuant to Section 6.4 hereof, may not (with respect to any Notes of such series held by a non-consenting Holder): 

  
 -74- 

 (a) reduce the principal amount of Notes of such series whose Holders must
consent to an amendment, supplement or waiver; 
 (b) reduce the principal of or change the Stated Maturity of any such Note
or alter the provisions with respect to the redemption of such Notes (excluding, for the avoidance of doubt, provisions relating to Sections 3.8, 3.14 and 4.14 hereof); 

(c) reduce the rate of or change the time for payment of interest on any such Note; 

(d) make any such Note payable in money other than U.S. dollars; 

(e) make any change in the provisions of this Indenture relating to waivers of past Defaults or the rights of Holders of such
Notes to receive payments of principal of, or interest or premium, if any, on such Notes; 
 (f) waive a redemption payment
with respect to any such Note (excluding, for the avoidance of doubt, a payment required by Sections 3.8, 3.14 and 4.14 hereof); 

(g) impair the right to institute suit for the enforcement of any payment on or with respect to such Notes; 

(h) modify the Note Guarantees with respect to such Notes in any manner adverse to the Holders of such Notes; or 

(i) make any change in the preceding amendment and waiver provisions with respect to a series of the Notes. 

In addition, without the consent of Holders of at least
662⁄3% in principal amount of the Notes of a series then outstanding (including, without limitation, consents obtained in connection with a purchase of, or tender
offer or exchange offer for, Notes), except as set forth in Section 10.5 hereof, no amendment or supplement may release the Note Guarantees with respect to the Notes of such series. 

It shall not be necessary for the consent of the Holders under this Section 9.2 to approve the particular form of any proposed amendment,
supplement or waiver, but it shall be sufficient if such consent approves the substance thereof. 
 Section 9.3 Notice of Amendment,
Supplement or Waiver. After an amendment, supplement or waiver under Section 9.1 or Section 9.2 becomes effective, the Company shall mail to the Holders affected thereby a notice briefly describing the amendment, supplement or waiver.
Any failure of the Company to mail such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such amendment, supplement or waiver. 

Section 9.4 Revocation and Effect of Consents. Until an amendment, supplement or waiver becomes effective, a consent to it by a
Holder is a continuing consent by the Holder and every subsequent Holder of a Note or portion of a Note that evidences the same debt as the consenting Holder’s Note, even if notation of the consent is not made on any Note. However, any such
Holder or subsequent Holder may revoke the consent as to its Note or portion of a Note if the Trustee receives the notice of revocation before the date the amendment, supplement or waiver becomes effective. 

After an amendment, supplement or waiver becomes effective, it shall bind every Holder, unless it makes a change described in any of clauses
(a) through (i) of Section 9.2 hereof. In that case the amendment, supplement or waiver shall bind each Holder of a Note who has consented to it and every subsequent Holder of a Note or portion of a Note that evidences the same debt as the
consenting Holder’s Note. 

  
 -75- 

 Section 9.5 Notation on or Exchange of Notes. If an amendment, supplement or
waiver changes the terms of a Note, the Trustee may require the Holder of the Note to deliver it to the Trustee. The Trustee may place an appropriate notation on the Note about the changed terms and return it to the Holder. Alternatively, if the
Company or the Trustee so determines, the Company in exchange for the Note shall issue and the Trustee shall authenticate a new Note that reflects the changed terms. 

Section 9.6 Trustee to Sign Amendments, Etc. The Trustee shall sign any amendment or supplemental indenture authorized pursuant to
this Article 9 if the amendment or supplemental indenture does not adversely affect the rights, duties, liabilities or immunities of the Trustee. If it does, the Trustee may, in its sole discretion, but need not sign it. In signing or refusing to
sign such amendment or supplemental indenture, the Trustee shall be provided with and, subject to Section 7.1 hereof, shall be fully protected in relying upon, an Opinion of Counsel and an Officers’ Certificate stating that such amendment
or supplemental indenture is authorized or permitted by this Indenture and all conditions precedent in this Indenture to such execution have been complied with. The Company may not sign an amendment or supplemental indenture until its Board of
Directors approves it in writing. 
 Section 9.7 Effect of Supplemental Indentures. Upon the execution of any supplemental
indenture under this Article 9, this Indenture shall be modified in accordance therewith, and such supplemental indenture shall form a part of this Indenture for all purposes with respect to any affected series of Notes; and every Holder of
applicable Notes theretofore or thereafter authenticated and delivered hereunder shall be bound thereby. 
 ARTICLE 10 

NOTE GUARANTEES 

Section 10.1 Note Guarantees. 

(a) Each of the Note Guarantors, jointly and severally, hereby unconditionally Guarantees (and subject in each case to the Agreed Guarantee
Principles set forth in any notation of Note Guarantee, supplemental indenture, or as contemplated by Section 4.15 hereof) to each Holder of a Note authenticated and delivered by the Trustee and to the Trustee and its successors and assigns,
irrespective of the validity and enforceability of this Indenture, the Notes or the obligations of the Company hereunder or thereunder that: (i) the due and punctual payment of principal, premium and interest on the Notes shall be promptly paid
in full when due, whether at maturity, by acceleration, redemption or otherwise, (ii) the due and punctual payment of interest on the overdue principal of and interest on the Notes, if any, if lawful, and all other obligations of the Company to
the Holders or the Trustee under this Indenture or any Note shall be promptly paid in full or performed, all in accordance with the terms hereof and thereof, and (iii) in case of any extension of time of payment or renewal of any Notes or any
of such other obligations, that same shall be promptly paid in full when due or performed in accordance with the terms of the extension or renewal, whether at stated maturity, by acceleration pursuant to Section 6.2 hereof or otherwise. Failing
payment when due of any amount so guaranteed or any performance so guaranteed for whatever reason, the Note Guarantors shall be jointly and severally obligated to pay the same immediately. Each Note Guarantor shall agree that this is a Guarantee of
payment and not a Guarantee of collection. 
 (b) Each of the Note Guarantors hereby agrees that its obligations with regard to its Guarantee
shall be joint and several, unconditional, irrespective of the validity or enforceability of the Notes or the obligations of the Company under this Indenture, the absence of any action to enforce the same, the recovery of any judgment against the
Company or any other obligor with respect to this Indenture, the Notes or the obligations of the Company under this Indenture or the Notes, any action to enforce the same or any other circumstances (other than complete performance) which might
otherwise constitute a legal or equitable discharge or defense of a Note Guarantor. Each Note Guarantor further, to the extent permitted by law, hereby waives and relinquishes all claims, rights and remedies accorded by applicable law to guarantors
and agrees not to assert or take advantage of any such claims, rights or remedies, including but not limited to: (i) any right to require any of the Trustee, the Holders or the Company (each a “Benefited Party”), as a condition
of payment or performance by such Note Guarantor, to (A) proceed against the Company, any other guarantor (including any other Note Guarantor) of the obligations under the Note Guarantees or any other person, (B) proceed against or exhaust
any security held from the Company, any such other guarantor or any other person, (C) proceed against or have resort to any balance of 

  
 -76- 

 
any deposit account or credit on the books of any Benefited Party in favor of the Company or any other person, or (D) pursue any other remedy in the power of any Benefited Party whatsoever;
(ii) any defense arising by reason of the incapacity, lack of authority or any disability or other defense of the Company including any defense based on or arising out of the lack of validity or the unenforceability of the obligations under the
Note Guarantees or any agreement or instrument relating thereto or by reason of the cessation of the liability of the Company from any cause other than payment in full of the obligations under the Note Guarantees; (iii) any defense based upon
any statute or rule of law which provides that the obligation of a surety must be neither larger in amount nor in other respects more burdensome than that of the principal; (iv) any defense based upon any Benefited Party’s errors or
omissions in the administration of the obligations under the Note Guarantees, except behavior which amounts to bad faith; (v) (A) any principles or provisions of law, statutory or otherwise, which are or might be in conflict with the terms of
the Note Guarantees and any legal or equitable discharge of such Note Guarantor’s obligations hereunder and under its Note Guarantee, (B) the benefit of any statute of limitations affecting such Note Guarantor’s liability hereunder
and under its Note Guarantee or the enforcement hereof and thereof, (C) any rights to set-offs, recoupments and counterclaims and (D) promptness, diligence and any requirement that any Benefited
Party protect, secure, perfect or insure any security interest or lien or any property subject thereto; (vi) notices, demands, presentations, protests, notices of protest, notices of dishonor and notices of any action or inaction, including
acceptance of the Note Guarantees, notices of default under the Notes or any agreement or instrument related thereto, notices of any renewal, extension or modification of the obligations under the Note Guarantees or any agreement related thereto,
and notices of any extension of credit to the Company and any right to consent to any thereof; (vii) to the extent permitted under applicable law, the benefits of any “One Action” rule; and (viii) any defenses or benefits that
may be derived from or afforded by law which limit the liability of or exonerate guarantors or sureties, or which may conflict with the terms of the Note Guarantees. Except as set forth in Section 10.5 hereof, each Note Guarantor covenants that
its Note Guarantee shall not be discharged except by complete performance of the obligations contained in its Note Guarantee and this Indenture. 

(c) If any Holder or the Trustee is required by any court or otherwise to return to the Company, the Note Guarantors or any custodian, trustee,
liquidator or other similar official acting in relation to either the Company or the Note Guarantors, any amount paid to either the Trustee or such Holder, any Guarantee, to the extent theretofore discharged, shall be reinstated in full force and
effect. 
 (d) Each Note Guarantor agrees that it shall not be entitled to any right of subrogation in relation to the Holders in respect of
any obligations guaranteed hereby until payment in full of all obligations guaranteed hereby. Each Note Guarantor shall further agree that, as between the Note Guarantors, on the one hand, and the Holders and the Trustee, on the other hand,
(i) the maturity of the obligations guaranteed hereby may be accelerated as provided in Section 6.2 hereof for the purposes of any Guarantee, notwithstanding any stay, injunction or other prohibition preventing such acceleration in respect
of the obligations guaranteed hereby and (ii) in the event of any declaration of acceleration of such obligations as provided in Section 6.2 hereof, such obligations (whether or not due and payable) shall forthwith become due and payable
by the Note Guarantors for the purpose of any such Guarantee. The Note Guarantors shall have the right to seek contribution from any non-paying Note Guarantor so long as the exercise of such right does not
impair the rights of the Holders under the applicable Guarantee. 
 Section 10.2 Execution and Delivery of Note Guarantees. To
evidence its Guarantee set forth in Section 10.1 hereof, each Note Guarantor hereby agrees that a notation of such Note Guarantee substantially in the form of Exhibit B hereto (as modified to reflect Agreed Guarantee
Principles to the extent contemplated by Section 4.15 hereof) or, in the case of a Note Guarantor organized under the laws of Canada or any province or territory thereof, a Canadian Note Guarantee, shall be endorsed by an officer of such Note
Guarantor, which notation shall be applicable to each Note authenticated and delivered by the Trustee, and that this Indenture shall be executed on behalf of such Note Guarantor by any of its Officers. Each of the Note Guarantors, jointly and
severally, hereby agrees that its Guarantee set forth in Section 10.1 hereof shall remain in full force and effect notwithstanding any failure to endorse a notation of such Note Guarantee. If an officer or Officer whose signature is on this
Indenture or on the Note Guarantee of a Note Guarantor no longer holds that office at the time the Trustee authenticates a Note, the Note Guarantee of such Note Guarantor shall be valid nevertheless. The delivery of any Note by the Trustee, after
the authentication thereof hereunder, shall constitute due delivery of the Note Guarantees set forth in this Indenture on behalf of the Note Guarantors. 

  
 -77- 

 Section 10.3 Limitation on Note Guarantor Liability. Each Note Guarantor
confirms, and by its acceptance of Notes, each Holder hereby confirms, that it is the intention of all such parties that any Guarantee of such Note Guarantor not constitute a fraudulent transfer or conveyance for purposes of Bankruptcy Law, the
Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act or any similar applicable law to the extent applicable to any Note Guarantee. To effectuate the foregoing intention, the Trustee and the Holders irrevocably agree, and the Note
Guarantors irrevocably agree, that the obligations of such Note Guarantor under this Article 10 shall be limited to the maximum amount as will, after giving effect to such maximum amount and all other contingent and fixed liabilities of such Note
Guarantor that are relevant under such laws, and after giving effect to any collections from, rights to receive contribution from or payments made by or on behalf of any other Note Guarantor in respect of the obligations of such other Note Guarantor
under this Article 10, result in the obligations of such Note Guarantor under its Note Guarantee not constituting a fraudulent transfer or conveyance. 

Section 10.4 Merger and Consolidation of Note Guarantors. 

(a) In case of any sale or other disposition, consolidation, amalgamation, merger, sale or conveyance and upon the assumption by the successor
person, by supplemental indenture, executed and delivered to the Trustee and satisfactory in form to the Trustee, of the Note Guarantee endorsed upon the Notes and the due and punctual performance of all of the covenants and conditions of this
Indenture to be performed by the Note Guarantor, such successor person shall succeed to and be substituted for the Note Guarantor with the same effect as if it had been named herein as a Note Guarantor. Such successor person thereupon may cause to
be signed any or all of the Note Guarantees to be endorsed upon all of the Notes available hereunder which theretofore shall not have been signed by the Company and delivered to the Trustee. All the Note Guarantees so issued shall in all respects
have the same legal rank and benefit under this Indenture as the Note Guarantees theretofore and thereafter issued in accordance with the terms of this Indenture as though all of such Note Guarantees had been issued at the date of the execution
hereof. 
 (b) Except as set forth in Articles 4 and 5 hereof, and notwithstanding clause (a) of this Section 10.4, nothing
contained in this Indenture or in any of the Notes shall prevent any consolidation, amalgamation or merger of a Note Guarantor with or into another Person, or shall prevent any sale or conveyance of the property of a Note Guarantor as an entirety or
substantially as an entirety. 
 Section 10.5 Release. 

(a) In the event (i) of a sale or other disposition of all or substantially all of the assets of any Note Guarantor, by way of merger,
amalgamation, consolidation or otherwise, or a sale or other disposition of all the Equity Interests of any Note Guarantor, then held by the Company and its Restricted Subsidiaries to a person that is not (either before or after giving effect to
such transactions) a Subsidiary of the Company, in each case so long as such sale or other disposition is permitted by this Indenture, including without limitation Section 4.14 hereof, (ii) of a designation by the Company of any Restricted
Subsidiary that is a Note Guarantor as an Unrestricted Subsidiary in accordance with the definition thereof or in the event that such Note Guarantor ceases to be a Restricted Subsidiary in accordance with the provisions of this Indenture,
(iii) in the case of any Note Guarantee issued on the Issue Date, upon the release or discharge of the Note Guarantee by such Note Guarantor in respect of the Credit Agreement, and in any other case upon the release or discharge of any Note
Guarantee in respect of any Indebtedness that resulted in the issuance after the Issue Date of the Note Guarantee by such Note Guarantor or (iv) the Company discharges the Notes of such series and its Obligations under this Indenture under
Section 8.1 hereof or exercises its legal or covenant defeasance options under Section 8.2 or 8.3 hereof, respectively, with respect to the Notes of a series, such Note Guarantor shall be released and relieved of any obligations under its
Note Guarantee (in the case of clause (iv), only with respect to the applicable series and not with respect to the other series of Notes) without any further action being required by the Trustee or any Holder. If the Company discharges this
Indenture under Section 8.1 hereof with respect to any series of Notes or exercises its legal or covenant defeasance options under Section 8.2 or 8.3 hereof with respect to any series of Notes, respectively, the Company and each Note
Guarantor shall be released and relieved of any obligations under its Note Guarantee with respect to such series of Notes and not with respect to the other series of Notes without any further action being required by the Trustee or any Holder. 

  
 -78- 

 (b) Upon delivery by the Company to the Trustee of an Officers’ Certificate and an
Opinion of Counsel to the effect that such sale or other disposition was made by the Company in accordance with the provisions of this Indenture, including without limitation Sections 4.8 and 4.14 hereof, the Trustee shall execute any documents
reasonably required in order to evidence the release of any Note Guarantor from its obligations under its Guarantee. 
 (c) Any Note
Guarantor not released from its obligations under its Note Guarantee (including in respect of a series of Notes) shall remain liable for the full amount of principal of and interest on the Notes and for the other obligations of any Note Guarantor
under this Indenture as provided in this Article 10. 
 ARTICLE 11 

MISCELLANEOUS 
 Section 11.1
Certain Trust Indenture Act Sections. The Company shall comply with Sections 314(a)(4), 314(c) and 314(e) of the TIA. No other provision of the TIA shall apply except where otherwise specifically provided. 

Section 11.2 Notices. Any demand, authorization notice, request, consent or communication shall be given in writing and delivered
in person or mailed by first-class mail, postage prepaid, addressed as follows or transmitted by facsimile transmission (confirmed by delivery in person or mail by first-class mail, postage prepaid, or by guaranteed overnight courier) to the
following facsimile numbers: 
 If to the Company, to: 

Bausch Health Companies Inc. 

400 Somerset Corporate Boulevard 

Bridgewater, NJ 08807 

Attention: Corporate Secretary 

Facsimile No.: (949) 461-6661 

With a copy to: 

Davis Polk & Wardwell LLP 

450 Lexington Avenue 

New York, New York 10017 

Attention: Michael Kaplan 

Facsimile No.: (212) 701-5111 

If to the Trustee, to: 

The Bank of New York Mellon 

240 Greenwich Street, Floor 7E 

New York, New York 10286 

Attn: Corporate Trust Administration 

Facsimile No.: (212) 815-5366 

Such notices or communications shall be effective when received. 

The Company or the Trustee by notice to the other may designate additional or different addresses for subsequent notices or communications.

 Any notice or communication mailed to a Holder shall be mailed by first-class mail or delivered by an overnight delivery service to it at
its address shown on the register kept by the Registrar. 

  
 -79- 

 Failure to mail a notice or communication to a Holder or any defect in it shall not affect
its sufficiency with respect to other Holders. If a notice or communication to a Holder is mailed in the manner provided above, it is duly given, whether or not the addressee receives it. 

The Trustee agrees to accept and act upon instructions or directions pursuant to this Indenture sent by unsecured e-mail, facsimile transmission or other similar unsecured electronic methods (including pdf files). If the party elects to give the Trustee e-mail or facsimile instructions
(or instructions by a similar electronic method) and the Trustee in its discretion elects to act upon such instructions, the Trustee’s understanding of such instructions shall be deemed controlling. The Trustee shall not be liable for any
losses, costs or expenses arising directly or indirectly from such party’s reliance upon and compliance with such instructions notwithstanding such instructions conflict or are inconsistent with a subsequent written instruction. The party
providing electronic instructions agrees to assume all risks arising out of the use of such electronic methods to submit instructions and directions to the Trustee including without limitation the risk of the Trustee acting on unauthorized
instructions, and the risk or interception and misuse by third parties. 
 Notwithstanding anything to the contrary contained herein, as
long as the Notes of a series are in the form of a Global Note, notice to the Holders of such Notes may be made electronically in accordance with procedures of the Depositary. 

Section 11.3 Communications by Holders With Other Holders. Noteholders may communicate pursuant to TIA Section 312(b) with
other Noteholders with respect to their rights under this Indenture or the Notes. The Company, the Trustee, the Registrar and any other person shall have the protection of TIA Section 312(c). 

Section 11.4 Certificate and Opinion of Counsel as to Conditions Precedent. 

(a) Upon any request or application by the Company to the Trustee to take any action under this Indenture other than the initial issuance of
the Notes and the Note Guarantees, the Company shall furnish to the Trustee at the request of the Trustee: 
 (A) an
Officers’ Certificate stating that, in the opinion of the signers, all conditions precedent (including any covenants, compliance with which constitutes a condition precedent), if any, provided for in this Indenture relating to the proposed
action have been complied with; and 
 (B) an Opinion of Counsel stating that, in the opinion of such counsel, all such
conditions precedent (including any covenants, compliance with which constitutes a condition precedent) have been complied with. 
 (b) Each
Officers’ Certificate and Opinion of Counsel with respect to compliance with a condition or covenant provided for in this Indenture shall include: 

(A) a statement that the person making such certificate or opinion has read such covenant or condition; 

(B) a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions
contained in such certificate or opinion are based; 
 (C) a statement that, in the opinion of such person, he or she has
made such examination or investigation as is necessary to enable him or her to express an informed opinion as to whether or not such covenant or condition has been complied with; and 

(D) a statement as to whether or not, in the opinion of such person, such condition or covenant has been complied with; 

provided, however, that with respect to matters of fact an Opinion of Counsel may rely on an Officers’ Certificate or certificates of
public officials. 

  
 -80- 

 Section 11.5 Record Date for Vote or Consent of Holders. The Company (or, in the
event deposits have been made pursuant to Section 8.1, 8.2 or 8.3 hereof, the Trustee) may set a record date for purposes of determining the identity of Holders of any series of Notes entitled to vote or consent to any action by vote or consent
authorized or permitted under this Indenture with respect to such series of Notes, which record date shall not be more than thirty (30) days prior to the date of the commencement of solicitation of such action. Notwithstanding the provisions of
Section 9.4 hereof, if a record date is fixed, those persons who were Holders of Notes of a series at the close of business on such record date (or their duly designated proxies), and only those persons, shall be entitled to take such action
with respect to such series of Notes by vote or consent or to revoke any vote or consent previously given, whether or not such persons continue to be Holders of Notes of such series after such record date. 

Section 11.6 Rules by Trustee, Paying Agent and Registrar. The Trustee may make reasonable rules (not inconsistent with the terms
of this Indenture) for action by or at a meeting of Holders. Any Registrar or Paying Agent may make reasonable rules for its functions. 

Section 11.7 Legal Holidays. A “Legal Holiday” is a Saturday, Sunday, or a day on which state or federally
chartered banking institutions in New York, New York, Montreal, Canada or, if applicable, the state in which the Corporate Trust Office is located are not required to be open. If a payment date, including any Redemption Date, Purchase Date, Change
of Control Purchase Date and Final Maturity Date, is a Legal Holiday, payment shall be made on the next succeeding day that is not a Legal Holiday, and no interest shall accrue for the intervening period on such payment. If an interest record date
is a Legal Holiday, the record date shall not be affected. 
 Section 11.8 Governing Law; Submission to Jurisdiction; Waiver of Jury
Trial. 
 (a) Unless specifically noted herein, this Indenture and the Notes shall be governed by, and construed in accordance with, the
laws of the State of New York, without regard to principles of conflicts of laws. 
 (b) The Company irrevocably submits to the non-exclusive jurisdiction of any New York State or United States Federal court sitting in The City of New York over any suit, action or proceeding arising out of or relating to this Indenture. The Company
irrevocably waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of venue of any such suit, action or proceeding brought in such a court and any claim that any such suit, action or proceeding
brought in such a court has been brought in an inconvenient forum. 
 (c) EACH OF THE COMPANY AND THE TRUSTEE HEREBY IRREVOCABLY WAIVES, TO
THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE NOTES, OR THE TRANSACTION CONTEMPLATED HEREBY. 

Section 11.9 No Adverse Interpretation of Other Agreements. This Indenture may not be used to interpret another indenture, loan or
debt agreement of the Company or a Subsidiary of the Company. Any such indenture, loan or debt agreement may not be used to interpret this Indenture. 

Section 11.10 No Recourse Against Others. All liability described in paragraph 13 of the Form of the Notes attached hereto as
Exhibit A-1 or Exhibit A-2, as applicable, of any director, officer, incorporator, employee or shareowner, as such, of the Company or
any Note Guarantor is waived and released. 
 Section 11.11 Successors. All agreements of the Company in this Indenture and the
Notes shall bind their successors. All agreements of the Trustee in this Indenture shall bind its successor. 
 Section 11.12
Multiple Counterparts. The parties may sign multiple counterparts of this Indenture. Each signed counterpart shall be deemed an original, but all of them together represent the same agreement. 

  
 -81- 

 Section 11.13 Separability. In case any provisions in this Indenture or in the
Notes shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

Section 11.14 Table of Contents, Headings, etc. The table of contents and headings of the Articles and Sections of this Indenture
have been inserted for convenience of reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof. 

Section 11.15 Calculations in Respect of the Notes. 

(a) The Company shall make all calculations under this Indenture and the Notes in good faith. In the absence of manifest error, such
calculations shall be final and binding on all Holders. The Company shall provide a copy of such calculations to the Trustee as required hereunder. 

(b) Notwithstanding anything to the contrary herein (including in connection with any calculation made on a pro forma basis), if the terms of
this Indenture require (1) compliance with any financial ratio or financial test (including, without limitation, any Secured Leverage Ratio test, any Total Leverage Ratio test and/or any Fixed Charge Coverage Ratio test) and/or any cap
expressed as a percentage of Consolidated Total Assets or Consolidated Cash Flow, (2) the absence of a Default or Event of Default (or any type of default or event of default) or (3) compliance with any basket or other condition, as a
condition to (a) the consummation of any transaction (including in connection with any acquisition or similar Investment or the assumption or incurrence of Indebtedness), and/or (b) the making of any Restricted Payment, the determination
of whether the relevant condition is satisfied may be made, at the election of the Company, (i) in the case of any acquisition or similar Investment or any Asset Sale and any transaction related thereto, at the time of (or on the basis of the
financial statements for the most recently ended four quarter period available at the time of) either (x) the execution of the definitive agreement with respect to such acquisition, Investment or Asset Sale (or, solely in connection with an
acquisition to which the United Kingdom City Code on Takeovers and Mergers applies, the date on which a “Rule 2.7 Announcement” of a firm intention to make an offer) or (y) the consummation of such acquisition, Investment or Asset
Sale, (ii) in the case of any Restricted Payment, at the time of (or on the basis of the financial statements for the most recently ended four quarter period available at the time of) (x) the declaration of such Restricted Payment or
(y) the making of such Restricted Payment, in each case, after giving effect to the relevant acquisition or similar Investment and/or Restricted Payment or other transaction on a pro forma basis (including, in each case, giving effect to the
relevant transaction, any relevant Indebtedness (including the intended use of proceeds thereof) and, at the election of the Company, giving pro forma effect to other prospective “limited conditionality” acquisitions or similar Investments
for which definitive agreements have been executed, and no Default or Event of Default shall be deemed to have occurred solely as a result of an adverse change in such financial ratio or test occurring after the time such election is made (but any
subsequent improvement in the applicable financial ratio or test may be utilized by the Company or any Restricted Subsidiary). For the avoidance of doubt, if the Company shall have elected the option set forth in this paragraph in respect of any
transaction, then the Company or its applicable Restricted Subsidiary shall be permitted to consummate such transaction even if any applicable test or condition shall cease to be satisfied subsequent to the Company’s election of such option.

 (c) Notwithstanding anything to the contrary herein, unless the Company otherwise elects, with respect to any amounts incurred or
transactions entered into (or consummated) in reliance on a provision of this Indenture that does not require compliance with a financial ratio or financial test (including any Secured Leverage Ratio test, any Total Leverage Ratio test and/or any
Fixed Charge Coverage Ratio test) (any such amounts, the “Fixed Amounts”) substantially concurrently with any amounts incurred or transactions entered into (or consummated) in reliance on a provision of this Indenture that requires
compliance with a financial ratio or financial test (including any Secured Leverage Ratio test, any Total Leverage Ratio test and/or any Fixed Charge Coverage Ratio test) (any such amounts, the “Incurrence-Based Amounts”) it is
understood and agreed that (A) the incurrence of the Incurrence-Based Amount shall be calculated first without giving effect to any Fixed Amount but giving full pro forma effect to the use of proceeds of such Fixed Amount and the related
transactions and (B) the incurrence of the Fixed Amount shall be calculated thereafter. Unless the Company elects otherwise, the Company shall be deemed to have used amounts under an Incurrence-Based Amount then available to the Company prior
to utilization of any amount under a Fixed Amount then available to the Company. 

  
 -82- 

 Section 11.16 Agent for Service and Waiver of Immunities. By the execution and
delivery of this Indenture, the Company and each Note Guarantor that is not a Domestic Subsidiary does, and with respect to any entity that becomes a Note Guarantor after the date hereof and is not a Domestic Subsidiary, within 10 days of becoming a
Note Guarantor, as applicable, will, (i) acknowledge that they will designate and appoint Bausch Health US, LLC, 400 Somerset Corporate Boulevard, Bridgewater, New Jersey 08807, or another Person satisfactory to the Trustee (the
“Authorized Agent”), as their authorized agent upon whom process may be served in any suit or proceeding arising out of or relating to this Indenture or the Notes that may be instituted in any federal or state court in the State of
New York or brought under federal or state securities laws, and acknowledge that the Authorized Agent has accepted such designation, (ii) submit to the jurisdiction of any such court in any such suit or proceeding, and (iii) agree that
service of process upon the Authorized Agent and written notice of said service to the Company or the Note Guarantor that is not a Domestic Subsidiary, as applicable, in accordance with Section 11.2 hereof shall be deemed effective service of
process in any such suit or proceeding. The Company and each Note Guarantor that is not a Domestic Subsidiary further agrees to take any reasonable action, including the execution and filing of any and all such documents and instruments, as may be
necessary to continue such designation and appointment of the Authorized Agent in full force and effect so long as any of the Notes shall be outstanding; provided, however, that the Company and each Note Guarantor that is not a
Domestic Subsidiary, as applicable, may, by written notice to the Trustee, designate such additional or alternative agent for service of process under this Section 11.16 that (i) maintains an office located in the Borough of Manhattan, The
City of New York, in the State of New York, (ii) is either (x) counsel for the Company or such Note Guarantor, as applicable or (y) a corporate service company which acts as agent for service of process for other persons in the
ordinary course of its business and (iii) agrees to act as agent for service of process in accordance with this Section 11.16. Such written notice shall identify the name of such agent for process and the address of the office of such
agent for process in the Borough of Manhattan, The City of New York, State of New York. Upon the written request of any Holder, the Trustee shall deliver a copy of such notice to such Holder. 

Section 11.17 Judgment Currency. The Company and each Note Guarantor shall indemnify each Holder and each Person, if any, who
controls any Holder within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act against any loss incurred by such party as a result of any judgment or order being given or made against the Company or any Note
Guarantor for any U.S. dollar amount due under this Indenture and such judgment or order being expressed and paid in a currency (the “Judgment Currency”) other than U.S. dollars and as a result of any variation as between
(i) the rate of exchange at which the U.S. dollar amount is converted into the Judgment Currency for the purpose of such judgment or order and (ii) the spot rate of exchange in The City of New York at which such party on the date of
payment of such judgment or order is able to purchase U.S. dollars with the amount of the Judgment Currency actually received by such party if such party had utilized such amount of Judgment Currency to purchase U.S. dollars upon such party’s
receipt thereof. The foregoing indemnity shall continue in full force and effect notwithstanding any such judgment or order as aforesaid. The term “spot rate of exchange” shall include any premiums and costs of exchange payable in
connection with the purchase of, or conversion into, U.S. dollars. 
 Section 11.18 Foreign Currency Equivalent. For purposes of
determining compliance with any U.S. dollar-denominated restriction or amount, the U.S. dollar equivalent principal amount of any amount denominated in a foreign currency will be the Dollar Equivalent calculated on the date the Indebtedness was
incurred or other transaction was entered into; provided, that if any Permitted Refinancing Indebtedness denominated in a currency other than U.S. dollars is incurred to refinance Indebtedness denominated in the same currency, and such
refinancing would cause the applicable U.S. dollar-denominated restriction to be exceeded if calculated on the date of such refinancing, such Permitted Refinancing Indebtedness shall be deemed not to exceed the principal amount of such Indebtedness
being refinanced. Notwithstanding any other provision in this Indenture, no restriction or amount will be exceeded solely as a result of fluctuations in the exchange rate of currencies. 

Section 11.19 Usury Savings Clause. If any provision of this Indenture or any Note would obligate the Company to make any payment
of or on account of interest or other amount in an amount or calculated at a rate which would result in a receipt by any Holder of interest at a criminal rate (as such term is construed under the Criminal Code (Canada)), then notwithstanding
such provisions, such amount or rate shall be deemed to have been adjusted with retroactive effect to the maximum amount or rate of interest, as the case may be, as would not so result in a receipt by such Holder of interest at a criminal rate, such
adjustment to be effected, to the extent necessary, as follows: (1) firstly, by reducing the amount or rate of interest required to be paid to such Holder, and (2) thereafter, by reducing any fees, commissions, premiums and other amounts
required to be paid to such Holder which would constitute “interest” for purposes of Section 347 of the Criminal Code (Canada). 
  

  
 -83- 

 Section 11.20 Interest Act (Canada). For purposes of disclosure pursuant to the
Interest Act (Canada), the annual rates of interest or fees to which the rates of interest or fees provided for in this Indenture and any Note (and stated herein or therein, as applicable, to be computed on the basis of a 360 day year or any
other period of time less than a calendar year) are equivalent are the rates so provided for multiplied by the actual number of days in the applicable calendar year and divided by 360 or the actual number of days in such other period of time,
respectively. Each of the Company and each Note Guarantor confirms that it understands and acknowledges that it is and will be able to calculate the rate of interest applicable under this Indenture and any Note based on the methodology for
calculating per annum rates provided for under this Indenture or the Notes. Each of the Company and each Note Guarantor confirms that it agrees not to plead or assert, whether by way of defense or otherwise, in any proceeding relating to this
Indenture or any Note, that the interest payable under this Indenture or any Note and the calculation thereof has not been adequately disclosed to the Company or Note Guarantor, as applicable, whether pursuant to Section 4 of the Interest
Act (Canada) or any other applicable law or legal principle. 
 Section 11.21 Tax Matters. Each of the parties hereto agree
to cooperate and to provide the other with such information as each may have in its possession to enable the determination of whether any payments pursuant to this Indenture are subject to the withholding requirements described in
Section 1471(b) of the Code or otherwise imposed pursuant to Sections 1471 through 1474 of the Code and any regulations, or agreements thereunder or official interpretations thereof (“Applicable Law”). The Trustee shall be entitled to
make any withholding or deduction from payments under this Indenture to the extent necessary to comply with Applicable Law. Nothing in the immediately preceding sentence shall be construed as obligating the Trustee to make any “gross up”
payment or similar reimbursement in connection with a payment in respect of which amounts are so withheld or deducted or affecting a Payor’s obligation to make any payments of Additional Amount pursuant to Section 4.21 of this Indenture.

 [SIGNATURE PAGES FOLLOW] 

  
 -84- 

 
			
	 Very truly yours,
  

BAUSCH HEALTH COMPANIES INC.

		
	By:	 	/s/ William N. Woodfield
		 	Name: William N. Woodfield
		 	Title: Vice President, Treasurer

  
 [Signature Page to
Indenture] 

 
			
	 GUARANTORS:
  

BAUSCH HEALTH AMERICAS, INC.

		
	By:	 	/s/ William N. Woodfield
		 	Name: William N. Woodfield
		 	Title: Vice President, Treasurer

  
 [Signature Page to
Indenture] 

 
			
	GUARANTORS:
	
	ALDEN OPTICAL LABORATORIES, INC.
		
	By:	 	/s/ William N. Woodfield
		 	Name: William N. Woodfield
		 	Title: Vice President, Treasurer
	
	BAUSCH & LOMB INCORPORATED
		
	By:	 	/s/ William N. Woodfield
		 	Name: William N. Woodfield
		 	Title: Vice President, Treasurer
	
	BAUSCH & LOMB INTERNATIONAL INC.
		
	By:	 	/s/ William N. Woodfield
		 	Name: William N. Woodfield
		 	Title: Vice President, Treasurer
	
	BAUSCH & LOMB SOUTH ASIA, INC.
		
	By:	 	/s/ William N. Woodfield
		 	Name: William N. Woodfield
		 	Title: Vice President, Treasurer
	
	 MEDICIS PHARMACEUTICAL

CORPORATION

		
	By:	 	/s/ William N. Woodfield
		 	Name: William N. Woodfield
		 	Title: Vice President, Treasurer
	
	OCEANSIDE PHARMACEUTICALS, INC.
		
	By:	 	/s/ William N. Woodfield
		 	Name: William N. Woodfield
		 	Title: Vice President, Treasurer

  
 [Signature Page to
Indenture] 

 
			
	ORAPHARMA, INC.
		
	By:	 	/s/ William N. Woodfield
		 	Name: William N. Woodfield
		 	Title: Vice President and Treasurer
	
	PRECISION DERMATOLOGY, INC.
		
	By:	 	/s/ William N. Woodfield
		 	Name: William N. Woodfield
		 	Title: Vice President, Treasurer
	
	PRESTWICK PHARMACEUTICALS, INC.
		
	By:	 	/s/ William N. Woodfield
		 	Name: William N. Woodfield
		 	Title: Vice President, Treasurer
	
	SALIX PHARMACEUTICALS, LTD.
		
	By:	 	/s/ William N. Woodfield
		 	Name: William N. Woodfield
		 	Title: Vice President, Treasurer
	
	SANTARUS, INC.
		
	By:	 	/s/ William N. Woodfield
		 	Name: William N. Woodfield
		 	Title: Vice President, Treasurer
	
	SOLTA MEDICAL, INC.
		
	By:	 	/s/ William N. Woodfield
		 	Name: William N. Woodfield
		 	Title: Vice President, Treasurer

  
 [Signature Page to
Indenture] 

 
			
	TECHNOLAS PERFECT VISION, INC.
		
	By:	 	/s/ William N. Woodfield
		 	Name: William N. Woodfield
		 	Title: Treasurer
	
	BAUSCH HEALTH US, LLC
		
	By:	 	/s/ William N. Woodfield
		 	Name: William N. Woodfield
		 	Title: Vice President, Capital Markets, Treasury
	
	VRX HOLDCO LLC
		
	By:	 	/s/ William N. Woodfield
		 	Name: William N. Woodfield
		 	Title: Treasurer

  
 [Signature Page to
Indenture] 

 
			
	SALIX PHARMACEUTICALS, INC.
		
	By:	 	/s/ Jeremy M. Lipshy
		 	Name: Jeremy M. Lipshy
		 	Title: Senior Vice President, Tax

  
 [Signature Page to
Indenture] 

					
	 Signed by
 Valeant Holdco 2 Pty Ltd (ACN
154 341 367)
 in accordance with section 127 of the

Corporations Act 2001 by two directors:
	 	 
 

        
 
	 	
			
	 /s/ Avinesh Prasad
	 		 	 /s/ William N. Woodfield

	Signature of director	 		 	Signature of director
			
	 Avinesh Prasad
	 		 	 William N. Woodfield

	Name of director (please print)	 		 	Name of director (please print)
			
	 Signed by
 Wirra Holdings Pty Limited
(ACN 122 216 577)
 in accordance with section 127 of the

Corporations Act 2001 by two directors:
	 		 	
			
	 /s/ Avinesh Prasad
	 		 	 /s/ William N. Woodfield

	Signature of director	 		 	Signature of director
			
	 Avinesh Prasad
	 		 	 William N. Woodfield

	Name of director (please print)	 		 	Name of director (please print)
			
	 Signed by
 Wirra Operations Pty Limited
(ACN 122 250 088)
 in accordance with section 127 of the

Corporations Act 2001 by two directors:
	 		 	
			
	 /s/ Avinesh Prasad
	 		 	 /s/ William N. Woodfield

	Signature of director	 		 	Signature of director
			
	 Avinesh Prasad
	 		 	 William N. Woodfield

	Name of director (please print)	 		 	Name of director (please print)

  
 [Signature Page to
Indenture] 

					
	 Signed by
 Wirra IP Pty Limited (ACN 122
536 350)
 in accordance with section 127 of the

Corporations Act 2001 by two directors:
	 	 
 

         
	 	
			
	 /s/ Avinesh Prasad
	 		 	 /s/ William N. Woodfield

	Signature of director	 		 	Signature of director
			
	 Avinesh Prasad
	 		 	 William N. Woodfield

	Name of director (please print)	 		 	Name of director (please print)
			
	 Signed by
 Bausch & Lomb
(Australia) Pty Limited
 (ACN 000 222 408)
 in accordance with
section 127 of the
 Corporations Act 2001 by two directors:
	 		 	
			
	 /s/ Avinesh Prasad
	 		 	 /s/ William N. Woodfield

	Signature of director	 		 	Signature of director
			
	 Avinesh Prasad
	 		 	 William N. Woodfield

	Name of director (please print)	 		 	Name of director (please print)

  
 [Signature Page to
Indenture] 

					
	 Signed by
 Valeant Pharmaceuticals
Australasia Pty
 Limited (ACN 001 083 352)
 in accordance with
section 127 of the
 Corporations Act 2001 by a director and

secretary/director:
	 	 
 

 

         
	 	
			
	 /s/ Avinesh Prasad
	 		 	 /s/ William N. Woodfield

	Signature of director	 		 	Signature of director/secretary
			
	 Avinesh Prasad
	 		 	 William N. Woodfield

	Name of director (please print)	 		 	Name of director/secretary (please print)
			
	 Signed by
 DermaTech Pty Limited (ACN 003
982 161)
 in accordance with section 127 of the

Corporations Act 2001 by a director and

secretary/director:
	 		 	
			
	 /s/ Avinesh Prasad
	 		 	 /s/ William N. Woodfield

	Signature of director	 		 	Signature of director/secretary
			
	 Avinesh Prasad
	 		 	 William N. Woodfield

	Name of director (please print)	 		 	Name of director/secretary (please print)
			
	 Signed by
 Private Formula International
Holdings Pty
 Ltd (ACN 095 450 918)
 in accordance with section
127 of the
 Corporations Act 2001 by a director and

secretary/director:
	 		 	
			
	 /s/ Avinesh Prasad
	 		 	 /s/ William N. Woodfield

	Signature of director	 		 	Signature of director/secretary
			
	 Avinesh Prasad
	 		 	 William N. Woodfield

	Name of director (please print)	 		 	Name of director/secretary (please print)

  
 [Signature Page to
Indenture] 

					
	 Signed by
 Private Formula International
Pty Ltd (ACN
 095 451 942)
 in accordance with section 127 of
the
 Corporations Act 2001 by a director and

secretary/director:
	 	 
 

 

         
	 	
			
	 /s/ Avinesh Prasad
	 		 	 /s/ William N. Woodfield

	Signature of director	 		 	Signature of director/secretary
			
	 Avinesh Prasad
	 		 	 William N. Woodfield

	Name of director (please print)	 		 	Name of director/secretary (please print)
			
	 Signed by
 Ganehill Pty Ltd (ACN 065 261
538)
 in accordance with section 127 of the
 Corporations
Act 2001 by a director and
 secretary/director:
	 		 	
			
	 /s/ Avinesh Prasad
	 		 	 /s/ William N. Woodfield

	Signature of director	 		 	Signature of director/secretary
			
	 Avinesh Prasad
	 		 	 William N. Woodfield

	Name of director (please print)	 		 	Name of director/secretary (please print)

  
 [Signature Page to
Indenture] 

					
	 Signed by
 Valeant (Australia) Pty
Limited (ACN 000
 650 251)
 in accordance with section 127 of
the
 Corporations Act 2001 by a director and

secretary/director:
	 	 
 

 

        
 
	 	
			
	 /s/ Avinesh Prasad
	 		 	 /s/ William N. Woodfield

	Signature of director	 		 	Signature of director/secretary
			
	 Avinesh Prasad
	 		 	 William N. Woodfield

	Name of director (please print)	 		 	Name of director/secretary (please print)

  
 [Signature Page to
Indenture] 

 
			
	BAUSCH & LOMB PHARMA S.A.
		
	By:	 	/s/ Pierre Guibourg
		 	Name: Pierre Guibourg
		 	Title: Director

  
 [Signature Page to
Indenture] 

 
			
	VALEANT CANADA GP LIMITED
		
	By:	 	/s/ William N. Woodfield
		 	Name: William N. Woodfield
		 	Title: Vice President, Treasurer
	
	 VALEANT CANADA S.E.C./VALEANT CANADA LP
  

By: Valeant Canada GP Limited, its general partner

		
	By:	 	/s/ William N. Woodfield
		 	Name: William N. Woodfield
		 	Title: Vice President, Treasurer
	
	V-BAC HOLDING CORP.
		
	By:	 	/s/ Jeremy M. Lipshy
		 	Name: Jeremy M. Lipshy
		 	Title: Vice President
	
	BAUSCH HEALTH, CANADA INC.
		
	By:	 	/s/ William N. Woodfield
		 	Name: William N. Woodfield
		 	Title: Vice President, Treasurer

  
 [Signature Page to
Indenture] 

 
			
	HUMAX PHARMACEUTICAL S.A.
		
	By:	 	/s/ Luis Alejandro Mendez Madriz
		 	Name: Luis Alejandro Mendez Madriz
		 	Title: Legal Representative

  
 [Signature Page to
Indenture] 

 
			
	VALEANT DWC-LLC
		
	By:	 	/s/ Eliane Nassour
		 	Name: Eliane Nassour
		 	Title: General Manager
		
	By:	 	/s/ Mahmoud Farhana
		 	Name: Mahmoud Farhana
		 	Title: Manager

  
 [Signature Page to
Indenture] 

 
	
	Executed by BAUSCH & LOMB U.K. LIMITED, acting by:
	
	 /s/ William Norman Woodfield

	Director
	
	Name of director: William Norman Woodfield in the presence of:
	
	 /s/ Michelle Stypulkoski

	Name of witness: Michelle Stypulkoski

  
 [Signature Page to
Indenture] 

 
			
	LABORATOIRE CHAUVIN S.A.S.
		
	By:	 	 /s/ Pierre Guibourg

		 	Name: Pierre Guibourg
		 	Title:   President
	
	BAUSCH & LOMB FRANCE S.A.S.
		
	By:	 	 /s/ Eberhard Kuehne

		 	Name: Eberhard Kuehne
		 	Title:   President
	
	BCF S.A.S.
		
	By:	 	 /s/ Eberhard Kuehne

		 	Name: Eberhard Kuehne
		 	Title:   President

  
 [Signature Page to
Indenture] 

 
			
	DR. GERHARD MANN CHEM.-PHARM. FABRIK GESELLSCHAFT MIT BESCHRÄNKTER HAFTUNG
		
	By:	 	 /s/ William N. Woodfield

		 	Name: William N. Woodfield
		 	Title:   Managing Director
	
	BAUSCH & LOMB GMBH
		
	By:	 	 /s/ William N. Woodfield

		 	Name: William N. Woodfield
		 	Title:   Managing Director
	
	B L E P HOLDING GMBH
		
	By:	 	 /s/ William N. Woodfield

		 	Name: William N. Woodfield
		 	Title:   Managing Director
	
	TECHNOLAS PERFECT VISION GMBH
		
	By:	 	 /s/ William N. Woodfield

		 	Name: William N. Woodfield
		 	Title:   Managing Director

  
 [Signature Page to
Indenture] 

 
			
	BAUSCH & LOMB (HONG KONG) LIMITED
		
	By:	 	 /s/ William N. Woodfield

		 	Name: William N. Woodfield
		 	Title:   Director

  
 [Signature Page to
Indenture] 

 
			
	VALEANT PHARMA HUNGARY LLC
		
	By:	 	 /s/ Balázs Tüske

		 	Name: Balázs Tüske
		 	Title:   Managing Director

  
 [Signature Page to
Indenture] 

 
			
	BAUSCH HEALTH IRELAND LIMITED
		
	By:	 	 /s/ Michael Kennan

		 	Name: Michael Kennan
		 	Title:   Director
	
	VALEANT HOLDINGS IRELAND
		
	By:	 	 /s/ Michael Kennan

		 	Name: Michael Kennan
		 	Title:   Director

  
 [Signature Page to
Indenture] 

 
			
	BAUSCH & LOMB-IOM S.P.A.
		
	By:	 	 /s/ William N. Woodfield

		 	Name: William N. Woodfield
		 	Title:   Director

  
 [Signature Page to
Indenture] 

 
			
	B.L.J. COMPANY, LTD.
		
	By:	 	 /s/ William N. Woodfield

		 	Name: William N. Woodfield
		 	Title:   Director

  
 [Signature Page to
Indenture] 

 
			
	UAB SANITAS
		
	By:	 	 /s/ Tomas Liesis

		 	Name: Tomas Liesis
		 	Title:   General Manager

  
 [Signature Page to
Indenture] 

 
			
	BIOVAIL INTERNATIONAL S.À R.L.
		
	By:	 	 /s/ Franck Deconinck

		 	Name: Franck Deconinck
		 	Title:   Authorized Signatory
	
	 VALEANT PHARMACEUTICALS
 LUXEMBOURG
S.À R.L.

		
	By:	 	 /s/ Franck Deconinck

		 	Name: Franck Deconinck
		 	Title:   Authorized Signatory
	
	BAUSCH & LOMB LUXEMBOURG S.À R.L.
		
	By:	 	 /s/ Franck Deconinck

		 	Name: Franck Deconinck
		 	Title:   Authorized Signatory
	
	VALEANT FINANCE LUXEMBOURG S.À R.L.
		
	By:	 	 /s/ Franck Deconinck

		 	Name: Franck Deconinck
		 	Title:   Authorized Signatory
	
	VALEANT HOLDINGS LUXEMBOURG S.À R.L.
		
	By:	 	 /s/ Franck Deconinck

		 	Name: Franck Deconinck
		 	Title:   Authorized Signatory

  
 [Signature Page to
Indenture] 

 
			
	BAUSCH & LOMB MEXICO, S.A. DE C.V.
		
	By:	 	 /s/ William N. Woodfield

		 	Name: William N. Woodfield
		 	Title:   Senior Vice President and Treasurer

  
 [Signature Page to
Indenture] 

 
			
	BAUSCH+LOMB OPS B.V.
		
	By:	 	 /s/ Patrick Emanuel Petrus Jacobus Gunther

		 	Name: Patrick Emanuel Petrus Jacobus Gunther
		 	Title:   Attorney-in-fact

  
 [Signature Page to
Indenture] 

							
	 SIGNED for and on behalf
 of VALEANT
PHARMACEUTICALS
 NEW ZEALAND LIMITED
	  	)
 )
 )
	  		  	

  

			
	 /s/ Avinesh Prasad
	 	 /s/ William N. Woodfield

	 Name: Avinesh Prasad
 Title:
  Director
	 	 Name: William N. Woodfield
 Title:
  Director

  
 [Signature Page to
Indenture] 

 
			
	PRZEDSIĘBIORSTWO FARMACEUTYCZNE JELFA S.A.
		
	By:	 	 /s/ Waldemar Stępień

		 	Name: Waldemar Stępień
		 	Title:   President of the Management Board
		
	By:	 	 /s/ Ryszard Bukowski

		 	Name: Ryszard Bukowski
		 	Title:   Member of the Management Board
	
	VALEANT SP. Z O. O.
		
	By:	 	 /s/ Cornelis Jan Heiman

		 	Name: Cornelis Jan Heiman
		 	Title:   Member of the Management Board
	
	VP VALEANT SPÓLKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ SP.J.
	
	By: Valeant sp. z o.o., in its capacity as General Partner
		
	By:	 	 /s/ Cornelis Jan Heiman

		 	Name: Cornelis Jan Heiman
		 	Title:   Member of the Management Board
	
	VALEANT PHARMA POLAND SPÓLKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
		
	By:	 	 /s/ Cornelis Jan Heiman

		 	Name: Cornelis Jan Heiman
		 	Title:   Member of the Management Board

  
 [Signature Page to
Indenture] 

 
			
	VALEANT LLC
		
	By:	 	 /s/ John Connolly

		 	Name: John Connolly
		 	Title:   General Director

  
 [Signature Page to
Indenture] 

 
			
	PHARMASWISS D.O.O.
		
	By:	 	 /s/ John Connolly

		 	Name: John Connolly
		 	Title:   Director

  
 [Signature Page to
Indenture] 

 
			
	BAUSCH & LOMB NORDIC AB
		
	By:	 	 /s/ Janice More

		 	Name: Janice More
		 	Title: Director

  
 [Signature Page to
Indenture] 

 
					
	PHARMASWISS SA
		
	By:	 	/s/ Matthias Courvoisier
		 	Name:	 	Matthias Courvoisier
		 	Title:	 	Director

  

					
	BAUSCH & LOMB SWISS AG
		
	By:	 	/s/ Matthias Courvoisier
		 	Name:	 	Matthias Courvoisier
		 	Title:	 	Member of the Board of Directors

  
 [Signature Page to
Indenture] 

 
					
	THE BANK OF NEW YORK MELLON, AS TRUSTEE
		
	By:	 	/s/ Wanda Camacho
		 	Name:	 	Wanda Camacho
		 	Title:	 	Vice President

  
 [Signature Page to
Indenture] 

 EXHIBIT A-1 

BAUSCH HEALTH COMPANIES INC. 

7.000% SENIOR NOTES DUE 2028 

[FORM OF FACE OF NOTE] 
 [UNLESS
THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO.
OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (AND ANY PAYMENT HEREON IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY
TRUST COMPANY), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. THIS NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE
INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS NOTE IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED
CIRCUMSTANCES DESCRIBED IN THE INDENTURE AND, UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE FORM, THIS NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE
OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY.]1 

[THIS NOTE HAS NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY
NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT AS SET FORTH BELOW. BY ITS ACQUISITION HEREOF, THE HOLDER (1) REPRESENTS THAT (A) IT IS A “QUALIFIED INSTITUTIONAL
BUYER” (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT), (B) IT IS NOT A U.S. PERSON AND IS ACQUIRING THIS NOTE IN AN OFFSHORE TRANSACTION IN COMPLIANCE WITH RULE 904 UNDER THE SECURITIES ACT OR (C) IT IS AN ACCREDITED INVESTOR (AS
DEFINED IN RULE 501(a)(1), (2), (3), OR (7) UNDER THE SECURITIES ACT (AN “ACCREDITED INVESTOR”)), (2) AGREES THAT IT WILL NOT PRIOR TO THE FIRST ANNIVERSARY OF THE ORIGINAL ISSUANCE OF THIS NOTE RESELL OR OTHERWISE TRANSFER THIS NOTE
EXCEPT (A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF, (B) INSIDE THE UNITED STATES TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE SECURITIES ACT, (C) INSIDE THE UNITED STATES TO AN ACCREDITED INVESTOR THAT,
PRIOR TO SUCH TRANSFER, FURNISHES (OR HAS FURNISHED ON ITS BEHALF BY A U.S. BROKER-DEALER) TO THE TRUSTEE A SIGNED LETTER CONTAINING CERTAIN REPRESENTATIONS AND AGREEMENTS RELATING TO THE RESTRICTIONS ON TRANSFER OF THIS NOTE (THE FORM OF WHICH
LETTER CAN BE OBTAINED FROM THE TRUSTEE FOR THIS NOTE), (D) OUTSIDE THE UNITED STATES IN AN OFFSHORE TRANSACTION IN COMPLIANCE WITH RULE 904 UNDER THE SECURITIES ACT (IF AVAILABLE), (E) PURSUANT TO THE EXEMPTION FROM REGISTRATION PROVIDED BY RULE
144 UNDER THE SECURITIES ACT (IF AVAILABLE), (F) IN ACCORDANCE WITH ANOTHER EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT (AND BASED UPON AN OPINION OF COUNSEL IF THE COMPANY SO REQUESTS), OR (G) PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND (3) AGREES THAT IT WILL GIVE TO EACH PERSON TO WHOM THIS NOTE IS TRANSFERRED A NOTICE SUBSTANTIALLY TO THE EFFECT 

 

	1 	 Include only if the Note is a Global Note. 

  
 A-1-1 

 OF THIS LEGEND. IN CONNECTION WITH ANY TRANSFER OF THIS NOTE WITHIN ONE YEAR AFTER THE ORIGINAL ISSUANCE OF
THIS NOTE, IF THE PROPOSED TRANSFEREE IS AN ACCREDITED INVESTOR, THE HOLDER MUST, PRIOR TO SUCH TRANSFER, FURNISH TO THE TRUSTEE AND THE COMPANY SUCH CERTIFICATIONS, LEGAL OPINIONS OR OTHER INFORMATION AS EITHER OF THEM MAY REASONABLY REQUIRE TO
CONFIRM THAT SUCH TRANSFER IS BEING MADE PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. AS USED HEREIN, THE TERMS “OFFSHORE TRANSACTION,” “UNITED STATES”
AND “U.S. PERSON” HAVE THE MEANING GIVEN TO THEM BY REGULATION S UNDER THE SECURITIES ACT.]2 

[THIS NOTE AND ANY RELATED DOCUMENTATION MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME TO MODIFY THE RESTRICTIONS ON RESALES AND OTHER
TRANSFERS OF THIS NOTE TO REFLECT ANY CHANGE IN APPLICABLE LAW OR REGULATION (OR THE INTERPRETATION THEREOF) OR IN PRACTICES RELATING TO THE RESALE OR TRANSFER OF RESTRICTED SECURITIES GENERALLY. THE HOLDER OF THIS NOTE SHALL BE DEEMED BY THE
ACCEPTANCE OF THIS NOTE TO HAVE AGREED TO ANY SUCH AMENDMENT OR SUPPLEMENT.]3 

[CANADIAN RESALE LEGEND 
 UNLESS
PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS NOTE MUST NOT TRADE THIS NOTE BEFORE THE DATE THAT IS 4 MONTHS AND A DAY AFTER MAY 23, 2019.]4 

 
  

	2 	 Include only if the Note is a Restricted Note. 

	3 	 Include only if the Note is a Restricted Note. 

	4 	 Include until no longer necessary under Canadian securities laws. 

  
 A-1-2 

 BAUSCH HEALTH COMPANIES INC. 

 

			
	 CUSIP: 144A: 071734 AD9, Reg. S: C07885 AB9
	  	
	 ISIN: 144A: US071734AD90, Reg. S: USC07885AB94
	  	No. [ ]

 7.000% SENIOR NOTES DUE 2028 

Bausch Health Companies Inc., a corporation continued under the laws of the Province of British Columbia (the “Company,”
which term shall include any successor corporation under the Indenture referred to on the reverse hereof) promises to pay to                      or
its registered assigns, the principal sum of                      Dollars
($                    ) on January 15, 2028 [or such greater or lesser amount as is indicated on the Schedule of Exchanges of Notes on the other
side of this Note]5 and to pay interest thereon as provided on the other side of this Note. 

Interest Payment Dates: January 15 and July 15, beginning July 15, 2019. 

Record Dates: January 1 and July 1. 

Additional provisions of this Note are set forth on the other side of this Note. 

 
  

	5 	 Include only if the Note is a Global Note. 

  
 A-1-3 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed. 

 

			
	BAUSCH HEALTH COMPANIES INC.
		
	By:	 	 
		 	Name:
		 	Title:

  
 A-1-4 

 Trustee’s Certificate of Authentication: 

This is one of the Notes referred to in the within- 
 mentioned
Indenture for the 7.000% Senior Notes 
 due 2028. 
  

			
	THE BANK OF NEW YORK MELLON, as Trustee
		
	By:	 	 
		 	Authorized Signatory
		
	Dated:	 	 

  
 A-1-5 

 [FORM OF REVERSE SIDE OF NOTE] 

BAUSCH HEALTH COMPANIES INC. 

7.000% SENIOR NOTES DUE 2028 
 1. INTEREST 

The Company shall pay interest on this Note semiannually in arrears on January 15 and July 15, each an “interest payment
date,” of each year, commencing on July 15, 2019, at the rate per annum specified in the title of this Note. Interest shall accrue from and including May 23, 2019 or else the most recent interest payment date to which interest had
been paid or duly provided for to but excluding the date on which such interest is paid. Interest on this Note will be computed on the basis of a 360-day year of twelve
30-day months. 
 The Company shall, (in immediately available funds) to the fullest extent
permitted by law, pay interest on overdue principal (including premium, if any) and overdue installments of interest from the original due date to the date paid, at the rate applicable to this Note, which interest shall be payable on demand. 

The interest so payable and punctually paid or duly provided for on any interest payment date will be paid to the Person in whose name this
Note is registered at the close of business on January 1 and July 1 preceding such interest payment date (the “Record Date”) except as provided in the Indenture. Payment of the principal of (and premium, if any) and
interest on this Note will be made in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts and as otherwise provided in the Indenture. 

2. METHOD OF PAYMENT 
 [The Company will make
payments in respect of this Note (including principal, premium, if any, interest) by wire transfer of immediately available funds to the accounts specified by the Holder.]6 [The Company will make
all payments of principal, interest and premium, if any, with respect to this Note by wire transfer of immediately available funds to the accounts specified by the Holders, in the case of a Holder holding an aggregate principal amount of Notes of
$1,000,000 or more, or, if no such account is specified or in the case of a Holder holding an aggregate principal amount of Notes of less than $1,000,000, by mailing a check to each such Holder’s registered address.]7 All payments shall be made in immediately available funds in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts.
Payments to any Holder holding an aggregate principal amount of Notes in excess of $1,000,000 shall be made by wire transfer in immediately available funds to an account maintained by such Holder in the United States, if such Holder has provided
wire transfer instructions to the Company at least 10 Business Days prior to the payment date. Any wire transfer instructions received by the Trustee will remain in effect until revoked by the Holder. Notwithstanding the foregoing, so long as this
Note is registered in the name of a Depositary or its nominee, all payments hereon shall be made by wire transfer of immediately available funds to the account of the Depositary or its nominee. 

3. PAYING AGENT AND REGISTRAR 
 Initially, The
Bank of New York Mellon (the “Trustee”) will act as Paying Agent and Registrar. The Company may change any Paying Agent or Registrar without notice to the Holder. The Company or any of their Subsidiaries may, subject to certain
limitations set forth in the Indenture, act as Paying Agent or Registrar. 
  
  

 

	6 	 Include only if the Note is a Global Note. 

	7 	 Include only if the Note is a Definitive Note. 

  
 A-1-6 

 4. INDENTURE, LIMITATIONS 

This Note is one of a duly authorized issue of Notes of the Company designated as its 7.000% Senior Notes due 2028 (the
“Notes”), issued under an Indenture dated as of May 23, 2019 (together with any supplemental indentures thereto, the “Indenture”), among the Company, the Note Guarantors and the Trustee. The terms of this Note
include those stated in the Indenture. This Note is subject to all such terms, and the Holder of this Note is referred to the Indenture and said Act for a statement of them. Capitalized terms used and not defined herein have the meanings assigned to
such terms in the Indenture. 
 The Company shall be entitled to issue Additional Notes pursuant to Section 2.1(c) of the Indenture.

 5. OPTIONAL REDEMPTION; PURCHASE OF NOTES AT OPTION OF HOLDER. 

(a) Optional Redemption. The Notes are redeemable at the option of the Company at the prices, and upon the terms and conditions, set
forth in Section 3.7 of the Indenture. 
 (b) Repurchase at Option of Holder. If there is a Change of Control, the Company shall
be required to make an offer (a “Change of Control Offer”) to repurchase all or any part (equal to $2,000 or an integral multiple of $1,000 in excess thereof) of each Holder’s Notes at a purchase price equal to 101% of the
aggregate principal amount thereof plus accrued and unpaid interest thereon, if any, to, but excluding, the date of purchase. Within 30 days following any Change of Control, the Company shall transmit a notice to each Holder setting forth the
procedures governing the Change of Control Offer as required by the Indenture. 
 If after the Company or a Restricted Subsidiary
consummates any Asset Sale, the Company may be required to purchase Notes, as further specified in the Indenture. 
 (d) Notice of
Redemption. Notice of redemption will be given at least 15 days but not more than 60 days before the redemption date to each Holder whose Notes are to be redeemed at its registered address. Notes in denominations larger than $2,000 may be
redeemed in part but only in whole multiples of $1,000, unless all of the Notes held by a Holder are to be redeemed. On and after the redemption date, subject to satisfaction of any conditions precedent, interest ceases to accrue on Notes or
portions thereof called for redemption. 
 6. DENOMINATIONS, TRANSFER, EXCHANGE, CANCELLATION 

The Notes are in registered form, without coupons, in denominations of $2,000 and integral multiples of $1,000 in excess thereof. A Holder may
register the transfer of or exchange Notes in accordance with the Indenture. The Registrar may require a Holder, among other things, to furnish appropriate endorsements and transfer documents and to pay any taxes or other governmental charges that
may be imposed in relation thereto by law or permitted by the Indenture. 
 All Notes surrendered for payment, registration of transfer or
exchange or conversion will, if surrendered to the Company or any of its other Agents with respect to the Notes, be delivered to the Trustee. The Trustee will promptly cancel all Notes delivered to it. No Notes will be authenticated in exchange for
any Notes cancelled, except as provided in the Indenture. 
 7. PERSONS DEEMED OWNERS 

The Holder of a Note may be treated as the owner of it for all purposes. 

8. GUARANTEES 
 This Note is guaranteed as set
forth in the Indenture. 

  
 A-1-7 

 9. UNCLAIMED MONEY 

If money for the payment of principal or interest remains unclaimed for two years, the Trustee or Paying Agent will pay the money back to the
Company at its written request, subject to applicable unclaimed property law. After that, Holders entitled to money must look to the Company for payment as general creditors unless an applicable abandoned property law designates another person. 

10. AMENDMENT, SUPPLEMENT AND WAIVER 
 Subject to
certain exceptions, the Indenture (with respect to the Notes) or the Notes may be amended or supplemented with the consent of the Holders of at least a majority in aggregate principal amount of the then outstanding, and an existing default or Event
of Default and its consequence or compliance with any provision of the Indenture or the Notes may be waived in a particular instance with the consent of the Holders of a majority in aggregate principal amount of the Notes then outstanding. Without
the consent of or notice to any Holder, the Company and the Trustee may amend or supplement the Indenture (with respect to the Notes) or the Notes to, among other things, cure any ambiguity, defect or inconsistency or make any other change that does
not adversely affect the rights of any Holder. 
 In addition, except as set forth under Article 10 of the Indenture, without the consent of
Holders of at least 66 2/3% in principal amount of the Notes then outstanding (including, without limitation, consents obtained in connection with a purchase of, or tender offer or exchange offer for, Notes), no amendment or supplement may release
the Note Guarantees. 
 11. SUCCESSOR ENTITY 

When a successor corporation assumes all the obligations of its predecessor under the Notes and the Indenture in accordance with the terms and
conditions of the Indenture, the predecessor corporation (except in certain circumstances specified in the Indenture) shall be released from those obligations. 

12. DEFAULTS AND REMEDIES 
 If an Event of
Default, as defined in the Indenture, occurs and is continuing, the Trustee or the Holders of at least 25% in principal amount of the Notes may declare all the Notes to be due and payable. If a bankruptcy or insolvency default with respect to the
Company occurs and is continuing, the Notes automatically become due and payable. Holders may not enforce the Indenture or the Notes except as provided in the Indenture. The Trustee may require indemnity satisfactory to it before it enforces the
Indenture or the Notes. Subject to certain limitations, Holders of a majority in principal amount of the Notes then outstanding may direct the Trustee in its exercise of remedies. 

13. TRUSTEE DEALINGS WITH THE COMPANY 
 The Bank
of New York Mellon, the Trustee under the Indenture, in its individual or any other capacity, may make loans to, accept deposits from and perform services for the Company or an Affiliate of the Company and may otherwise deal with the Company or an
Affiliate of the Company as if it were not the Trustee. 
 14. NO RECOURSE AGAINST OTHERS 

A director, officer, employee, incorporator, or shareowner, as such, of the Company or any Note Guarantor shall not have any liability for any
obligations of the Company or any Note Guarantor under the Notes or the Indenture nor for any claim based on, in respect of or by reason of such obligations or their creation. The Holder of this Note by accepting this Note waives and releases all
such liability. The waiver and release are part of the consideration for the issuance of this Note. 

  
 A-1-8 

 15. AUTHENTICATION 

This Note shall not be valid until the Trustee or an authenticating agent manually signs the certificate of authentication on the other side of
this Note. 
 16. ABBREVIATIONS AND DEFINITIONS 

Customary abbreviations may be used in the name of the Holder or an assignee, such as: TEN COM (= tenants in common), TEN ENT (= tenants by the
entireties), JT TEN (= joint tenants with right of survivorship and not as tenants in common), CUST (= Custodian) and UGMA (= Uniform Gifts to Minors Act). 

17. INDENTURE TO CONTROL; GOVERNING LAW 
 In the
case of any conflict between the provisions of this Note and the Indenture, the provisions of the Indenture shall control. This Note shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to
principles of conflicts of law. 
 The Company will furnish to any Holder, upon written request and without charge, a copy of the Indenture.
Requests may be made to: Bausch Health Companies Inc., 400 Somerset Corporate Boulevard, Bridgewater, New Jersey 08807, Telephone: (905) 286-3000, Attention: Investor Relations. 

  
 A-1-9 

 ASSIGNMENT FORM 

To assign this Note, fill in the form below: 

I or we assign and transfer this Note to 
  

 
 (Insert assignee’s soc. sec. or
tax I.D. no.) 
  
  

 
  
  

 
 (Print or type assignee’s name,
address and zip code) 
 and irrevocably appoint 
  

 
 agent to transfer this Note on the books of the
Company. The agent may substitute another to act for him or her. 
  

							
		  	    	  	    	  	Your Signature:
	Date:	  	
                 
	  		  	
                 

		  		  		  	(Sign exactly as your name appears on the other side of this Note)

  

	*	 Signature guaranteed by: 

By:
                                        
     
  

	*	 The signature must be guaranteed by an institution which is a member of one of the following recognized
signature guaranty programs: (i) the Securities Transfer Agent Medallion Program (STAMP); (ii) the New York Stock Exchange Medallion Program (MSP); (iii) the Stock Exchange Medallion Program (SEMP); or (iv) such other guaranty program
acceptable to the Trustee. 

  
 A-1-10 

 OPTION TO ELECT PURCHASE 

If you want to elect to have this Note purchased by the Company pursuant to Section 3.8 or Section 4.14 of the Indenture, check the appropriate box
below: 
 ☐     Section 3.8            
☐     Section 4.14 
 If you want to elect to have only part of the Note purchased by the Company pursuant to
Section 3.8 or Section 4.14 of the Indenture, state the amount you elect to have purchased: 

$                       
   
 Date:
                                        
     
  

			
	Your Signature:
	
	  
 (Sign exactly as your
name appears on the face of this Note)

	Tax Identification No.:	 	  

 Signature Guarantee*:
                                       
      
  

	*	 Participant in a recognized Signature Guarantee Medallion Program (or other signature guarantor acceptable to
the Trustee). 

  
 A-1-11 

 SCHEDULE OF EXCHANGES OF NOTES8 

The following exchanges, repurchases or conversions of a part of this global Note have been made: 

 

							
	 PRINCIPAL AMOUNT
 OF THIS GLOBAL

NOTE FOLLOWING
 SUCH DECREASE DATE

OF EXCHANGE

(OR INCREASE)
	  	 AUTHORIZED

SIGNATORY OF
 NOTES

CUSTODIAN
	  	 AMOUNT OF DECREASE

IN PRINCIPAL AMOUNT
 OF THIS
GLOBAL
 NOTE
	  	 AMOUNT OF INCREASE

IN PRINCIPAL AMOUNT
 OF THIS
GLOBAL
 NOTE

  

 

	8	 This schedule should be included only if the Note is a Global Note. 

  
 A-1-12 

 CERTIFICATE TO BE DELIVERED UPON EXCHANGE OR REGISTRATION 

OF TRANSFER OF RESTRICTED SECURITIES9 

 

	Re:	 7.000% Senior Notes due 2028 (the “Notes”) of Bausch Health Companies Inc. (the
“Company”). 

 This certificate relates to
$                         principal amount of Notes owned in (check applicable box) 

☐ book-entry or ☐ definitive form
by                         (the “Transferor”). 

The Transferor has requested a Registrar or the Trustee to exchange or register the transfer of such Notes. 

In connection with such request and in respect of each such Note, the Transferor does hereby certify that the Transferor is familiar with
transfer restrictions relating to the Notes as provided in Section 2.12 of the Indenture dated as of May 23, 2019 among Bausch Health Companies Inc., the Note Guarantors party and thereto The Bank of New York Mellon, as trustee (the
“Indenture”), and the transfer of such Note is in accordance with any applicable securities laws of any state and is being made pursuant to an effective registration statement under the Securities Act of 1933, as amended (the
“Securities Act”) (check applicable box) or the transfer or exchange, as the case may be, of such Note does not require registration under the Securities Act because (check applicable box): 

 

	 	☐	 Such Note is being transferred pursuant to an effective registration statement under the Securities Act.

  

	 	☐	 Such Note is being acquired for the Transferor’s own account, without transfer. 

 

	 	☐	 Such Note is being transferred to the Company or a Subsidiary (as defined in the Indenture) of the Company.

  

	 	☐	 Such Note is being transferred to a person the Transferor reasonably believes is a “qualified
institutional buyer” (as defined in Rule 144A or any successor provision thereto (“Rule 144A”) under the Securities Act) that is purchasing for its own account or for the account of a “qualified institutional buyer,”
in each case to whom notice has been given that the transfer is being made in reliance on such Rule 144A, and in each case in reliance on Rule 144A. 

  

	 	☐	 Such Note is being transferred pursuant to and in compliance with an exemption from the registration
requirements under the Securities Act in accordance with Rule 144 (or any successor thereto) (“Rule 144”) under the Securities Act. 

  

	 	☐	 Such Note is being transferred to a Non-U.S. Person in an offshore
transaction in compliance with Rule 904 of Regulation S under the Securities Act (or any successor thereto). 

  

	 	☐	 Such Note is being transferred to an institutional “accredited investor” (as defined in Rule
501(a)(1), (2), (3) or (7) of the Securities Act) that has provided a letter addressed to the Company, in the form of Exhibit C attached to the Indenture, containing certain representations and agreements.

  

							
	Date:	  	          
	  	        	  	  

		  		  		  	(Insert Name of Transferor)

  

	9 	 This certificate should be included only if this Note is a Restricted Note. 

  
 A-1-13 

 EXHIBIT A-2 

BAUSCH HEALTH COMPANIES INC. 

7.250% SENIOR NOTES DUE 2029 

[FORM OF FACE OF NOTE] 
 [UNLESS
THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO.
OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (AND ANY PAYMENT HEREON IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY
TRUST COMPANY), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. THIS NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE
INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS NOTE IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED
CIRCUMSTANCES DESCRIBED IN THE INDENTURE AND, UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE FORM, THIS NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE
OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY.]1 

[THIS NOTE HAS NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY
NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT AS SET FORTH BELOW. BY ITS ACQUISITION HEREOF, THE HOLDER (1) REPRESENTS THAT (A) IT IS A “QUALIFIED INSTITUTIONAL
BUYER” (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT), (B) IT IS NOT A U.S. PERSON AND IS ACQUIRING THIS NOTE IN AN OFFSHORE TRANSACTION IN COMPLIANCE WITH RULE 904 UNDER THE SECURITIES ACT OR (C) IT IS AN ACCREDITED INVESTOR (AS
DEFINED IN RULE 501(a)(1), (2), (3), OR (7) UNDER THE SECURITIES ACT (AN “ACCREDITED INVESTOR”)), (2) AGREES THAT IT WILL NOT PRIOR TO THE FIRST ANNIVERSARY OF THE ORIGINAL ISSUANCE OF THIS NOTE RESELL OR OTHERWISE TRANSFER THIS NOTE
EXCEPT (A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF, (B) INSIDE THE UNITED STATES TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE SECURITIES ACT, (C) INSIDE THE UNITED STATES TO AN ACCREDITED INVESTOR THAT,
PRIOR TO SUCH TRANSFER, FURNISHES (OR HAS FURNISHED ON ITS BEHALF BY A U.S. BROKER-DEALER) TO THE TRUSTEE A SIGNED LETTER CONTAINING CERTAIN REPRESENTATIONS AND AGREEMENTS RELATING TO THE RESTRICTIONS ON TRANSFER OF THIS NOTE (THE FORM OF WHICH
LETTER CAN BE OBTAINED FROM THE TRUSTEE FOR THIS NOTE), (D) OUTSIDE THE UNITED STATES IN AN OFFSHORE TRANSACTION IN COMPLIANCE WITH RULE 904 UNDER THE SECURITIES ACT (IF AVAILABLE), (E) PURSUANT TO THE EXEMPTION FROM REGISTRATION PROVIDED BY RULE
144 UNDER THE SECURITIES ACT (IF AVAILABLE), (F) IN ACCORDANCE WITH ANOTHER EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT (AND BASED UPON AN OPINION OF COUNSEL IF THE COMPANY SO REQUESTS), OR (G) PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND (3) AGREES THAT IT WILL GIVE TO EACH PERSON TO WHOM THIS NOTE IS TRANSFERRED A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND. IN CONNECTION WITH ANY TRANSFER OF THIS NOTE WITHIN ONE YEAR
AFTER 
  

	1 	 Include only if the Note is a Global Note. 

  
 A-2-1 

 
THE ORIGINAL ISSUANCE OF THIS NOTE, IF THE PROPOSED TRANSFEREE IS AN ACCREDITED INVESTOR, THE HOLDER MUST, PRIOR TO SUCH TRANSFER, FURNISH TO THE TRUSTEE AND THE COMPANY SUCH CERTIFICATIONS,
LEGAL OPINIONS OR OTHER INFORMATION AS EITHER OF THEM MAY REASONABLY REQUIRE TO CONFIRM THAT SUCH TRANSFER IS BEING MADE PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. AS USED
HEREIN, THE TERMS “OFFSHORE TRANSACTION,” “UNITED STATES” AND “U.S. PERSON” HAVE THE MEANING GIVEN TO THEM BY REGULATION S UNDER THE SECURITIES ACT.]2 [THIS NOTE AND
ANY RELATED DOCUMENTATION MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME TO MODIFY THE RESTRICTIONS ON RESALES AND OTHER TRANSFERS OF THIS NOTE TO REFLECT ANY CHANGE IN APPLICABLE LAW OR REGULATION (OR THE INTERPRETATION THEREOF) OR IN PRACTICES
RELATING TO THE RESALE OR TRANSFER OF RESTRICTED SECURITIES GENERALLY. THE HOLDER OF THIS NOTE SHALL BE DEEMED BY THE ACCEPTANCE OF THIS NOTE TO HAVE AGREED TO ANY SUCH AMENDMENT OR SUPPLEMENT.]3

 [CANADIAN RESALE LEGEND 

UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS NOTE MUST NOT TRADE THIS NOTE BEFORE THE DATE THAT IS 4 MONTHS AND A DAY
AFTER MAY 23, 2019.]4 
  
  

 
  

	2 	 Include only if the Note is a Restricted Note. 

	3 	 Include only if the Note is a Restricted Note. 

	4 	 Include until no longer necessary under Canadian securities laws. 

  
 A-2-2 

 BAUSCH HEALTH COMPANIES INC. 

 

					
	CUSIP: 144A: 071734 AF4, Reg. S: C07885 AC7	  	
	ISIN: 144A: US071734AF49 Reg. S: USC07885AC77	  	        	  	No. [ ]

 7.250% SENIOR NOTES DUE 2029 

Bausch Health Companies Inc., a corporation continued under the laws of the Province of British Columbia (the “Company,”
which term shall include any successor corporation under the Indenture referred to on the reverse hereof) promises to pay to
                                     or its registered assigns, the
principal sum of                                      Dollars
($                ) on May 30, 2029 [or such greater or lesser amount as is indicated on the Schedule of Exchanges of Notes on the other side of this Note]5 and to pay interest thereon as provided on the other side of this Note. 
 Interest
Payment Dates: May 30 and November 30, beginning November 30, 2019. 
 Record Dates: May 15 and November 15. 

Additional provisions of this Note are set forth on the other side of this Note. 

 
  

	5 	 Include only if the Note is a Global Note. 

  
 A-2-3 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed. 

 

			
	BAUSCH HEALTH COMPANIES INC.
		
	By:	 	  

		 	Name:
		 	Title:

  
 A-2-4 

 Trustee’s Certificate of Authentication: 

This is one of the Notes referred to in the within- 
 mentioned
Indenture for the 7.250% Senior Notes 
 due 2029. 
  

			
	THE BANK OF NEW YORK MELLON, as Trustee
		
	By:	 	  

		 	Authorized Signatory
		
	Dated:	 	  

  
 A-2-5 

 [FORM OF REVERSE SIDE OF NOTE] 

BAUSCH HEALTH COMPANIES INC. 

7.250% SENIOR NOTES DUE 2029 
  

	1.	 INTEREST 

The Company shall pay interest on this Note semiannually in arrears on May 30 and November 30, each an “interest payment
date,” of each year, commencing on November 30, 2019, at the rate per annum specified in the title of this Note. Interest shall accrue from and including May 23, 2019 or else the most recent interest payment date to which interest
had been paid or duly provided for to but excluding the date on which such interest is paid. Interest on this Note will be computed on the basis of a 360-day year of twelve
30-day months. 
 The Company shall, (in immediately available funds) to the fullest extent
permitted by law, pay interest on overdue principal (including premium, if any) and overdue installments of interest from the original due date to the date paid, at the rate applicable to this Note, which interest shall be payable on demand. 

The interest so payable and punctually paid or duly provided for on any interest payment date will be paid to the Person in whose name this
Note is registered at the close of business on May 15 and November 15 preceding such interest payment date (the “Record Date”) except as provided in the Indenture. Payment of the principal of (and premium, if any) and
interest on this Note will be made in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts and as otherwise provided in the Indenture. 

 

	2.	 METHOD OF PAYMENT 

[The Company will make payments in respect of this Note (including principal, premium, if any, interest) by wire transfer of immediately
available funds to the accounts specified by the Holder.]6 [The Company will make all payments of principal, interest and premium, if any, with respect to this Note by wire transfer of immediately
available funds to the accounts specified by the Holders, in the case of a Holder holding an aggregate principal amount of Notes of $1,000,000 or more, or, if no such account is specified or in the case of a Holder holding an aggregate principal
amount of Notes of less than $1,000,000, by mailing a check to each such Holder’s registered address.]7 All payments shall be made in immediately available funds in such coin or currency of
the United States of America as at the time of payment is legal tender for payment of public and private debts. Payments to any Holder holding an aggregate principal amount of Notes in excess of $1,000,000 shall be made by wire transfer in
immediately available funds to an account maintained by such Holder in the United States, if such Holder has provided wire transfer instructions to the Company at least 10 Business Days prior to the payment date. Any wire transfer instructions
received by the Trustee will remain in effect until revoked by the Holder. Notwithstanding the foregoing, so long as this Note is registered in the name of a Depositary or its nominee, all payments hereon shall be made by wire transfer of
immediately available funds to the account of the Depositary or its nominee. 
  

	3.	 PAYING AGENT AND REGISTRAR 

Initially, The Bank of New York Mellon (the “Trustee”) will act as Paying Agent and Registrar. The Company may change any
Paying Agent or Registrar without notice to the Holder. The Company or any of their Subsidiaries may, subject to certain limitations set forth in the Indenture, act as Paying Agent or Registrar. 

 

	6 	 Include only if the Note is a Global Note. 

	7 	 Include only if the Note is a Definitive Note. 

  
 A-2-6 

	4.	 INDENTURE, LIMITATIONS 

This Note is one of a duly authorized issue of Notes of the Company designated as its 7.250% Senior Notes due 2029 (the
“Notes”), issued under an Indenture dated as of May 23, 2019 (together with any supplemental indentures thereto, the “Indenture”), among the Company, the Note Guarantors and the Trustee. The terms of this Note
include those stated in the Indenture. This Note is subject to all such terms, and the Holder of this Note is referred to the Indenture and said Act for a statement of them. Capitalized terms used and not defined herein have the meanings assigned to
such terms in the Indenture. 
 The Company shall be entitled to issue Additional Notes pursuant to Section 2.1(c) of the Indenture.

  

	5.	 OPTIONAL REDEMPTION; PURCHASE OF NOTES AT OPTION OF HOLDER. 

(a) Optional Redemption. The Notes are redeemable at the option of the Company at the prices, and upon the terms and conditions, set
forth in Section 3.7 of the Indenture. 
 (b) Repurchase at Option of Holder. If there is a Change of Control, the Company shall
be required to make an offer (a “Change of Control Offer”) to repurchase all or any part (equal to $2,000 or an integral multiple of $1,000 in excess thereof) of each Holder’s Notes at a purchase price equal to 101% of the
aggregate principal amount thereof plus accrued and unpaid interest thereon, if any, to, but excluding, the date of purchase. Within 30 days following any Change of Control, the Company shall transmit a notice to each Holder setting forth the
procedures governing the Change of Control Offer as required by the Indenture. 
 If after the Company or a Restricted Subsidiary
consummates any Asset Sale, the Company may be required to purchase Notes, as further specified in the Indenture. 
 (d) Notice of
Redemption. Notice of redemption will be given at least 15 days but not more than 60 days before the redemption date to each Holder whose Notes are to be redeemed at its registered address. Notes in denominations larger than $2,000 may be
redeemed in part but only in whole multiples of $1,000, unless all of the Notes held by a Holder are to be redeemed. On and after the redemption date, subject to satisfaction of any conditions precedent, interest ceases to accrue on Notes or
portions thereof called for redemption. 
  

	6.	 DENOMINATIONS, TRANSFER, EXCHANGE, CANCELLATION 

The Notes are in registered form, without coupons, in denominations of $2,000 and integral multiples of $1,000 in excess thereof. A Holder may
register the transfer of or exchange Notes in accordance with the Indenture. The Registrar may require a Holder, among other things, to furnish appropriate endorsements and transfer documents and to pay any taxes or other governmental charges that
may be imposed in relation thereto by law or permitted by the Indenture. 
 All Notes surrendered for payment, registration of transfer or
exchange or conversion will, if surrendered to the Company or any of its other Agents with respect to the Notes, be delivered to the Trustee. The Trustee will promptly cancel all Notes delivered to it. No Notes will be authenticated in exchange for
any Notes cancelled, except as provided in the Indenture. 
  

	7.	 PERSONS DEEMED OWNERS 

The Holder of a Note may be treated as the owner of it for all purposes. 

 

	8.	 GUARANTEES 

This Note is guaranteed as set forth in the Indenture. 

  
 A-2-7 

	9.	 UNCLAIMED MONEY 

If money for the payment of principal or interest remains unclaimed for two years, the Trustee or Paying Agent will pay the money back to the
Company at its written request, subject to applicable unclaimed property law. After that, Holders entitled to money must look to the Company for payment as general creditors unless an applicable abandoned property law designates another person. 

 

	10.	 AMENDMENT, SUPPLEMENT AND WAIVER 

Subject to certain exceptions, the Indenture (with respect to the Notes) or the Notes may be amended or supplemented with the consent of the
Holders of at least a majority in aggregate principal amount of the Notes then outstanding, and an existing default or Event of Default and its consequence or compliance with any provision of the Indenture or the Notes may be waived in a particular
instance with the consent of the Holders of a majority in aggregate principal amount of the Notes then outstanding. Without the consent of or notice to any Holder, the Company and the Trustee may amend or supplement the Indenture (with respect to
the Notes) or the Notes to, among other things, cure any ambiguity, defect or inconsistency or make any other change that does not adversely affect the rights of any Holder. 

In addition, except as set forth under Article 10 of the Indenture, without the consent of Holders of at least 66 2/3% in principal amount of
the Notes then outstanding (including, without limitation, consents obtained in connection with a purchase of, or tender offer or exchange offer for, Notes), no amendment or supplement may release the Note Guarantees. 

 

	11.	 SUCCESSOR ENTITY 

When a successor corporation assumes all the obligations of its predecessor under the Notes and the Indenture in accordance with the terms and
conditions of the Indenture, the predecessor corporation (except in certain circumstances specified in the Indenture) shall be released from those obligations. 
  

	12.	 DEFAULTS AND REMEDIES 

If an Event of Default, as defined in the Indenture, occurs and is continuing, the Trustee or the Holders of at least 25% in principal amount
of the Notes may declare all the Notes to be due and payable. If a bankruptcy or insolvency default with respect to the Company occurs and is continuing, the Notes automatically become due and payable. Holders may not enforce the Indenture or the
Notes except as provided in the Indenture. The Trustee may require indemnity satisfactory to it before it enforces the Indenture or the Notes. Subject to certain limitations, Holders of a majority in principal amount of the Notes then outstanding
may direct the Trustee in its exercise of remedies. 
  

	13.	 TRUSTEE DEALINGS WITH THE COMPANY 

The Bank of New York Mellon, the Trustee under the Indenture, in its individual or any other capacity, may make loans to, accept deposits from
and perform services for the Company or an Affiliate of the Company and may otherwise deal with the Company or an Affiliate of the Company as if it were not the Trustee. 
  

	14.	 NO RECOURSE AGAINST OTHERS 

A director, officer, employee, incorporator, or shareowner, as such, of the Company or any Note Guarantor shall not have any liability for any
obligations of the Company or any Note Guarantor under the Notes or the Indenture nor for any claim based on, in respect of or by reason of such obligations or their creation. The Holder of this Note by accepting this Note waives and releases all
such liability. The waiver and release are part of the consideration for the issuance of this Note. 

  
 A-2-8 

 15. AUTHENTICATION 

This Note shall not be valid until the Trustee or an authenticating agent manually signs the certificate of authentication on the other side of
this Note. 
 16. ABBREVIATIONS AND DEFINITIONS 

Customary abbreviations may be used in the name of the Holder or an assignee, such as: TEN COM (= tenants in common), TEN ENT (= tenants by the
entireties), JT TEN (= joint tenants with right of survivorship and not as tenants in common), CUST (= Custodian) and UGMA (= Uniform Gifts to Minors Act). 

17. INDENTURE TO CONTROL; GOVERNING LAW 
 In the
case of any conflict between the provisions of this Note and the Indenture, the provisions of the Indenture shall control. This Note shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to
principles of conflicts of law. 
 The Company will furnish to any Holder, upon written request and without charge, a copy of the Indenture.
Requests may be made to: Bausch Health Companies Inc., 400 Somerset Corporate Boulevard, Bridgewater, New Jersey 08807, Telephone: (905) 286-3000, Attention: Investor Relations. 

  
 A-2-9 

 ASSIGNMENT FORM 

To assign this Note, fill in the form below: 
  

			
	I or we assign and transfer this Note to	  	
	  

		  	(Insert assignee’s soc. sec. or tax I.D. no.)

  
  

 
  
  

 
 (Print or type assignee’s name,
address and zip code) 
 and irrevocably appoint 
  

 
 agent to transfer this Note on the books of the
Company. The agent may substitute another to act for him or her. 
  

											
		 		 		 		 	Your Signature:	 	  

		 	Date:	 	                                      
              	 		 	  
	 	  

		 		 		 	    	 	    (Sign exactly as your name appears on the other side of this Note)

  
 *Signature guaranteed by: 

By:
                                        
                             
  

	*	 The signature must be guaranteed by an institution which is a member of one of the following recognized
signature guaranty programs: (i) the Securities Transfer Agent Medallion Program (STAMP); (ii) the New York Stock Exchange Medallion Program (MSP); (iii) the Stock Exchange Medallion Program (SEMP); or (iv) such other guaranty program
acceptable to the Trustee. 

  
 A-2-10 

 OPTION TO ELECT PURCHASE 

If you want to elect to have this Note purchased by the Company pursuant to Section 3.8 or Section 4.14 of the Indenture, check the appropriate box
below: 
  

							
		  	☐ Section 3.8                     ☐ Section 4.14	  	

 If you want to elect to have only part of the Note purchased by the Company pursuant to Section 3.8 or Section 4.14
of the Indenture, state the amount you elect to have purchased: 

$                       
                                       

Date:                         
                                         
        
  

	
	Your Signature:
	  

	(Sign exactly as your name appears on the face of this Note)
	
	Tax Identification No.:
                                         
               

 Signature Guarantee*:
                                        
                     
  

	*	 Participant in a recognized Signature Guarantee Medallion Program (or other signature guarantor acceptable to
the Trustee). 

  
 A-2-11 

 SCHEDULE OF EXCHANGES OF NOTES8 

The following exchanges, repurchases or conversions of a part of this global Note have been made: 

 

							
	 PRINCIPAL AMOUNT
 OF THIS GLOBAL

NOTE FOLLOWING
 SUCH DECREASE DATE

OF EXCHANGE

(OR INCREASE)
	  	 AUTHORIZED

SIGNATORY OF
 NOTES

CUSTODIAN
	  	 AMOUNT OF DECREASE

IN PRINCIPAL AMOUNT
 OF THIS
GLOBAL
 NOTE
	  	 AMOUNT OF INCREASE

IN PRINCIPAL AMOUNT
 OF THIS
GLOBAL
 NOTE

  

 

	8	 This schedule should be included only if the Note is a Global Note. 

  
 A-2-12 

 CERTIFICATE TO BE DELIVERED UPON EXCHANGE OR REGISTRATION 

OF TRANSFER OF RESTRICTED SECURITIES9 

 

	Re:	 7.250% Senior Notes due 2029 (the “Notes”) of Bausch Health Companies Inc. (the
“Company”). 

 This certificate relates to
$                     principal amount of Notes owned in (check applicable box) 

☐ book-entry or ☐ definitive form
by                     (the “Transferor”). 

The Transferor has requested a Registrar or the Trustee to exchange or register the transfer of such Notes. 

In connection with such request and in respect of each such Note, the Transferor does hereby certify that the Transferor is familiar with
transfer restrictions relating to the Notes as provided in Section 2.12 of the Indenture dated as of May 23, 2019 among Bausch Health Companies Inc., the Note Guarantors party thereto and The Bank of New York Mellon, as trustee (the
“Indenture”), and the transfer of such Note is in accordance with any applicable securities laws of any state and is being made pursuant to an effective registration statement under the Securities Act of 1933, as amended (the
“Securities Act”) (check applicable box) or the transfer or exchange, as the case may be, of such Note does not require registration under the Securities Act because (check applicable box): 

 

	 	☐	 Such Note is being transferred pursuant to an effective registration statement under the Securities Act.

  

	 	☐	 Such Note is being acquired for the Transferor’s own account, without transfer. 

 

	 	☐	 Such Note is being transferred to the Company or a Subsidiary (as defined in the Indenture) of the Company.

  

	 	☐	 Such Note is being transferred to a person the Transferor reasonably believes is a “qualified
institutional buyer” (as defined in Rule 144A or any successor provision thereto (“Rule 144A”) under the Securities Act) that is purchasing for its own account or for the account of a “qualified institutional buyer,”
in each case to whom notice has been given that the transfer is being made in reliance on such Rule 144A, and in each case in reliance on Rule 144A. 

  

	 	☐	 Such Note is being transferred pursuant to and in compliance with an exemption from the registration
requirements under the Securities Act in accordance with Rule 144 (or any successor thereto) (“Rule 144”) under the Securities Act. 

  

	 	☐	 Such Note is being transferred to a Non-U.S. Person in an offshore
transaction in compliance with Rule 904 of Regulation S under the Securities Act (or any successor thereto). 

  

	 	☐	 Such Note is being transferred to an institutional “accredited investor” (as defined in Rule
501(a)(1), (2), (3) or (7) of the Securities Act) that has provided a letter addressed to the Company, in the form of Exhibit C attached to the Indenture, containing certain representations and agreements.

  

							
		  		  		  	
	Date: 	  	  
	  		  	  

		  		  		  	(Insert Name of Transferor)

  
  

 

	9 	 This certificate should be included only if this Note is a Restricted Note. 

  
 A-2-13 

 EXHIBIT B 

FORM OF GUARANTEE 
 [Name of Note
Guarantor] and its successors under the Indenture, jointly and severally with any other Note Guarantors, hereby irrevocably and unconditionally (i) guarantee the due and punctual payment of the principal of, premium, if any, and interest on the
Notes, whether at maturity, by acceleration, redemption or otherwise, the due and punctual payment of interest on the overdue principal of and interest, if any, on the Notes, to the extent lawful, and the due and punctual performance of all other
obligations of Bausch Health Companies Inc. (the “Company”) to the Holders or the Trustee, all in accordance with the terms set forth in Article 10 of the Indenture and (ii) in case of any extension of time of payment or
renewal of any Notes or any of such other obligations, guarantee that the same will be promptly paid in full when due or performed in accordance with the terms of the extension or renewal, whether at stated maturity, by acceleration or otherwise.
Capitalized terms used herein have the meanings assigned to them in the Indenture unless otherwise indicated. 
 No stockholder, officer,
director or incorporator, as such, past, present or future, of [name of Note Guarantor] shall have any personal liability under this Note Guarantee by reason of his, her or its status as such stockholder, officer, director or incorporator. This Note
Guarantee shall be binding upon [name of Note Guarantor] and its successors and assigns and shall inure to the benefit of the successors and assigns of the Trustee and the Holders and, in the event of any transfer or assignment of rights by any
Holder or the Trustee, the rights and privileges herein conferred upon that party shall automatically extend to and be vested in such transferee or assignee, all subject to the terms and conditions hereof. 

This Note Guarantee shall not be valid or obligatory for any purpose until the certificate of authentication on the Note upon which this Note
Guarantee is noted shall have been executed by the Trustee under the Indenture by the manual signature of one of its authorized officers. 

THE TERMS OF ARTICLE 10 OF THE INDENTURE ARE INCORPORATED HEREIN BY REFERENCE. 

This Note Guarantee shall be governed by and construed in accordance with the laws of the State of New York. 

 

			
	[NAME OF NOTE GUARANTOR]
		
	By:	 	  

		 	Name:
		 	Title:

  
 B-1 

 EXHIBIT C 

FORM OF CERTIFICATE FROM ACQUIRING 

INSTITUTIONAL ACCREDITED INVESTOR 
 Bausch Health
Companies Inc. 
 400 Somerset Corporate Boulevard 

Bridgewater, NJ 08807 
 Attention: General Counsel 

Facsimile No.: (949) 461-6609 
  

	 	Re:	 ☐ 7.000% SENIOR NOTES DUE 2028 

     CUSIP: 144A: 071734 AD9, Reg. S: C07885 AB9 

     ISIN: 144A: US071734AD90, Reg. S: USC07885AB94 

 

	 	    	 ☐ 7.250% SENIOR NOTES DUE 2029 

     CUSIP: 144A: 071734 AF4, Reg. S: C07885 AC7 

     ISIN: 144A: US071734AF49 Reg. S: USC07885AC77 

Dear Sirs: 
 Reference is hereby made to the
Indenture, dated as of May 23, 2019 (the “Indenture”), among Bausch Health Companies Inc., as issuer (the “Company”), the Note Guarantors party thereto and The Bank of New York Mellon, as the Trustee.
Capitalized terms used but not defined herein shall have the meanings given to them in the Indenture. 
 In connection with our proposed
purchase of $                     aggregate principal amount of [7.000% Senior Notes due 2028] [7.250% Senior Notes due 2029] (the
“Notes”), we confirm that: 
 1. We understand that any subsequent transfer of the Notes or any interest therein is subject
to certain restrictions and conditions set forth in the Indenture and the undersigned agrees to be bound by, and not to resell, pledge or otherwise transfer the Notes or any interest therein except in compliance with, such restrictions and
conditions and the United States Securities Act of 1933, as amended (the “Securities Act”). 
 2. We understand that the
offer and sale of the Notes have not been registered under the Securities Act, and that the Notes and any interest therein may not be offered or sold except as permitted in the following sentence. We agree, on our own behalf and on behalf of any
accounts for which we are acting as hereinafter stated, that if we should sell the Notes or any interest therein, we will do so only (A) to the Company or any of its subsidiaries, (B) in accordance with Rule 144A under the Securities Act
to a “qualified institutional buyer” (as defined therein), (C) inside the United States to an institutional “accredited investor” (as defined below) purchasing for its own account or for the account of another institutional
accredited investor that, prior to such transfer, furnishes (or has furnished on its behalf by a U.S. broker-dealer) to you and to the Company a signed letter substantially in the form of this letter, (D) pursuant to the provisions of Rule 144
under the Securities Act (if available), (E) in accordance with another exemption from the registration requirements of the Securities Act (and based upon an opinion of counsel acceptable to the Company) or (F) pursuant to an effective
registration statement under the Securities Act, and we further agree to provide to any person purchasing the Notes from us in a transaction meeting the requirements of clauses (A) through (F) of this paragraph a notice advising such purchaser
that resales thereof are restricted as stated herein. 
 3. We understand that, on any proposed resale of the Notes or beneficial interest
therein, we will be required to furnish to you and the Company such certifications, legal opinions and other information as you and the Company may reasonably require to confirm that the proposed sale complies with the foregoing restrictions. We
further understand that the Notes purchased by us will bear a legend to the foregoing effect. 

  
 C-1 

 4. We are an institutional “accredited investor” (as defined in Rule 501(a)(1),
(2), (3) or (7) of Regulation D under the Securities Act) and have such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of our investment in the Notes, and we and any accounts for
which we are acting are each able to bear the economic risk of our or its investment. 
 5. We are acquiring the Notes or beneficial interest
therein purchased by us for our own account or for one or more accounts (each of which is an institutional “Accredited Investor”) as to each of which we exercise sole investment discretion. 

You and the Company are entitled to rely upon this letter and are irrevocably authorized to produce this letter or a copy hereof to any
interested party in any administrative or legal proceedings or official inquiry with respect to the matters covered hereby. 
 Dated: 

 

			
	[Insert Name of Accredited Investor]
		
	By:	 	  

		 	Name:
		 	Title:

  
 C-2 

 EXHIBIT D 

FORM OF CANADIAN NOTE GUARANTEE 

Re: ☐ 7.000% SENIOR NOTES DUE 2028 

  CUSIP: 144A: 071734 AD9, Reg. S: C07885 AB9 

  ISIN: 144A: US071734AD90, Reg. S: USC07885AB94 

       ☐ 7.250% SENIOR NOTES DUE 2029 

  CUSIP: 144A: 071734 AF4, Reg. S: C07885 AC7 

  ISIN: 144A: US071734AF49 Reg. S: USC07885AC77 

THIS CANADIAN NOTE GUARANTEE (as amended, restated, modified, renewed or extended from time to time, and including, for the avoidance of any
doubt, the preamble and recitals hereto, this “Canadian Note Guarantee”), is executed and delivered as of ☐ by ☐ (“Guarantor”) in favour of The Bank of New York Mellon, as the Trustee, Registrar and
Paying Agent, for the benefit of each Holder (together with the Trustee, collectively, the “Beneficiaries”). 
 RECITALS: 

 

	A.	 Reference is made to that Indenture dated as of May 23, 2019 among Bausch Health Companies Inc., a
corporation continued under the laws of the Province of British Columbia (the “Company”) and the Trustee (as amended, supplemented, restated, extended, renewed, or replaced from time to time, the “Indenture”).

  

	B.	 Guarantor is an Affiliate of the Company, and, as such, will benefit by virtue of the financial accommodations
extended to the Company pursuant to the Indenture. 

 THEREFORE, Guarantor agrees as follows: 

Section 1. 

Definitions and Principles of Interpretation 

1.1. Definitions. 
 All capitalized terms used and not
defined elsewhere in this Canadian Note Guarantee, and all capitalized terms used and not defined in the provisions incorporated by reference into this Canadian Note Guarantee, shall have the meanings ascribed to them in the Indenture (such meanings
to be determined as if such terms were to be interpreted in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable in the Province of Ontario) and shall be incorporated by reference into this Canadian Note
Guarantee, and the following words and terms have the meanings set out below: 
 “Guaranteed Obligations” has the meaning
given to it in Section 2.1(a). 
 “Indenture” has the meaning given to it in the recitals to this Canadian Note
Guarantee. 
 1.2. Certain Rules of Interpretation. 
 In
this Canadian Note Guarantee: 
  

	(a)	 Governing Law – This Canadian Note Guarantee (including terms incorporated by reference to the
Indenture) is a contract made under and shall be governed by and construed in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable in the Province of Ontario. 

  
 Schedule D-1 

	(b)	 Headings – Headings of Articles and Sections are inserted for convenience of reference only and
shall not affect the construction or interpretation of this Canadian Note Guarantee. 

  

	(c)	 Including – Where the word “including” or “includes” is used in this Canadian
Note Guarantee, it means “including (or includes) without limitation.” 

  

	(d)	 No Strict Construction – The language used in this Canadian Note Guarantee is the language chosen
by the parties to express their mutual intent, and no rule of strict construction shall be applied against any party. 

  

	(e)	 Number and Gender – Unless the context otherwise requires, words importing the singular include the
plural and vice versa and words importing gender include all genders. 

  

	(f)	 Statutory references – A reference to a statute includes all regulations made pursuant to such
statute and, unless otherwise specified, the provisions of any statute or regulation which amends, revises, restates, supplements or supersedes any such statute or any such regulation. 

 

	(g)	 Time – Time is of the essence in the performance of Guarantor’s obligations under this
Canadian Note Guarantee. 

 Section 2. 

GUARANTEE 
  

	2.1.	 Guarantee of the Obligations. 

 

	(a)	 Guarantor hereby unconditionally Guarantees to each Holder of a Note authenticated and delivered by the Trustee
and to the Trustee and its successors and assigns, irrespective of the validity and enforceability of the Indenture, the Notes or the obligations of the Company thereunder that: (i) the due and punctual payment of principal, premium and
interest on the Notes shall be promptly paid in full when due, whether at maturity, by acceleration, redemption or otherwise, (ii) the due and punctual payment of interest on the overdue principal of and interest on the Notes, if any, if
lawful, and all other obligations of the Company to the Holders or the Trustee under the Indenture or any Note shall be promptly paid in full or performed, all in accordance with the terms thereof, and (iii) in case of any extension of time of
payment or renewal of any Notes or any of such other obligations, that same shall be promptly paid in full when due or performed in accordance with the terms of the extension or renewal, whether at stated maturity, by acceleration pursuant to
Section 6.2 of the Indenture or otherwise (collectively, the “Guaranteed Obligations”). Guarantor agrees that this Canadian Note Guarantee is a guarantee of payment and not a guarantee of collection. Failing payment when due of
any Guaranteed Obligations for whatever reason, Guarantor shall be obligated to pay the same immediately. 

  

	(b)	 Guarantor hereby agrees that its obligations with regard to its Canadian Note Guarantee shall be unconditional,
irrespective of the validity or enforceability of the Notes or the obligations of the Company under the Indenture, the absence of any action to enforce the same, the recovery of any judgment against the Company or any other obligor with respect to
the Indenture, the Notes or the obligations of the Company under the Indenture or the Notes, any action to enforce the same or any other circumstances (other than complete performance) which might otherwise constitute a legal or equitable discharge
or defense of a guarantor. Guarantor further, to the extent permitted by applicable law, hereby waives and relinquishes all claims, rights and remedies accorded by applicable law to guarantors and shall agree not to assert or take advantage of any
such claims, rights or remedies, including but not limited to: (i) any right to require any Beneficiary, as a condition of payment or performance by Guarantor, to (A) proceed against the Company, any other guarantor (including any other
Note Guarantor) of the Guaranteed Obligations or any other person, (B) proceed against or exhaust any security held from the Company, any such other guarantor or any other person, (C) proceed against or have resort to any balance of any
deposit account or credit on the books of any Beneficiary in favour of the Company or any other person, or (D) pursue any other 

  
 Schedule D-2 

	 	
remedy in the power of any Beneficiary whatsoever; (ii) any defense arising by reason of the incapacity, lack of authority or any disability or other defense of the Company including any
defense based on or arising out of the lack of validity or the unenforceability of the Guaranteed Obligations or any agreement or instrument relating thereto or by reason of the cessation of the liability of the Company from any cause other than
payment in full of the Guaranteed Obligations; (iii) any defense based upon any statute or rule of law which provides that the obligation of a surety must be neither larger in amount nor in other respects more burdensome than that of the
principal; (iv) any defense based upon any Beneficiary’s errors or omissions in the administration of the Guaranteed Obligations, except behavior which amounts to bad faith; (v) (A) any principles or provisions of law, statutory or
otherwise, which are or might be in conflict with the terms of this Canadian Note Guarantee and any legal or equitable discharge of Guarantor’s obligations hereunder and under this Canadian Note Guarantee, (B) the benefit of any statute of
limitations affecting Guarantor’s liability hereunder or the enforcement hereof, (C) any rights to set-offs, recoupments and counterclaims and (D) promptness, diligence and any requirement that
any Beneficiary protect, secure, perfect or insure any security interest or lien or any property subject thereto; (vi) notices, demands, presentations, protests, notices of protest, notices of dishonor and notices of any action or inaction,
including acceptance of this Canadian Note Guarantee, notices of default under the Notes or any agreement or instrument related thereto, notices of any renewal, extension or modification of the Guaranteed Obligations or any agreement related
thereto, and notices of any extension of credit to the Company and any right to consent to any thereof; and (vii) any defenses or benefits that may be derived from or afforded by law which limit the liability of or exonerate guarantors or
sureties, or which may conflict with the terms of this Canadian Note Guarantee. 

  

	(c)	 If any Holder or the Trustee is required by any court or otherwise to return to the Company, any Note Guarantor
or any custodian, trustee, liquidator or other similar official acting in relation to either the Company or any Note Guarantor, any amount paid to either the Trustee or such Holder, this Canadian Note Guarantee, to the extent theretofore discharged,
shall be reinstated in full force and effect. 

  

	(d)	 Guarantor agrees that it shall not be entitled to any right of subrogation in relation to the Holders in
respect of any obligations guaranteed hereby until payment in full of all Guaranteed Obligations. Guarantor further agrees that, as between Guarantor, on the one hand, and the Holders and the Trustee, on the other hand, (i) the maturity of the
Guaranteed Obligations may be accelerated as provided in Section 6.2 of the Indenture for the purposes of this Canadian Note Guarantee, notwithstanding any stay, injunction or other prohibition preventing such acceleration in respect of the
Guaranteed Obligations and (ii) in the event of any declaration of acceleration of such obligations as provided in Section 6.2 of the Indenture, such obligations (whether or not due and payable) shall forthwith become due and payable by
Guarantor for the purpose of this Canadian Note Guarantee. Guarantor shall not exercise any right to seek contribution from any non-paying Note Guarantor if the exercise of such right impairs the rights of the
Holders under the Note Guarantees. 

  

	2.2.	 Merger and Consolidation of Guarantors 

 

	(a)	 In case of any sale or other disposition, consolidation, merger, amalgamation or conveyance and upon the
assumption by the successor person on terms and conditions satisfactory to the Trustee of the obligations of Guarantor under this Canadian Note Guarantee, and the due and punctual performance of all of the covenants and conditions of the Indenture
to be performed by Guarantor, such successor person shall succeed to and be substituted for Guarantor under this Canadian Note Guarantee with the same effect as if it had been named herein as Guarantor. 

 

	(b)	 Except as set forth in Articles 4 and 5 of the Indenture, and notwithstanding clause (a) of this
Section 2.2, nothing contained in the Indenture or in any of the Notes shall prevent any consolidation, merger or amalgamation of a Note Guarantor with or into another Person, or shall prevent any sale or conveyance of the property of a Note
Guarantor as an entirety or substantially as an entirety. 

  
 Schedule D-3 

	2.3.	 Release 

  

	(a)	 In the event (i) of a sale or other disposition of all or substantially all of the assets of any
Guarantor, by way of merger, amalgamation, consolidation or otherwise, or a sale or other disposition of all the Equity Interests of any Guarantor, then held by the Company and its Restricted Subsidiaries to a person that is not (either before or
after giving effect to such transactions) a Subsidiary of the Company, in each case so long as such sale or other disposition is permitted by the Indenture, including without limitation Section 4.14 thereof, (ii) of a designation by the
Company of any Restricted Subsidiary that is a Guarantor as an Unrestricted Subsidiary in accordance with the definition thereof or in the event that such Guarantor ceases to be a Restricted Subsidiary in accordance with the provisions of the
Indenture, (iii) in the case of any Canadian Note Guarantee issued on the Issue Date, upon the release or discharge of the Canadian Note Guarantee by such Guarantor in respect of the Credit Agreement, and in any other case upon the release or
discharge of any Canadian Note Guarantee in respect of any Indebtedness that resulted in the issuance after the Issue Date of the Canadian Note Guarantee by such Guarantor or (iv) the Company discharges the Notes of such series and its
Obligations under the Indenture under Section 8.1 thereof or exercises its legal or covenant defeasance options under Section 8.2 or 8.3 thereof, respectively, with respect to the Notes of a series or, in the case of a sale or other
disposition of all or substantially all of the assets of Guarantor, the Person acquiring such property, shall be released and relieved of any obligations under this Canadian Note Guarantee (in the case of clause (iv), only with respect to the
applicable series) without any further action being required by the Trustee or any Holder. 

  

	(b)	 Upon delivery by the Company to the Trustee of an Officers’ Certificate and an Opinion of Counsel to the
effect that such sale or other disposition was made by the Company in accordance with the provisions of the Indenture, including without limitation Sections 4.8 and 4.14 thereof, the Trustee shall execute any documents reasonably required in order
to evidence the release of Guarantor from its obligations under this Canadian Note Guarantee. 

 Section 3.

 Miscellaneous 
  

	3.1.	 Limitations Act, 2002 (Ontario) 

Any and all limitation periods provided for in the Limitations Act, 2002 (Ontario), as amended from time to time, or any other applicable law limiting
the time for which an action may be commenced shall be excluded from application to the obligations of Guarantor hereunder to the fullest extent permitted by such Act or applicable law. 

 

	3.2.	 Usury Savings Clause 

If any provision of this Canadian Note Guarantee, the Indenture or any Note would obligate any Canadian Note Guarantor to make any payment of or on account of
interest or other amount in an amount or calculated at a rate which would result in a receipt by any Holder of interest at a criminal rate (as such term is construed under the Criminal Code (Canada)), then notwithstanding such provisions,
such amount or rate shall be deemed to have been adjusted with retroactive effect to the maximum amount or rate of interest, as the case may be, as would not so result in a receipt by such Holder of interest at a criminal rate, such adjustment to be
effected, to the extent necessary, as follows: (1) firstly, by reducing the amount or rate of interest required to be paid to such Holder, and (2) thereafter, by reducing any fees, commissions, premiums and other amounts required to be
paid to such Holder which would constitute “interest” for purposes of Section 347 of the Criminal Code (Canada). 
  

	3.3.	 Interest Act (Canada) 

For purposes of disclosure pursuant to the Interest Act (Canada), the annual rates of interest or fees to which the rates of interest or fees provided
for in this Canadian Note Guarantee, the Indenture or the Notes (and stated herein or therein, as applicable, to be computed on the basis of a 360 day year or any other period of time less than a calendar year) are equivalent are the rates so
provided for multiplied by the actual number of days in the applicable calendar year and divided by 360 or the actual number of days in such other period of time, respectively. 

  
 Schedule D-4 

 The Guarantor confirms that it understands and acknowledges that it is and will be able to calculate the
rate of interest applicable under this Canadian Note Guarantee, the Indenture or the Notes based on the methodology for calculating per annum rates provided for under this Canadian Note Guarantee, the Indenture or the Notes. The Guarantor confirms
that it agrees not to plead or assert, whether by way of defense or otherwise, in any proceeding relating to this Canadian Note Guarantee, the Indenture or the Notes, that the interest payable under this Canadian Note Guarantee, the Indenture or the
Notes and the calculation thereof has not been adequately disclosed to the Guarantor, whether pursuant to Section 4 of the Interest Act (Canada) or any other applicable law or legal principle. 

 

	3.4.	 Counterparts; Execution 

This Canadian Note Guarantee may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and
delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same agreement. Delivery of an executed counterpart of this Canadian Note Guarantee by facsimile or other similar method of
electronic transmission (including by way of email attachment) shall be equally as effective as delivery of an original executed counterpart of this Canadian Note Guarantee. 
  

	3.5.	 Severability 

If, in any jurisdiction, any provision of this Canadian Note Guarantee or its application to any party or circumstance is restricted, prohibited or
unenforceable, such provision shall, as to that jurisdiction, be ineffective only to the extent of such restriction, prohibition or unenforceability without invalidating the remaining provisions of this Canadian Note Guarantee and without affecting
the validity or enforceability of such provision in any other jurisdiction or without affecting its application to other parties or circumstances. 
  

	3.6.	 Notices 

All notices and other communications hereunder shall be in writing and shall be mailed, sent, or delivered in accordance with the terms of the Indenture. 

 

	3.7.	 Successors 

This Canadian Note Guarantee shall be binding upon Guarantor and its successors and shall inure to the benefit of the successors of the Beneficiaries. 

 

	3.8.	 Judgment Currency 

Guarantor shall indemnify each Holder and each Person, if any, who controls any Holder within the meaning of Section 15 of the Securities Act or
Section 20 of the Exchange Act against any loss incurred by such party as a result of any judgment or order being given or made against Guarantor for any U.S. dollar amount due under this Canadian Note Guarantee and such judgment or order being
expressed and paid in a currency (the “Judgment Currency”) other than U.S. dollars and as a result of any variation as between (i) the rate of exchange at which the U.S. dollar amount is converted into the Judgment Currency for
the purpose of such judgment or order and (ii) the spot rate of exchange in The City of New York at which such party on the date of payment of such judgment or order is able to purchase U.S. dollars with the amount of the Judgment Currency
actually received by such party if such party had utilized such amount of Judgment Currency to purchase U.S. dollars upon such party’s receipt thereof. Any amount due from Guarantor under this Section 3.8 shall be due as a separate debt
and shall not be affected by such judgment or order as aforesaid. The term “spot rate of exchange” shall include any premiums and costs of exchange payable in connection with the purchase of, or conversion into, U.S. dollars. 

  
 Schedule D-5 

	3.9.	 Payment of Additional Amounts 

 

	(a)	 All payments made under or with respect to this Canadian Note Guarantee by Guarantor will be made free and
clear of any withholding or deduction for or on account of any tax, duty, levy, impost, assessment or other governmental charge of whatever nature (collectively, “Tax”) imposed or levied by or on behalf of Canada or any other
jurisdiction in which Guarantor is organized, resident or doing business for tax purposes or from or through which Guarantor makes any payment on the Canadian Note Guarantee or any department or political subdivision thereof (each, a
“Relevant Taxing Jurisdiction”), unless Guarantor (or an applicable withholding agent) is required to withhold or deduct Taxes by law. If Guarantor (or an applicable withholding agent) is required by law to withhold or deduct any
amount for or on account of Taxes of a Relevant Taxing Jurisdiction from any payment made under or with respect to this Canadian Note Guarantee, Guarantor, subject to the exceptions listed below, will pay additional amounts (“Additional
Amounts”) as may be necessary to ensure that the net amount received by each Holder or beneficial owner of the Notes after such withholding or deduction (including withholding or deduction attributable to Additional Amounts payable
hereunder) will not be less than the amount the Holder or beneficial owner would have received if such Taxes had not been required to be so withheld or deducted. 

 

	(b)	 Guarantor will not, however, pay Additional Amounts to a Holder or beneficial owner of Notes:

  

	 	(i)	 to the extent the Taxes giving rise to such Additional Amounts would not have been imposed but for the
existence of any present or former connection between the Holder or beneficial owner (or between a fiduciary, settler, beneficiary, member or shareholder of, or possessor of a power over, such Holder or beneficial owner, if such Holder or beneficial
owner is an estate, trust, partnership or corporation) and the Relevant Taxing Jurisdiction (other than any connection resulting solely from the acquisition, ownership, holding or disposition of Notes, the receipt of payments thereunder or under
this Canadian Note Guarantee and/or the exercise or enforcement of rights under any Notes or this Canadian Note Guarantee); 

  

	 	(ii)	 to the extent the Taxes giving rise to such Additional Amounts would not have been imposed but for the failure
of the Holder or beneficial owner of Notes, following Guarantor’s written request addressed to the Holder, to the extent such Holder or beneficial owner is legally eligible to do so, to comply with any certification, identification, information
or other reporting requirements, whether required by statute, treaty, regulation or administrative practice of a Relevant Taxing Jurisdiction, as a precondition to exemption from, or reduction in the rate of deduction or withholding of, Taxes
imposed by the Relevant Taxing Jurisdiction (including, without limitation, a certification that the Holder or beneficial owner is not resident in the Relevant Taxing Jurisdiction); 

 

	 	(iii)	 with respect to any estate, inheritance, gift, sales, transfer, capital gains, excise or personal property tax
or any similar Taxes; 

  

	 	(iv)	 to the extent the Taxes giving rise to such Additional Amounts would not have been imposed but for the
presentation by the Holder or beneficial owner of any Note, where presentation is required, for payment on a date more than 30 days after the date on which payment became due and payable or the date on which payment thereof is duly provided
for, whichever occurs later; 

  

	 	(v)	 to the extent the Taxes giving rise to such Additional Amounts would not have been imposed but for the Holder
or beneficial owner not dealing at arm’s length, within the meaning of the Income Tax Act (Canada), with the Company or Guarantor; 

  

	 	(vi)	 to the extent the Taxes giving rise to such Additional Amounts would not have been imposed but for such Holder
or beneficial owner being, or not dealing at arm’s length (within the meaning of the Income Tax Act (Canada)) with, a “specified shareholder” of the Company as defined in subsection 18(5) of the Income Tax Act
(Canada) for purposes of the thin capitalization rules in the Income Tax Act (Canada); 

  
 Schedule D-6 

	 	(vii)	 to the extent the Taxes giving rise to such Additional Amounts are United States federal withholding tax
imposed pursuant to Sections 1471 through 1474 of the Internal Revenue Code of 1986, as amended (the “Code”), as in effect on the date hereof (or any amended or successor version that is substantively comparable and not materially more
onerous to comply with), any current or future regulations, official interpretations or administrative authority promulgated thereunder and any agreements entered into pursuant to Section 1471(b)(1) of the Code as in effect on the date hereof
(or any amended or successor version that is substantively comparable and not materially more onerous to comply with), and, for the avoidance of doubt, any intergovernmental agreement (and related legislation, rules or practices) implementing the
foregoing (taken together, “FATCA”), except to the extent that such Taxes result from a failure of any Paying Agent to comply with FATCA; and 

 

	 	(viii)	 any combination of items (i), (ii), (iii), (iv), (v), (vi) and (vii). 

Additional Amounts also shall not be paid with respect to any payment on a Note to a beneficial owner who is a fiduciary, a partnership (or
entity treated as a partnership for tax purposes), or anyone other than the sole beneficial owner of that payment to the extent that payment would be required by the laws of the Relevant Taxing Jurisdiction to be included in the income, for tax
purposes, of a beneficiary or settlor with respect to the fiduciary, a member of that partnership, or a beneficial owner who would not have been entitled to the Additional Amounts had that beneficiary, settlor, member or interest holder been the
beneficial owner. 
  

	(c)	 Guarantor or applicable withholding agent will (i) make any such withholding or deduction required by
applicable law and (ii) timely remit the full amount deducted or withheld to the Relevant Taxing Jurisdiction in accordance with applicable law. Guarantor will make reasonable efforts to obtain certified copies of tax receipts evidencing the
payment of any Taxes so deducted or withheld from each Relevant Taxing Jurisdiction imposing such Taxes. Guarantor will provide to the Trustee, within a reasonable time after the date the payment of any Taxes so deducted or withheld are due pursuant
to applicable law, either a certified copy of tax receipts evidencing such payment, or, if such tax receipts are not reasonably available to Guarantor, such other documentation that provides reasonable evidence of such payment by Guarantor.

  

	(d)	 Where Tax is payable pursuant to Regulation 803 of the Income Tax Act (Canada) by a Holder or beneficial
owner of the Notes in respect of any amount payable under the Canadian Note Guarantee to the Holder (other than by reason of a transfer of the Notes to a person resident in Canada with whom the transferor does not deal at arm’s length for the
purposes of such Act), but no Additional Amount is paid in respect of such Tax, Guarantor will pay as or on account of interest to the Holder an amount equal to such Tax (a “Regulation 803 Reimbursement”) plus an amount equal to any
Tax required to be paid by the Holder or a beneficial owner as a result of such Regulation 803 Reimbursement within 45 days after receiving from the Holder a notice containing reasonable particulars of the Tax so payable, provided such Holder
or beneficial owner would have been entitled to receive Additional Amounts on account of such Tax (and only to the extent of such Additional Amounts that such Holder or beneficial owner would have been entitled to receive) but for the fact that it
is payable otherwise than by deduction or withholding from payments made under or with respect to the Canadian Note Guarantee. 

  

	(e)	 Prior to the date on which the payment of any Additional Amounts are due, Guarantor will deliver to the Trustee
such Additional Amounts payable, together with an Officers’ Certificate setting forth the Additional Amounts, stating that such Additional Amounts will be payable on the applicable payment date and setting forth such other information necessary
to enable the Trustee to pay such Additional Amounts to Holders on the applicable payment date. Any such Officers’ Certificate will be delivered to the Trustee at least two Business Days in advance of when the payments in question are required
to be made (unless a shorter period of time is acceptable to the Trustee in its reasonable discretion). Guarantor will promptly publish a notice in accordance with Section 11.2 of the Indenture stating that such Additional Amounts will be
payable and describing the obligation to pay such amounts. 

  
 Schedule D-7 

	(f)	 Guarantor will reimburse the Holders or beneficial owners of Notes, upon written request of such Holder or
beneficial owner of Notes and certified proof of payment for the amount of (i) any Taxes levied or imposed by a Relevant Taxing Jurisdiction and payable by such Holder or beneficial owner in connection with payments made under or with respect
to this Canadian Note Guarantee; and (ii) any Taxes levied or imposed with respect to any reimbursement under the foregoing clause (i) or this clause (ii), so that the net amount received by such Holder or beneficial owner after such
reimbursement will not be less than the net amount such Holder or beneficial owner would have received if the Taxes giving rise to the reimbursement described in clauses (i) and/or (ii) had not been imposed, provided,
however, that the indemnification obligation provided for in this Section 3.9(f) shall not extend to Taxes imposed for which the Holder or beneficial owner of the Notes would not have been eligible to receive payment of Additional
Amounts hereunder by virtue of clauses (i) through (viii) of Section 3.9(b) hereof, or to the extent such Holder or beneficial owner received Additional Amounts with respect to such payments. 

 

	(g)	 In addition, Guarantor will pay any stamp, issue, registration, court, documentary, excise or other similar
taxes, charges and duties, including interest and penalties with respect thereto, imposed by any Relevant Taxing Jurisdiction at any time in respect of the execution, issuance, registration or delivery of this Canadian Note Guarantee or any other
document or instrument referred to thereunder and any such taxes, charges or duties imposed by any Relevant Taxing Jurisdiction at any time as a result of, or in connection with, (i) any payments made pursuant to any Guarantee or any other such
document or instrument referred to thereunder and/or (ii) the enforcement of this Canadian Note Guarantee or any other such document or instrument referred to thereunder. 

 

	(h)	 Obligations described under this Section 3.9 will survive any termination, defeasance or discharge of the
Indenture and will apply mutatis mutandis to any successor Person to Guarantor and to any jurisdiction in which such successor is organized, doing business or is otherwise resident for Tax purposes or any jurisdiction from or through which
payment is made by such successor or its respective agents. 

  

	(i)	 Whenever this Canadian Note Guarantee refers to, in any context, the payment of principal, premium, if any,
interest or any other amount payable under or with respect to any Note or under this Canadian Note Guarantee, such reference includes the payment of Additional Amounts or other payments that would be payable pursuant to this Section 3.9, if
applicable. 

 - remainder of page intentionally left blank - 

  
 Schedule D-8 

 IN WITNESS WHEREOF, Guarantor has executed and delivered this Guarantee as of the
first date written above. 
  

			
	 ☐, as Canadian Note Guarantor

		
	By:	 	 
		 	 Name:

		 	 Title:

  
 Schedule D-9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]